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1Introduction
11
A general introduction
The major epochs in the history of biology have led towards a preference 
for quantitative principles founded on a physical understanding of biological 
systems.  Biology, as it was practiced in the 18th century, was defined in large 
part by systematics, the classification of various kinds of biological entity into 
their respective groups with respect towards their phenotypic differences. 
But rather than emphasize distinctions, biology of the 19th century asserted 
in contrast that all life is fundamentally physicochemical,  in conjunction 
with developments in chemistry and the physical sciences at the time. Now, 
the dominant paradigm of biology in the 20th and 21st centuries has been the 
informational basis of life, that biological phenotype is digitally encoded in 
an organism’s DNA molecules.  Watson and Crick’s foundational insight, 
the structure of this genetic information encoded in molecular form (DNA), 
is perhaps the single most disseminated achievement in molecular biology1-3. 
Yet since then, biologists have been laboring to unravel the mechanisms by 
which one “genome” is sufficient to produce essentially every component of a 
functional cell and, moreover, how these components are utilized differentially 
to specify the multiplicity of individual cell types that constitute a complex, 
multi-cellular organism. Indeed, the discovery by Jacob, Monod and others 
that expression of gene transcripts and thereby proteins is regulated and this 
regulation is sensitive to environmental changes represents another pillar of 
contemporary molecular biology4-6.  The realization that gene expression, 
unlike the underlying genetic information itself, is defined contextually solved 
the problem of the specification of diverse cellular phenotypes from a single 
genomic state. An unspecified cell could “differentiate” into a more defined 
state on the basis of its internal state (i.e., the combination of all differentially 
expressed biomolecules present in that cell at a certain time) and the respective 
changes in the abundances of those biomolecules dictated by external stimuli. 
However, this immediately begs the question: how are these changes in 
regulation, in transcription, enacted? If the level of expression of a gene is 
subject to change, what factors mediate that change? The current biological 
consensus, and the overarching topic of this thesis, is that gene expression is 
predominantly regulated by cis- or trans-acting DNA-binding transcription 
factors and by chromatin state, the three-dimensional epigenetic structure of 
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Chapter 1
12
the underlying DNA, which is itself regulated by DNA-binding chromatin 
remodeling and modifying enzymes. 
Though the defining event of 21st century biology is almost indisputably the 
decoding of the human genome, following closely behind is the more general 
movement towards a systems biology perspective. This movement has been 
spurred by the sheer complexity uncovered in such transcriptional regulatory 
mechanisms over the last fifty-odd years. In general, the mechanistic basis of 
biological information translation is increasingly embedded within a holistic 
network framework that encompasses the entirety of the cell’s or organism’s 
components. New paradigms often stem from new technologies, and the field 
of biology is no exception to this principle. Advances most notably in next 
generation sequencing (NGS) technologies and workflows and also, most 
relevantly to this thesis, proteomics and particularly mass spectrometry-
based proteomics have contributed heavily to a new big data, multi-omics 
biology7. Although the intrinsic meaningfulness of these terms is occasionally 
overstated, the basic premise is quite simple: to assess a complex systems with 
many interacting components, many measurements must be performed, and 
each measurement should evaluate many components. Although this approach 
is often fundamentally descriptive (or, in other words, hypothesis generating), 
useful biological inferences can often be made on the basis of genome-wide, 
proteome-wide,  etc. datasets. For example, ChIP-seq experiments8,9  simply 
describe the genomic locations of histone marks or the binding sites of DNA 
binding proteins genome-wide, yet from these genomic locations, potential gene 
regulatory relationships can be inferred. Interaction proteomics10 experiments 
describe all the binding partners of a given bait (protein, DNA, small molecule, 
etc.) proteome-wide, yet from these binding partners, potential higher-order 
multimeric complexes and co-regulatory relationships can be inferred. A 
continually open question in scientific research is how novel and existing 
technologies can be best leveraged to solve outstanding problems. This thesis 
will address the technological question of how –omics approaches, specifically 
proteomics approaches, can shed new insights into problems in transcriptional 
regulation, cancer genomics, chromatin biology, and protein biochemistry. 
In the next sections, I will provide a more detailed introduction to the 
biological and technological components of this thesis. These include but are 
not necessarily limited to: 
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1) Transcriptional regulation by transcription factors
2) The relationship between transcription and chromatin state
3) The regulatory potential of DNA sequence, structure, and motif architecture
4) Cancer genomics, cancer-associated DNA variants, and deregulation of 
gene expression in cancer
5) Mass spectrometry for studying protein-DNA and protein-nucleosome 
interactions
Transcriptional regulation by transcription factors
While Pardee, Jacob, and Monod5,6 first identified a protein component 
that functionally regulated the expression of a different protein component, it 
has since been realized that factors with such capacity, transcription factors 
(TFs), are a large (~1600 proteins in humans) and diverse class of proteins11. 
In their simplest conception, TFs are proteins that simply influence the 
expression of gene products i.e. other proteins. However, in general, the current 
conception of TFs refers to sequence-specific DNA binding factors that regulate 
transcriptional processes. TF regulation may be direct through recruitment of 
RNA polymerases12 or basal transcription machinery13, or indirect through 
recruitment of chromatin remodeling or modifying enzymes14. Similarly,  TFs 
may regulate transcription via sequence-specific genomic binding that is nearby 
to the regulated gene or quite far away 15. The large number of TFs are sub-
categorized by the presence of characteristic DNA binding domains (DBDs). 
There are often many homologous members within a TF family defined by a 
particular ancestral DBD. These homologous family members regularly have 
similar sequence preferences defined by their DBDs, yet individual factors 
often vary slightly on the theme of the consensus family motif. Different 
DBD families can have characteristic multimerization preferences, and this 
combinatorial action further expands the library of TF regulatory potential. 
For example, C2H2 zinc fingers (ZF) often bind as monomers, basic helix-
loop-helix (bHLH) or basic leucine zipper (bZIP) are obligate homo- or hetero-
dimers, and even higher order multimers are observed in some TF families11. 
Alternatively, TF families can utilize both homomeric and heteromeric binding 
modes. Within the human ETS family, for instance, nearly all members 
recognize a similar sequence motif and have the ability to do so monomerically, 
yet the heterodimer GABP (alpha and beta subunits) recognizes a similar motif 
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as an obligate multimer16-18. As an example of these various complementary 
modes of TF-dependent transcriptional regulation of a target gene, I will briefly 
introduce a case of sequence-specific transcriptional regulation of human 
telomerase (TERT)  expression by a TF. 
Numerous sequence variants, both inherited variants (germline) in the 
TERT locus19-21 and acquired (somatic) variants in the TERT promoter 22-25, 
have previously been associated specifically with melanoma and many other 
cancers. In short, a causal variant (rs36115365) for the germline multi-cancer 
TERT risk locus was associated with differential, sequence variant-specific 
binding of the C2H2-ZF TF ZNF14826. Although, relevantly for this thesis, 
the identity of ZNF148 as a sequence-specific TF was initially established by 
mass spectrometry based workflows, a bevy of biochemical assays and cell-
based assays were necessary to confirm that ZNF148 indeed: a) directly bound 
rs36115365 DNA b) bound to rs36115365 in vivo c) increased TERT expression 
allele-specifically d) had a downstream effect on telomere length via regulation 
of TERT expression. Intriguingly, the rs36115365 is located approximately 
18kb upstream of the 5’ end of the TERT gene and is, in fact, more proximal 
to the CLPTM1L gene. Therefore, ZNF148 regulation of TERT expression 
is an example of long-range transcriptional regulation where, importantly, 
assigning a regulatory interaction to the nearest gene in 1D sequence space 
would implicate the incorrect gene-variant relationship. As such, ZNF148 acts 
at a transcriptional enhancer of TERT expression and lies at a genomic location 
epigenetically marked by the characteristic H3K27ac/H3K4me1 histone post-
translational modifications (PTMs). Chapter 2 of this thesis describes a related 
example of somatic variants in the TERT promoter inducing sequence-specific 
transcriptional up-regulation by the TF GABP27. The biological and oncological 
relevance of transcriptional TERT reactivation will be discussed in greater 
detail later in this introduction.
The relationship between transcription and chromatin state
The connection between transcriptional regulation by TFs at an enhancer 
or promoter element and the presence of defined histone PTMs or DNA 
modifications warrants a more detailed treatment, particularly because it is 
deeply connected to the idea of chromatin state as a major component of gene 
expression regulation28-32. 
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The need for a model of DNA packing and compaction results directly 
from two simple observations: that DNA molecules carry a large negative 
charge, and that the molecular size of a “genome” is typically large relative 
to a cell’s or a nuclei’s internal volume. Electrostatic repulsion between DNA 
molecules and strands obviates the need for an active packing mechanism. In 
fact, Roger Kornberg proposed in 1974 that chromatin structure consisted of 
discrete, repetitive protein-DNA units, a DNA “super-coil” wrapped around 
an octamer of positively charge histone proteins33. In Kornberg’s model, these 
“repeating units” could then flexibly assemble into a higher-order chromatin 
fiber. A landmark study in 1984 by Tim Richmond, Daniela Rhodes, Aaron 
Klug, and colleagues solved the structure of this super-helical DNA-histone 
complex, termed the nucleosome, at intermediate 7Å resolution34. This result 
was improved to an atomic resolution of 2.8Å by Karolin Luger working with 
Tim Richmond in 199735. Further structural and functional studies focused on 
the higher-order assembly of individual nucleosomes into the so-called 30nM 
chromatin fiber. Reported 30nM fiber structures have been somewhat discrepant. 
Tim Richmond and colleagues solved the intermediate 9Å structure of a tetra-
nucleosome36, which, in combination with additional functional and electron 
microscopy data, led them to propose a two-start helical model for the 30nM 
fiber37. In contrast, Daniela Rhodes and colleagues proposed an interdigitated 
one-start helical model, highlighting the importance of linker histone H1 and 
longer linker lengths between nucleosome units38,39. These different structural 
models, possibly, reflect independent and functional chromatin states40. 
However, a beautiful and more recent study suggested that a two-start double 
helical 30nM chromatin fiber forms in the presence of linker histone H1 and 
low salt, and is not strongly dependent on DNA linker length41. Perhaps more 
interestingly, whether or not the 30nM chromatin fiber actually forms in vivo, 
and if so in what conditions, is a topic of ongoing discussion42,43. A recent study, 
utilizing fluorescent dye enabled deposition of contrast enhancing polymers for 
electron microscopy tomography, concluded based on novel in vivo chromatin 
imaging data that the 30nM fiber is not observed in interphase or mitotic 
chromatin44. Instead, the authors claim, human cells organize their chromatin 
as a 5-24nM flexible bead-like polymer, where only nucleosome concentration 
dictates chromatin compaction, as opposed to any structured, higher-order 
chromatin fiber folding. 
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Though more work is necessary to comprehensively resolve the details 
of chromatin folding in vivo, the relevance of chromatin compaction to gene 
expression regulation is clear: chromatin structure can represent a substantial 
steric block for the transcriptional machinery45. Indeed, the earliest description 
of distinct chromatin states, by Heitz in 1928, distinguished two main chromatin 
states based on their level of compaction46. Chromatin compaction, it has since 
emerged, is intrinsically related to transcriptional potential in the underlying 
genetic region; euchromatin, decondensed chromatin, is gene-rich, accessible, 
and transcriptionally active, while heterochromatin, tightly condensed 
chromatin, is gene-poor, inaccessible, and transcriptionally silent47. In fact, the 
relationship between chromatin condensation state and transcription is so strong 
that heterochromatin must be actively remodeled, oftentimes an ATP-consuming 
process, to facilitate transcription48. On the one hand, this remodeling is enacted 
by a sub-class of TFs, commonly referred to as pioneer factors49-51. Pioneer 
transcription factors are, by definition, TFs that have the capacity to recognize 
their DNA motif in the context of a nucleosome particle. Key pioneer TFs can 
partially recognize exposed “half-motifs” along the nucleosomal super-helix52. 
However, cell- and tissue-specificity in pioneer TF site remodeling can also 
depend on the presence of cooperative interactions with other TF co-factors53,54. 
On the other hand, nucleosome and chromatin remodeling by pioneer TFs 
is correlated with modifications to histone post-translational modifications 
(PTMs) at those loci48,55. Indeed, eu- and heterochromatin can be distinguished 
by characteristic histone tail PTMs (i.e., H3K27 acetylation at euchromatin 
v. H3K9 tri-methylation at heterochromatin). With few exceptions56, histone 
PTMs do not affect the core structure of the nucleosome57. Rather, histone 
modifications seem to affect nucleosome stability, dynamics, higher-order 
chromatin folding, and interactions with histone chaperones or chromatin 
remodellers58,59. Foundational papers for the field of epigenetics established 
the regulatory and phenotypic importance of histone tails (and thereby histone 
tail PTMs)60 and the enzymes that deposit and remove them61. The paradigm 
of histone tail PTM “readers, writers, and erasers” has recently culminated in 
an intense effort to identify, proteome-wide, functional PTM-specific proteins 
and protein complexes62-65.  These chromatin modifiers and remodelers, through 
steric regulation via nucleosome positioning and chromatin state regulation via 
histone PTM modifications, subsequently regulate transcription in development 
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and cell differentiation66. Thus, the initiation and maintenance of chromatin 
states is a complex and multi-faceted process that facilitates specification of 
diverse cell states via differential gene expression regulation. 
The regulatory potential of DNA sequence, structure, and 
motif architecture
Although I have, so far, considered the regulatory potential of DNA itself 
purely in the context of its 1D sequence (and thereby its interactions with 
sequence-specific TFs), DNA is of course a molecule that exists in 3D space. 
Correspondingly, recent research has revealed surprising structural aspects of 
DNA elements that influence their gene regulatory function. First, like histone 
proteins, DNA can be post-translationally modified, predominantly via CpG 
methylation, with concurrent effects on gene expression regulation67. DNA 
methylation was discovered by chemical means as early as 194868, though 
its generally repressive effect on gene expression was discovered relatively 
later69,70. In line with its gene regulatory function, CpGs are depleted genome-
wide in mammalian genomes71, yet unmethylated CpG regions preferentially 
associate with genes72. Similarly, mCpGs are predominantly located in 
heterochromatic regions, and they co-localize with and are mechanistically 
linked to the heterochromatic H3K9me3 histone mark73. Aberrant gene-specific 
CpG (hypo)-methylation has been associated with cancer in human tumors74. 
The identification of the regulatory function of mCpG has, as with histone 
PTMs, led to the identification of mCpG specific “reader” proteins including 
MeCP275. Proteome-wide approaches have greatly expanded the known 
repertoire of mCpG (and its chemical derivatives) specific reader proteins76. 
In addition to functional modulation by epigenetic modifications, the DNA 
molecule itself has a shape component, which is related to but also distinct 
from its sequence component. Ground-breaking work from Remo Rohs and 
colleagues demonstrated that shape features of dsDNA, including minor groove 
width, roll, propeller twist, and helix turn77, can improve predictive models of 
TF DNA binding78-81. Such shape-based features have recently been applied 
to epigenetic data, suggesting that DNA methylation affects local DNA shape 
and thereby protein binding82 (although structural data shows that local shape 
changes are modest and global DNA shape changes are absent83,84). Binding 
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models considering histone modifications may improve TF DNA binding 
predictions for some families of TF85. Furthermore, not only DNA shape but 
also allosteric effects induced by binding at distal DNA elements can affect 
protein-DNA binding86,87. Moreover, while Watson and Crick’s famous solution 
of the DNA structure1 represents the B-form of DNA,  double-stranded DNA 
(dsDNA) can adopt alternate conformations including A-DNA and Z-DNA88. 
Beyond dsDNA forms, DNA can adopt a variety of more exotic single-stranded 
(ssDNA), triplex (three-stranded), or quadruplex (four-stranded) structures89. 
Although some of these structures, most notably G-quadruplexes (G4s), have 
been associated with various modes of gene expression regulatory function, 
the role of DNA structures in mediating gene expression, if any, is still an 
active area of research90-93. Chemical approaches stabilizing G4 structures with 
small molecule ligands have been associated with transcriptional changes in 
nearby genes, for example, downregulation of c-Myc expression upon G4-
stabilizing ligand treatment93,94. Concomitantly, G4-stabilizing molecules 
induce local epigenetic reprogramming including the removal of H3K4me3 
(a mark of active promoters) and induction of heterochromatic H3K9me3 and 
DNA CpG methylation95. More recently, NGS approaches have facilitated 
the mapping of G-quadruplexes, non-B DNA, and even RNA-DNA triplexes 
(R-loops) genome-wide, leading to the observation that many non-canonical 
DNA structures map to regulatory regions (as distinguished by epigenetic 
marks)96-100. Because many techniques and reagents for studying DNA and 
RNA secondary structures have emerged relatively recently, however, protein 
mediators of any regulatory function assigned to such secondary structures 
remain largely uncovered. Many reported DNA and RNA G4 binding proteins 
are helicases related to G-quadruplex unwinding101,102. Although there are a 
few reports of G-quadruplex interactions with chromatin remodeling103,104 or 
modifying enzymes105-107, a thorough explanation for the connection between 
G-quadruplex structure and chromatin state is lacking. Chapter 4 of this thesis 
presents data suggesting that stable G-quadruplexes might act as recognition 
motifs for some chromatin remodeling and modifying enzymes. Similarly, 
although it seems clear that G-quadruplexes and non-canonical DNA structures 
have some link to cancer development and progression108,109, possibly via effects 
on genome maintenance and instability related to DNA repair and chromatin 
modulation110-113, this area of research is relatively immature.  Chapter 3 of this 
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thesis presents an interesting case of allele-specific DNA secondary structure 
formation in a cancer-associated insertion/deletion variant correlated with 
differential helicase binding and gene expression at the target locus114.
Cancer-associated DNA variants, cancer genomics, and 
deregulation of gene expression in cancer
It is clear that there exists great complexity among the mechanisms 
by which a cell might differentially regulate the expression of genes. This 
complexity is, on the one hand, a benefit, because it facilitates an incredible 
diversity of cell phenotypes, cell responses to perturbation, and underlying gene 
regulatory mechanisms and networks. On the other hand, cancer development 
proceeds via the subversion of normal, healthy cellular growth pathways and 
the gene regulatory networks that maintain them to produce an unrestrained, 
immortalized growth phenotype. In a sense, cancer is an evolutionary 
disease115. Selection at the level of the (eukaryotic, multi-cellular) individual 
selects for cancer suppressive or resistant genotypes, in order to protect the 
life and reproductive potential of the organism as a whole. Selection at the 
level of the cell selects for, simply, propagation. Therefore, complex gene 
regulatory mechanisms have the disadvantage of presenting numerous distinct 
opportunities for the cell to acquire advantageous growth phenotypes. It has 
been proposed that the cancer phenotype can be distinguished by the acquisition 
of a few key molecular and cellular traits, famously referred to as the “hallmarks 
of cancer”116,117. In many ways, the “hallmarks of cancer” paradigms has shaped 
and defined cancer research for the last fifteen odd years, and progress has 
been made towards elucidating the mechanisms behind, and proposing targeted 
therapeutic interventions for, each of the cancer hallmarks. For example, 
BRAF mutations (V600E) are frequent in a variety of cancers, particularly 
melanoma and are associated with constitutively active growth signaling via 
the MAP kinase pathway118. And indeed, targeted therapeutic options for BRAF 
V600E (i.e., vemurafenib) exist and are in clinical use119. However, in line 
with the complexity and resiliency of oncogenic pathways, acquired resistance 
to vemurafenib treatment is common. Furthermore, paradoxically, targeted 
BRAF inhibition is often associated with MAP kinase signaling activation 
and, as such, can induce additional cutaneous lesions. Similarly, it has become 
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clear that BRAF mutations are not the only molecular mechanism by which 
cancer cells can constitutively activate MAP kinase signaling pathways120,121. 
In sum, despite the considerable progress that has been made in understanding 
the mechanisms driving cancer formation, more research is still necessary to 
outsmart cancer via novel clinical avenues. 
While coding mutations in “driver” oncogenes or “tumor suppressor” genes 
have received much study over the past two decades122,123, especially with the 
advent of NGS technologies and cancer genomics studies, the role of non-
coding mutations in cancer has been of more recent interest124. Large-scale 
cancer genomics sequencing studies have identified genome-wide mutational 
signatures that, in some cases, were cancer specific125. Additional studies 
implicated “hotspots” for non-coding somatic mutations, most often in promoter 
regions or 5’ untranslated regions (UTRs)126,127. Of interest, hotspot somatic 
mutations in the TERT promoter were the most consistently and significantly 
mutated non-coding region across all cancers, in line with previous findings22-24. 
Certainly, it should not be surprising that promoter mutations associated with 
TERT reactivation are the most frequent significant of all non-coding variation. 
Indeed, TERT reactivation represents a classic “hallmark of cancer” by enabling 
replicative immortality. Without TERT expression or some other telomere 
elongating mechanism, gradual telomere shortening and eventual senescence 
are an insurmountable obstacle to oncogenesis128. Therefore, cancer cells are 
under intense selective pressure to activate telomerase expression, or activate 
an Alternative Lengthening of Telomeres pathway129. Because TERT expression 
is generally silenced in differentiated cells, activating coding mutations in the 
telomerase protein are not often seen. Mechanisms of TERT reactivation are, 
therefore, often by non-coding means such as promoter mutations or gene 
amplifications (indeed, it is currently thought that most cancer-associated 
non-coding variants act via sequence-specific TF binding and allele-specific 
transcriptional regulatory mechanisms). A pan-cancer cancer genomics analysis 
highlighted the significance of mutations in the TERT promoter130. It was noted 
very early on that both of the most frequent TERT promoter mutations create 
non-endogenous ETS TF family binding motifs. Indeed, as demonstrated in 
Chapter 2 of this thesis, the ETS factor GABP binds heterotetramerically to 
the TERT promoter via both endogenous ETS motifs and non-endogenous, 
mutation-specific ETS motifs simultaneously, thereby activating mono-allelic 
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TERT expression and inducing an epigenetic switch marked by active histone 
PTMs27,131,132. GABP activation of TERT is additionally related to BRAF V600E 
signaling via aberrant FOS activation133. TERT reactivation via ETS family 
motifs led researchers to seek mutation-specific changes to ETS family motifs in 
non-coding hotspot mutations near other genes. It was suggested that promoter 
mutations at the SDHD gene might also downregulate SDHD expression via the 
loss of ETS factor binding, and in this case the ETS factor ELF1 was proposed 
as the likely causal factor based on bioinformatics analysis127. However, later 
research, also shown in Chapter 2 of this thesis, demonstrated that mutation-
specific loss of GABP binding, as with TERT promoter mutations, was largely 
responsible for the reduction of SDHD expression in mutated tumors134. Finally, 
in addition to coding driver mutations and somatic non-coding variants, the 
explosion of genome-wide association studies (GWAS) over the last decade 
has identified an overwhelming number of germline variants that have been 
associated with hereditary risk for many diseases, including cancers135,136. In 
melanoma alone, there are ~20 loci associated with hereditary risk20. Each 
locus often contains tens or hundreds of potential causal variants. Therefore, 
unraveling the molecular mechanism by which a locus confers risk for the 
disease is so far often performed on a case-by-case basis and is highly non-
trivial114. Ultimately, the functional annotation of non-coding variants in cancer, 
both germline and somatic, will be a major direction for concerted future effort. 
Mass spectrometry for studying protein-DNA and protein-
nucleosome interactions
For profiling the function of non-coding, cancer-associated sequence 
variants, there exist many classic molecular and cellular biology experimental 
techniques. Among these, techniques such as luciferase assays and Pol II 
chromatin immunoprecipitation followed by qPCR (ChIP) can monitor 
variant-specific transcriptional activity; EMSA, affinity purification followed 
by western blot, or ChIP-qPCR can identify variant specific protein binding; 
isothermal titration calorimetry (ITC), fluorescence polarization (FP) or Förster 
resonance energy transfer (FRET), surface plasmon resonance (SPR), and 
EMSA are biochemical assays that can directly assess the allele-specific affinity 
of protein-DNA interactions. High-throughput approaches for determining 
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protein-DNA interaction specificities have attracted recent attention137. 
Although these techniques are powerful and have been widely utilized in many 
functional genomics studies, their general disadvantage is that they are targeted. 
In contrast, mass spectrometry based interaction proteomics has emerged as an 
unbiased tool for identifying specific protein interactions, including variant-
specific binding of proteins to DNA10,138,139. Mass spectrometry based workflows 
have yielded large-scale protein-protein interaction networks at the level of 
entire proteomes, or thousands of individual baits140-142. Cross-linking mass 
spectrometry (XL-MS) workflows, similarly, are now capable of measuring 
thousands of residue-level interactions in vivo143,144. However, methods and 
applications of mass spectrometry for studying protein-DNA interactions have 
received less attention, despite the potential of mass spectrometry for providing 
insights into such regulatory interactions. Butter, Mann, and colleagues provided 
an initial demonstration that quantitative mass spectrometry could be used for 
the identification of DNA-binding proteins and, perhaps more critically, the 
identification of sequence-specific protein-DNA interactions145,146. Additional 
studies identified specific interactors of ultra-conserved DNA elements147 and 
interaction-based evolution of the telomere-protecting shelterin complex148. 
Protein-RNA interactions have been assayed using mass spectrometry using 
similar workflows, or UV-crosslinking based workflows149-151. Spruijt et al. 
identified modification and differentiation stage-specific interactors of mCpG 
DNA and its various chemical derivatives including hydroxyl-methylation76. 
Edupuganti et al. performed a conceptually similar studying, identifying and 
functionally profiling specific readers of N6-methyladenosine (m6A) modified 
RNA152. In addition to epigenetic DNA modifications, specific readers of histone 
PTMs in a histone tail peptide context62,64 and a nucleosome context63 have 
been identified by mass spectrometry. Fang et al. used a mass spectrometry 
approach to identify variant specific TFs for a common, multicancer-associated 
SNP in the TERT locus26. In Chapter 2 of this thesis, Makowski et al.27 and 
Zhang et al.134 used mass spectrometry to identify somatic variant specific TFs, 
observing gain of GABP binding and upregulation of TERT or loss of GABP 
binding and downregulation of SDHD, respectively.  Chapter 3 of this thesis 
uses mass spectrometry with an insertion/deletion DNA bait to detect specific 
protein binding associated with transcriptional regulation of the PARP1 gene in 
melanoma114. Though these relatively few examples demonstrate the promise of 
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mass spectrometry applied to protein-DNA interactions, most importantly for 
uncovering possible regulatory interactions, the massive number of putatively 
functional disease-associated variants demands much additional work.
A
B
C
D
Figure 1. Modes of transcriptional gene expression regulation
A Canonical gene expression regulation. A single repressor transcription factor (TF) regulates the 
expression of a target gene. In the presence of a stimulatory ligand, the repressor is sterically 
blocked from DNA binding and thus transcription can commence.
B Long-range gene regulation. Regulatory TFs can bind in trans and activate transcription of a 
target gene from long distances (tens or hundreds of kilobases). If the stabilizing effect of this 
long-distance interaction is lost due to inhibition of regulatory TFs, the basal transcriptional 
machinery binds inefficiently and gene expression is decreased.
C Gene expression regulation by chromatin remodellers and modifiers. If activating TFs are 
inhibited from binding, chromatin remodelling or modiffying enzymes might bind instead 
and remodel local chromatin state, thereby using nucleosomes to compact DNA and sterically 
repress expression of the target gene.
D Gene expression regulation by DNA structural elements. DNA secondary structural elements 
may recruit regulatory TF complexes, which activate target gene expression. Inhibition of this 
DNA structure-TF complex interaction by small molecule ligands subsequently decreases 
expression of the target gene. 
[Note: In this figure, I generally refer to “activating” and “repressive” modes of gene expression 
regulation in mutually exclusive terms. However, it is well established and should be noted that 
almost all modes of gene expression regulation can both activate and repress gene expression 
depending on the context.]
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Outline of this thesis
This thesis argues, in the form of a few case studies, that the application 
of mass spectrometry to the study of protein-DNA interactions represents 
a powerful and versatile tool for uncovering potential mechanisms of 
transcriptional gene expression regulation, particularly aberrant gene regulation 
in the context of cancer. 
Chapter 2 shows examples of somatic (promoter) mutation specific binding 
by the GABP protein. Using mass spectrometry, we see that recurrent promoter 
mutations in the TERT promoter are associated with novel ETS family TF 
motifs that subsequently induce GABP binding and thereby transcriptional 
TERT reactivation. However, intriguingly, recurrent promoter mutations at the 
SDHD gene disrupt native ETS motifs and thus decrease SDHD expression. 
Based on motif architecture and AP-MS experiments, our data suggests that 
activating GABP binding at TERT uses a tetrameric mode, while wild-type 
binding at SDHD utilizes a dimeric mode. Therefore, despite the identification 
of a single factor (GABP) associated with mutation specific binding at two 
recurrently mutated promoters, the binding mechanism leading to oncogenic 
transcriptional deregulation is entirely different.
My contributions to this chapter included conceiving of and designing the 
TERT study with M.V. and K.M.B., performing DNA binding assays including 
EMSA and western blot experiments with E.W., performing, measuring, and 
analyzing mass spectrometry experiments, writing the TERT manuscript with 
input from all authors, and contributing to the writing of the SDHD manuscript 
by T.Z. and K.M.B.
In Chapter 3, we identify allele-specific regulatory potential and allele-
specific protein binding at a common, germline variant in the melanoma-
associated PARP1 risk locus. The variant is an insertion/deletion that falls 
inside a short hexameric repeat and therefore creates no novel sequence motifs. 
Instead, we observed allele-specific binding of a number of proteins annotated 
as recognizing DNA structural features including the DNA helicase RECQL, 
which regulates PARP1 expression. Finally, we provide additional analysis 
of the structure-specific protein binding properties of this insertion/deletion 
variant using chemical structural perturbations. 
My contributions to this chapter included molecular biology assays of 
candidate SNPs including EMSA and luciferase assays, DNA binding assays 
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and dimethyl labeling and TMT mass spectrometry experiments, analyzing 
mass spectrometry data and making figures, and contributing to the writing of 
the manuscript by J.C. and K.M.B.
Mass spectrometry workflows described in Chapter 2 & 3 use relative, semi-
quantitative labeling to identify sequence-specific protein binding. Chapter 4 
describes an absolutely quantitative mass spectrometry workflow for assessing 
protein-DNA or protein-nucleosome apparent binding affinities (Kd
App). 
Titrated DNA sequences or nucleosomes are used for affinity purifications, 
after which isobaric TMT labeling and multiplexed mass spectrometry analysis 
are performed.  After performing benchmarking studies with the consensus SP/
KLF motif, we perform a larger survey of a canonical set of ssDNA and dsDNA 
motifs. Notably, we observe a number of chromatin remodeling and modifying 
complexes, including SWI/SNF, ISWI, PRC2, and NuRD, binding with high 
affinity to a reported DNA G-quadruplex forming sequence from the c-Myc 
promoter. These interactions appear to be somewhat structurally specific, as 
chemical perturbation of the G-quadruplex structure resulted in a decreased 
DNA affinity for many of these complexes. Further, we observe high affinity 
interactions between SWI/SNF and ISWI subunits and modified and unmodified 
nucleosomes. Intriguingly, we see high affinity binding for catalytic SWI/SNF 
subunits even in the absence of H3 modifications; however, accessory SWI/
SNF subunits bind to the nucleosome with high affinity only in the presence 
of H3K9AcK14Ac. We foresee fully quantitative binding analysis providing 
a link between absolute, copy-number proteome analysis and transcriptional 
output as measured by absolutely quantitative RNA-seq workflows. 
My contributions to this chapter included conceiving of and designing the 
study with M.V., performing DNA binding assays including EMSA and western 
blot experiments with C.G., performing DNA cross-linking and recombinant 
protein experiments, performing, measuring, and analyzing mass spectrometry 
experiments with C.G., analyzing other data and making figures, and writing 
the manuscript with input from all authors.
In the Conclusion, I discuss more informally the main research findings of 
this thesis and offer a broad perspective on future research into protein-DNA 
interactions using mass spectrometry.
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Figure 2     Mass spectrometry based methods for studying protein-DNA and protein-
nucleosome interactions
A Semi-quantitative analysis of sequence-specific protein-DNA interactions. Nuclear proteins are 
isolated from cancer cell lines and are enriched by affinity purification using biotinylated DNA 
oligonucleotides encompassing either a wild-type or a variant sequence. Proteins are digested 
to peptides, and these peptides are chemically labelled, most often using dimethyl chemical 
labeling. Binding ratios are calculated based on relative quantification in the MS1 spectra of the 
isotopically labelled peptides. Outliers are called from a background cloud of non-specifically 
binding proteins. 
B Absolute quantification of protein-DNA or protein-nucleosome KdApp values. A series of DNA 
oligonucleotide or nucleosome affinity purifications is performed as above, using a titrated bait 
of known concentration. Bound proteins are digested to peptides and labelled with isobaric 
TMT labels. Mass spectrometry analysis of the multiplexed peptide mixture is performed. 
Protein ratios are quantified from peptide reporter ions analyzed in MS3 spectra. KdApp values 
are quantified by fitting measured protein ratios using a Hill-like curve.
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Abstract
Recurrent somatic mutations in the human telomerase reverse transcriptase 
(TERT) promoter region, predominantly localized to two nucleotide positions, 
are highly prevalent in many cancer types. Indeed, aberrant telomerase 
reactivation in differentiated cells represents a major event in oncogenic 
transformation. Both mutations create novel consensus E26 transformation-
specific (ETS) motifs and are associated with increased TERT expression. Here, 
we performed an unbiased proteome-wide survey of transcription factor binding 
at TERT promoter mutations in melanoma. We observed ELF1 binding at both 
mutations in vitro, yet we showed that increased recruitment of GABP is enabled 
by the spatial architecture of native and novel ETS motifs in the TERT promoter 
region. We characterized the dynamics of competitive binding between ELF1 
and GABP and provided evidence for ELF1 exclusion by transcriptionally active 
GABP.  Similarly, across cancer types, recurrent SDHD promoter mutations 
occur exclusively in melanomas, at a frequency of 4-5%. These mutations are 
predicted to disrupt consensus ETS-transcription factor binding sites and are 
correlated with both reduced SDHD gene expression and poor prognosis. Here, 
we found that expression of SDHD in melanoma correlated with the expression 
of multiple ETS-transcription factors, particularly in SDHD promoter wild-
type samples. Consistent with the predicted loss of ETS-transcription factor 
binding, we observed that recurrent hotspot mutations resulted in decreased 
luciferase activity in reporter assays. Furthermore, we demonstrated specific 
GABPA and GABPB1 binding to probes containing the wild-type promoter 
sequences, with binding disrupted by the SDHD hotspot promoter mutations 
in both quantitative mass spectrometry and band-shift experiments. Finally, 
using siRNA-mediated knockdown across multiple melanoma cell lines, we 
determined that loss of GABPA resulted in reduced SDHD expression at both 
RNA and protein levels. These data are consistent with a key role for GABPA/
B1 as the critical ETS-transcription factors deregulating TERT and SDHD 
expression in the context of highly recurrent promoter mutations in melanoma. 
Thus, we suggest a more careful search for other recurrent promoter mutations 
creating or disrupting GABPA consensus sequences is warranted.
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Introduction
Compared to other human cancer types, cutaneous melanomas have a high 
mutation burden attributable to ultraviolet radiation (UVR) exposure1,2. The 
high number of mutations has complicated efforts to distinguish driver versus 
passenger mutations in large-scale sequencing studies3-9. To date, most genome-
scale sequencing studies have relied heavily on analysis of exomes, identifying 
a spectrum of driver genes with recurrent protein-coding somatic mutations 
and establishing a generalized framework for the genomic classification of 
cutaneous melanoma4-6,8,10: BRAF-mutant, RAS-mutant, NF1-mutant, and 
“triple wild-type”. Still, there is an emerging body of literature suggesting an 
important role for non-coding somatic mutations in melanoma development4,5, 
including those found within the 5’-untranslated (UTR) regions of genes4,11 and 
gene promoters12-18. Perhaps most notably, highly recurrent TERT promoter 
mutations that create consensus E26 transformation-specific transcription 
factor (ETS) binding motifs have been found in 50-85% of melanomas12-14, as 
well as in the germline of two high-density melanoma families12,15. 
Telomerase reactivation, associated with senescence bypass and essentially 
unlimited proliferative capacity, is a classic hallmark of cancer 19,20. However, 
because telomerase is typically silenced in differentiated cells, telomerase 
reactivation is thought to proceed through transcriptional mechanisms 21. A 
number of factors have previously been implicated in TERT reactivation via 
various transcriptional pathways 22-24. More recent work has begun to unravel the 
functional mechanisms by which TERT promoter mutations exert their oncogenic 
effect. For example, TERT promoter mutations were recently implicated 
in overcoming differentiation-associated transcriptional silencing of TERT 
expression, effectively extending telomere length and potentially contributing 
to tumorigenic immortalization 25,26.  Additionally, both mutations create novel 
E26 transformation-specific (ETS) transcription factor motifs within the TERT 
promoter region 27,28. However, the exact factor or factors influencing TERT 
expression specifically via promoter mutation sites remained elusive until a 
recent study demonstrated that GABP, an ETS-family transcription factor, was a 
major functional interactor 29. The identification of GABP as a mutation-specific 
interactor is particularly interesting, as multiple transcriptionally active binding 
modes for GABP have been previously been reported, including a heterodimer 
(GABPA/B) and a heterotetramer (GABPA2/B2) 
30-34. The heterotetrameric 
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binding mode of GABP was associated with TERT promoter mutation specific 
interactions. In particular, a precise spatial architecture between native ETS 
motifs and novel, mutation-specific ETS motifs was indicated as crucial for 
tetrameric GABP binding 29. Very recently, another report indicated that mutation 
specific GABP binding is concurrent with a switch to active chromatin marks 35. 
Recently, in an effort to identify similar hotspot mutations in gene 
promoters across multiple cancers sequenced as a part of The Cancer Genome 
Atlas (TCGA) project, Weinhold and colleagues identified recurrent mutations 
in the SDHD promoter exclusively in melanoma18. These mutations were 
associated with reduced levels of SDHD expression, as well as poor prognosis. 
These findings were replicated by Scholz and colleagues, who analyzed 451 
melanomas and found that approximately 4% of samples harbored SDHD 
promoter hotspot mutations36. Consistent with the role of UVR in melanoma 
biology, SDHD promoter mutations occur primarily as C>T alterations in sun-
exposed melanomas. The major mutations are located at chr.11:111,957,523 
(TTCC>TTTC, C523T), chr.11:111,957,541 (TTCC>TTTC, C541T) and 
chr.11:111,957,544 (CTTCC>TTTCC, C544T)18,36, within or adjacent to highly 
conserved TTCC motifs utilized by most ETS transcription factors37. While the 
ETS transcription factor family is one of the largest families of transcription 
factors, including more than 29 human genes38, expression of ELF1 was 
observed to be positively correlated with SDHD expression in TCGA samples 
without SDHD promoter mutation18, suggesting a functional role for ELF1 in 
regulating SDHD transcription. Still, a direct role for ELF1 or other ETS family 
transcription factors in the regulation of SDHD in melanoma remains to be 
established. 
Despite progress in elucidating the molecular function of TERT and 
SDHD promoter mutations, most studies thus far have targeted ETS-family 
factors. Complementary to targeted molecular studies, our group and others 
have previously established workflows for AP-MS/MS based identification of 
sequence specific protein-DNA binding on a proteome-wide scale 39,40.  Here, 
we perform an unbiased, proteome-wide survey of TERT promoter mutation 
specific transcription factor binding. We identify specific binding of multiple 
factors, including ELF1/2 and ETV6, and we confirm GABP as a direct, specific 
interactor in melanoma. We provide further characterization of the spatial 
architecture that promotes GABP binding at native and novel ETS motifs in 
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the TERT promoter. Additionally, we analyze competitive binding dynamics 
between ELF1 and GABP and propose a model in which multimeric GABP 
binding to a native and novel ETS motif excludes ELF1 and activates TERT 
expression. Similarly, we evaluate the incidence of SDHD promoter mutations 
in the three largest melanoma whole-genome and -exome datasets (TCGA/
Broad/Yale). We then functionally assess the consequence of SDHD promoter 
mutations in melanoma using the same mass spectrometry based approach. We 
find that the ETS transcription factors GABPA and GABPB1 specifically bind 
to wild-type SDHD promoter sequences, with this binding disrupted by hotspot 
promoter mutations. Our findings here highlight the importance of transcription 
factors GABPA/B1 as key regulators of expression of select ‘driver’ genes in 
melanoma.
Materials and Methods
Cell culture and nuclear lysate extraction
Melanoma cell lines were grown in adherent culture in RPMI 1640 (Gibco) 
supplemented with 10% FBS, 200 mM HEPES (pH 7.9), 100 U/ml penicilin 
and 100 µg/ml streptomycin (Gibco). 
Nuclear lysates were collected essentially as described previously 40. Briefly, 
cells were incubated in hypotonic Buffer A (10 mM HEPES (pH 7.9), 1.5 
mM MgCl2, 10 mM KCl and 0.15% NP40). Cells were then lysed by dounce 
homogenizer. Crude nuclei were collected by centrifugation and lysed in Buffer 
C (420 mM NaCl2, 20 mM HEPES (pH 7.9), 20% (v/v) glycerol, 2 mM MgCl2, 
0.2 EDTA, 0.1% NP40, EDTA-free complete protease inhibitors (Roche), and 
0.5 mM DTT) by rotation for one hour at 4C. Nuclear lysates were collected as 
the soluble fraction, snap frozen in liquid nitrogen, and stored at -80C. 
DNA pulldown and on-bead sample preparation 
Oligo baits were ordered via custom synthesis from Biomers or IDT with 
5’-biotinylation of the forward strand. Oligos were combined with 1.5X 
molar excess of the reverse strand in 2X annealing buffer (20 mM TRIS, pH 
8.0, 100 mM NaCl and 2 mM EDTA) and denatured at 98C for 10 minutes. 
Oligos were allowed to anneal by cooling to room temperature overnight and 
subsequently stored at -20C. For each pulldown reaction, 20 µl bead slurry (10 
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µl beads) of Streptavidin-Sepharose beads (GE Healthcare) were used. Each 
pulldown was performed in duplicate for outlier calling. Label swapping was 
performed between replicates to eliminate labeling bias. All pulldowns from 
each labeling reaction (forward and reverse) were performed simultaneously. 
Beads were washed once with 0.1% NP40 in 1X PBS and once with DNA 
binding buffer (DBB: 1M NaCl, 0.05% NP40, 10 mM TRIS, pH 8.0 and 1 mM 
ETDA).  Annealed oligo (500pmol) was diluted in 600 µl DBB final volume 
and rotated for 30 min at 4C. Subsequent steps were all carried out at 4C. Beads 
with immobilized oligonucleotides were washed once with DBB and twice with 
protein binding buffer (PBB: 150 mM NaCl, 0.25% NP40, 50 mM TRIS, pH 
8.0, EDTA-free complete protease inhibitors, and 1 mM DTT). Nuclear extracts 
(500ug) and 10 µg of competitor DNA (5 µg poly-dIdC, 5 µg poly-dAdT) 
were added to beads in a 600 µL final volume.  For all AP-MS/MS analyses, 
nuclear extract from UACC903 cells (TERT C228T-positive) was used.  Beads 
were incubated for 90 min on a rotation wheel at 4°C. The beads were then 
washed three times with PBB and two times with 1X PBS. All supernatant was 
carefully removed with a syringe. The proteins were reduced in elution buffer 
(2 M urea, 10 mM DTT, and 100 mM ammonium bicarbonate) for 20 minutes 
with shaking at room temperature. Samples were alkylated by addition of 50 
mM iodoacetamide (IAA) in the dark with shaking at room temperature for 10 
minutes. Proteins were then subjected to on-bead trypsin digestion (0.25 µg) for 
2 hours at room temperature plus shaking. The supernatant was transferred to a 
new tube and digested with an additional 0.1 µg trypsin overnight.
On-StageTip Dimethyl Labeling
Tryptic peptides were purified on C18 stage-tips (without acidification) 
as described previously 41. Buffer A was 0.1% formic acid and Buffer B was 
80% acetonitrile and 0.1% formic acid.  On-StageTip dimethyl labeling was 
performed as described previously 42. Briefly, 300 µl of labeling reagent (16.2 
µl 37% CH2O (light) or 30.0 µl 20% CD2O (medium) plus 6 mg sodium 
cyanoborohydride in 3mL of labeling buffer [10 mM NaH2PO4, 35 mM 
Na2HPO4]) was applied to the StageTip and spun through at 2200g for 10 min. 
StageTips were then washed once with 100uL of Buffer A and stored at 4C for 
MS analysis.
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Mass spectrometry analysis
Labeled samples were eluted from the StageTips with 30 µl of Buffer B 
while combining the respective light and medium labeled pairs into the same 
tube. Acetonitrile was evaporated by SpeedVac centrifuge at room temperature. 
After resuspension with 7 µl of Buffer A, 5 µl of sample was loaded onto a 30 
cm column (heated at 40°C) packed in-house with 1.8 µm Reprosil-Pur C18-
AQ (Dr Maisch). The peptides were eluted from the column using a gradient 
from 7 to 32% Buffer B in Buffer A over 120 minutes at flow rate 250 nl/min 
using an Easy-nLC 1000 (Thermo Fisher Scientific). 
TERT C228T and C250T and all SDHD mutation samples were eluted and 
sprayed directly into a Thermo Fisher QExactive mass spectrometer. The mass 
spectrometer was operated in top10 data-dependent acquisition mode. Target 
values for full MS were set to 3e6 AGC target and a maximum injection time 
of 20 ms. Full MS were recorded at a resolution of 70,000 over a scan range 
of 300-1650 m/z. Target values for MS/MS were set at 1e5 AGC target with 
a maximum injection time of 120 ms. The MS/MS spectra were recorded at 
a resolution of 17,500. The isolation width was set to 3.0 m/z, the collision 
energy to NCE=25, and the intensity threshold to 8.3e2. Dynamic exclusion 
was enabled for 20 s. Peptides with single or unknown charge state were 
excluded for MS/MS analysis.
TERT C228T+ETS samples were eluted and sprayed directly into a Thermo 
Fisher Orbitrap Fusion Tribrid mass spectrometer. Target values for full MS 
were set to 4e5 AGC target and a maximum injection time of 50 ms. Full MS 
were recorded at a resolution of 120,000 at a scan range of 400-1500 m/z. Most 
intense precursors with a charge state between 2 and 7 were selected for MS/
MS analysis, with an intensity threshold of 5000 and dynamic exclusion for 
60 s. Target values for MS/MS were set at 1e4 AGC target with a maximum 
injection time of 35 ms. Ion trap scan rate was set to ‘Rapid’, with an isolation 
width of 1.6 m/z and collision energy of 35%.
Data analysis
Raw MS spectra were analyzed using MaxQuant software (version 1.5.1.0) 
with standard settings 43,44. For dimethyl labelled samples, the respective built 
in N-terminal and lysine modification for dimethyl labeling was specified 
under “Labels”. Carbamidomethylation was specified as a fixed modification 
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on cysteines. N-terminal acetylation and methionine oxidation were allowed 
as variable modifications. Trypsin was selected as specific enzyme, and two 
missed cleavages were allowed. Data was searched against the human UniProt 
database (fasta file downloaded 2014.09.03) using the integrated search engine. 
The search was performed with a mass tolerance of 4.5 ppm mass accuracy for 
the precursor ion and 20 ppm for fragment ions. Peptides and proteins were 
both accepted at an FDR of 0.01. For quantification, at least two ratio counts 
were required. Protein identifications and calculated ratios are included as the 
proteinGroups output file from MaxQuant analysis. Plots were generated with 
Python essentially as described previously 45. Briefly, protein identifications 
were filtered for contaminants and reverse hits. Proteins groups were required to 
have two identified peptides, of which at least one was unique, to be considered 
as identified. The required outlier significance was 3.0 IQRs (inter-quartile 
range) for both forward and reverse experiments.
Band-shift analysis of recombinant protein-DNA interactions
Band-shift experiments were performed by incubating 20 fmol of biotin 
labeled double stranded oligos with recombinant human ELF1 protein (Origene, 
TP760629) or recombinant GABPA/B (Abnova, GABPA: H00002551-P01, 
GABPB: H00002553-P01) in a total volume of 20 µl of protein binding buffer 
(PBB: 150 mM NaCl, 0.25% NP40, 50 mM TRIS, pH 8.0, and 1 mM DTT) 
for 30 minutes. For GABP experiments, GABPA and GABPB were mixed at 
equimolar concentrations for 20 minutes at room temperature prior to addition 
of the oligo, In GABP experiments, the molecular weights listed in the figures 
refers to the total molecular weight of protein used (GABPA/B combined). The 
resulting protein complexes were resolved on 4-20% TBE gels (Biorad) in a 
Mini-PROTEAN tetra cell (Biorad) at 100V for approximately 3 hours in 1X 
TBE. Samples were transferred onto a nylon membrane (Biodyne) in a Trans-
Blot Turbo Transfer semi-dry transfer system (Biorad) at 400 mA for 10 minutes. 
Membranes were UV cross-linked and oligos were detected using streptavidin-
HRP conjugate and a chemiluminescent substrate (Chemiluminescent Nucleic 
Acid Detection Module, Pierce). 
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Western blotting
For TERT mutation western blot analysis, DNA pulldowns were performed 
as described above. After the final PBS wash, samples were resuspended in 
MilliQ water plus 1X sample buffer and boiled at 95C for ten minutes. Samples 
were then resolved on a poly-acrylamide gel, transferred to a nitrocellulose 
membrane, blocked with 5% milk, and incubated with primary antibody at 
4C overnight (ELF1: Santa Cruz, sc-631; GABPA: Santa Cruz, sc-22810). 
Samples were then incubated with HRP-conjugated secondary antibody (Dako) 
for one hour at room temperature, and imaged using an ECL Western Blotting 
Substrate (Pierce). 
For SDHD mutation western blot analysis, total cell lysates were generated 
with RIPA (Thermo Scientific, Pittsburgh, PA) and subjected to water bath 
sonication. Samples were resolved by 4-12% Bis-Tris ready gel (Invitrogen) 
electrophoresis. The primary antibodies used were rabbit anti-SDHD 
(ab189945, Abcam), rabbit anti-GABPA (ABE1047, Millipore), mouse anti-
GABPB1 (sc271571, Santa Cruz Biotechnology), and mouse anti-b-actin 
(A5316, Sigma-Aldrich). 
RNA and genomic DNA extraction
RNA was extracted using an RNeasy Plus Mini Kit (Qiagen). Genomic 
DNA was isolated using the ZR genomic DNATM kit (D3050, ZYMO Research) 
and assessed by Nanodrop 8000 (Thermo Scientific). 
Long PCR and sequencing of TA clones
PCR was carried out using genomic DNAs from 7 UACC melanoma 
cell lines as indicated in Figure 4A. The PCR primers used were: 
GGGCCGCAGCTGCTCCTTGTCG and CAGGCCGGGCTCCCAGTGG. 
PCR conditions were 98C  for 10 minutes to initially denature, followed by 38 
cycles of: 98C for 30s, 60C for 30s, and 72C for 90s, with a 7-min final extension 
at the end. The PCR products were cloned into TA vector (Life Technologies). 
Single colonies of bacteria were selected and PCR sequenced in 96-well plate 
format. The PCR reaction was performed in the same manner as above.  Sanger 
sequencing was used to determine the sequences of the PCR product. 
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Real-time quantitative PCR and allele specific TERT expression
For TERT mutations, gene expression levels were quantified by quantitative 
real-time PCR using TaqMan assays for TERT (Hs00972656_m1), ELF1 
(Hs01111177_m1), ELF2 (Hs00959420_g1), GABPA (Hs01022016_m1), 
and GAPDH (cat#4333764) from Life Technologies. siRNA knockdown 
experiments were performed using siRNAs purchased from Dharmacon 
targeting GABPA (D-001810-01-05), ELF1 (L-012669-00-0005), and ELF2 
(L-012754-00-0005). A non-targeting scrambled siRNA was used as the control 
(D-001810-01-05). Gene expression levels of TERT, ELF1 and ELF2 were 
normalized to GAPDH. Allele specific TERT expression was determined using 
an allelic discrimination TaqMan assay for rs2736098 (assay C_26414916_20, 
Life Technologies), and the gene expression of each allele of TERT was also 
normalized to the gene expression of GAPDH. Each experiment was performed 
in triplicate and repeated three times. 
For SDHD mutations, pools of 4 siRNAs each respectively targeting one 
transcription factor gene (ELF1, PRDM1, IRF4, GABPA and GABPB1), as 
well as a non-specific control siRNA, were purchased from GE Dharmacon. 
siRNAs were transfected into human melanoma cell lines using Lipofectamine 
RNAiMAX (Life Technologies). At day 2-7 following transfection, total RNA 
was extracted from cells using RNeasy Minikit (Qiagen), followed by cDNA 
synthesis (iScript™ cDNA Synthesis Kit; BioRad, Hercules, CA). Quantitative 
real-time PCR was performed using Taqman assays (Invitrogen, Carlsbad, 
CA). GAPDH served as an internal control. For western blot analysis, total 
cell lysates were generated with RIPA (Thermo Scientific, Pittsburgh, PA) and 
subjected to water bath sonication. Samples were resolved by 4-12% Bis-Tris 
ready gel (Invitrogen) electrophoresis. The primary antibodies used were rabbit 
anti-SDHD (ab189945, Abcam), rabbit anti-GABPA (ABE1047, Millipore), 
mouse anti-GABPB1 (sc271571, Santa Cruz Biotechnology), and mouse anti-
b-actin (A5316, Sigma-Aldrich). 
Melanoma sequencing datasets
Melanoma whole-exome sequencing (WES) or whole-genome sequencing 
(WGS) datasets (BAM files) were downloaded from CGHub (https://cghub.
ucsc.edu) for TCGA SKCM samples (n=470; http://cancergenome.nih.gov)4, 
or dbGaP (http://www.ncbi.nlm.nih.gov/gap)  for Broad Institute3 and Yale7,8 
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datasets (Broad, n=122, phs000452.v1.p1; Yale, n=213, phs000933.v1.p1). 
TCGA mRNA expression data was downloaded from cBioPortal (http://www.
cbioportal.org; RNA Seq V2 RSEM)46.  We additionally collected exome 
sequencing data from previously published47 (n=44; European Nucleotide 
Archive, PRJEB11984) and 55 additional melanoma cell lines (obtained from 
the University of Arizona Cancer Center in 2007; UACC). Cell lines were 
initially characterized via Sanger sequencing of 10 melanoma driver genes, re-
authenticated via exome sequencing (cells were simultaneously microsatellite 
profiled at that time, 2012; AmpFLSTR Identifiler, ThermoFisher) and re-
authenticated via microsatellite profiling immediately prior to functional 
experiments described below (2016). Reads for all samples were aligned to the 
human genome (hg19) with the Burrows-Wheeler Aligner (BWA 0.6.2)48 and 
processed with the Genome Analysis Toolkit (GATK 2.3)49,50 including local 
realignment and base quality recalibration.
SDHD promoter mutation identification
We applied a pipeline utilizing bam files to all WGS/WES data in this 
study. SDHD promoter regions were defined as being 0-500 bp upstream in 
RefGene (http://genome.ucsc.edu/cgiDbin/hgTables). bam-readcount was used 
to count bases51, and the following criteria was applied to identify recurrent 
promoter mutations: (1) mutation was only found in tumors; (2) sequencing 
depth for each mutation location was greater than 6; (3) alternative base count 
was greater than 2; (4) average mapping quality of each mutation location 
was greater than 20; (5) average base quality of each mutation location was 
greater than 20. Cell line mutations were validated by Sanger sequencing on a 
3730xl DNA analyzer (ABI) (primers, F: TCCGCCATTGTTCGCCTC and R: 
CTCCAGAGAACCGCCATCTC), with forward and reverse traces analyzed 
using Mutation Surveyor (SoftGenetics). Expression correlation and statistical 
tests were performed using R (https://www.r-project.org). 
Motif analysis
Prediction of mutation effects on transcription factor binding sites was 
performed using the motifbreakR package52 and a comprehensive collection of 
human transcription factor binding sites models (HOCOMOCO)53. We applied 
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the information content algorithm as the method, and used a threshold of 0.0001 
as the maximum P-value for a transcription binding site match in motifbreakR.
SDHD promoter luciferase reporter assays
Five luciferase constructs for SDHD mutations (wild-type, C523T, 
C524T, C541T and C544T) were generated to containing 163bp 
of the genomic sequence surrounding SDHD promoter mutations 
(Chr11: 111,957,437-111,957,599). The fragment was PCR-amplified 
(primers, F: CTGAACTctcgagCTCCGCCATTGTTCGCCTC, R: 
GTCACTGTagatctACCCGGAACCACTTAGGCGAC) from genomic DNA 
purified from cells harboring wild-type and mutant SDHD promoter, sub-
cloned into pGL4.23[luc2/minP] (Promega) luciferase vector, and constructs 
sequence-verified. Constructs were co-transfected with pGL4.74 (renilla 
luciferase) into human melanoma cell lines using Lipofectamine 2000 (Life 
Technologies). Cells were collected 24 hrs after transfection and luciferase 
activity was measured using the Dual-Luciferase reporter system (Promega) on 
GLOMAX Multi Detection System (Promega).
Results
ELF1 binds specifically to both TERT promoter mutations
We used an AP-MS/MS based workflow to identify the proteome-wide 
interactomes of both TERT promoter mutations. Oligo baits were designed 
to encompass both mutation sites concurrently, with one mutation per oligo 
(Fig 1A). For AP-MS/MS analysis, we used UACC903 metastatic melanoma 
derived cell lines, characterized as C228T-positive. We identified ELF1 and 
ELF2 as specific interactors at both the C228T and C250T mutation sites and 
ETV6 as a specific interactor at the C250T mutation site (Fig. 1B, 1E). We 
confirmed the specificity and robustness of the ELF1 interaction via bandshift 
with recombinant protein (Fig. 1C, 1F).  JASPAR in silico motif prediction 
agrees with mutation specific binding for ELF1 and GABPA (Fig. 1D, 1G) 
54,55. However, we did not observe a specific GABP interaction with either 
TERT promoter mutation by MS analysis. Intriguingly, band-shift experiments 
using pure, recombinant GABP revealed a subtle preference for the C228T and 
C250T mutations over the wild-type sequence (Fig. 1C, 1F). This potentially 
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Figure 1.  AP-MS/MS identifies TERT promoter mutation specific interactors
A Custom oligos were 5’ biotinylated and designed to cover both the C228T and C250T mutation 
sites. Oligos are referred to by mutation as shown in the diagram. 
B AP-MS/MS analysis of the C228T TERT promoter mutation interactors. Interactors with a ratio 
of at least 3 IQR (inter-quartile range) in both experiments are colored in red.  Ratios are shown 
after log2 transformation. Labels were swapped between replicates to avoid labeling bias, hence 
specific interactors showing a high ratio in one experiment, and a low ratio in the other.  Outlier 
proteins not observed consistently across experiments are noted at the bottom of the chart.  
C Band-shift experiments with the C228T TERT promoter mutation oligo.  Recombinant human 
protein was incubated with annealed oligo and resolved on a TBE polyacrylamide gel. Band-
shift experiments for each protein-oligo combination were resolved on the same gel at the same 
exposure. 
D JASPAR motif prediction agrees with mutation specific ELF1 and GABPA binding at C228T 
54,55. The underlying wild-type sequence surrounding the C228T mutation is shown beneath the 
JASPAR motifs, and the mutation is indicated by arrow. 
E AP-MS/MS analysis of C250T TERT promoter mutation interactors. 
F Band-shift experiments with the C250T TERT promoter mutation oligo and recombinant human 
protein.  
G JASPAR motif prediction agrees with mutation specific ELF1 and GABPA binding at C250T. 
The underlying wild-type sequence surrounding the C250T mutation is indicated below the 
JASPAR motifs as in E).
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indicates that the stabilizing effect of a single mutation (and thus a single 
canonical motif) is sufficient to relatively increase recombinant GABP binding 
in vitro. Indeed, comparison between previous GABP electrophoresis analysis 
and TERT promoter bandshift experiments suggests that the low-mobility 
complex we observed is indeed the GABPA/B heterotetramer 56. However, 
GABP concentrations in nuclear lysates are likely far lower than those used in 
bandshift experiments, which explains why GABP was not identified by AP-
MS/MS Our data thus suggests that ELF1 is a significant, specific interactor 
of single ETS motifs created by recurrent mutations in the TERT promoter. 
However, TERT promoter mutation-specific GABP binding at single novel 
ETS motifs, while present, appears to be of lower affinity.
GABP binding at novel and native ETS motifs excludes ELF1 and 
activates TERT expression
To resolve the discrepancy between ELF1 binding at TERT promoter 
mutations in vitro and its lack of transcriptional effect in vivo, we again 
performed AP-MS/MS analysis of TERT promoter mutations, utilizing the 
C228T mutation with two upstream native ETS motifs as a representative case 
(Fig. 2A)29. This oligo design facilitated study of combinatorial binding with 
novel and native ETS motifs. Indeed, recent work indicates that in the case of 
250T, GABP still binds using ETS-195 and ETS-200 instead of upstream ETS 
motifs 29. These native motifs (ETS-195, ETS-200) represent a different spatial 
architecture with either C228T or C250T compared to C228T and C250T with 
each other, which likely has implications for the mutual exclusivity of C228T 
and C250T mutations in vivo. For C228T+ETS, we observed robust and specific 
binding of GABP by MS analysis, and we could confirm the relative specificity 
of this binding by band-shift assay (Fig 2B, 2C).   
We observed increased GABP binding concurrent with a reduction in 
specific ELF1 and ELF2 binding; indeed, neither reached significance at 
thresholds chosen in our previous analysis. By competition band-shift assay, 
we were able to directly compare ELF1 and GABP binding using both the 
C228T and the C228T+ETS oligos. With the C228T oligo, we observed 
relatively higher ELF1 binding compared with GABP in equimolar conditions 
(Fig 2D). However, with the C228T+ETS oligo, we observed increased binding 
for GABP in equimolar conditions (Fig. 2E). This supports our MS analysis 
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C228T and the C228T+ETS oligos. With the C228T oligo, we observed 
relatively higher ELF1 binding compared with GABP in equimolar conditions 
(Fig 2D). However, with the C228T+ETS oligo, we observed increased binding 
for GABP in equimolar conditions (Fig. 2E). This supports our MS analysis 
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indicating that heterotetrameric GABP binding excludes ELF1 by occupying 
both the native and the novel ETS motifs present in this sequence.  This further 
indicates that the stabilizing effect of a single TERT promoter mutation, in 
conjunction with binding at native ETS motifs present in C228T+ETS recruits 
GABP binding more robustly than does C228T or C250T. Furthermore, by 
western blot we were able to support our MS and band-shift data, showing 
increased ELF1 binding over wild-type at the C228T, C250T, and to a lesser 
extent the C228T+ETS sequences, and increased GABP binding over wild-type 
at the C250T and C228T+ETS sequences but not the C228T sequence (Fig. 
2F). This strongly indicates that the GABP binding observed at C228T+ETS 
critically depends on the native ETS motif, as no specific binding is seen at 
C228T. Also, preferential binding at C250T but not C228T, suggests GABP 
binding at 228T versus C250T might operate under different kinetics 29,57. 
To study the relationship between GABP, ELF1, and ELF2 binding and 
TERT expression in vivo, we used a PCR-based Sanger sequencing approach 
to identify seven melanoma cell lines with both a heterozygous germline SNP 
variant (rs2736098) and a haplotype-phased heterozygous TERT promoter 
mutation. In these cell lines, we observed mono-allelic TERT expression in 
which the expressed SNP allele always correlated with a phased TERT promoter 
mutation (Fig. 3A). Then, we used siRNA-mediated knockdown to discern the 
direct transcriptional effects of ELF1/2 and GABPA on TERT expression. In 
two separate cell lines, we observed a substantial reduction in TERT expression 
upon GABPA knockdown but only minimally reduced TERT expression upon 
combined ELF1/2 knockdown (Fig. 3B, 3C). Thus, this data strongly indicates 
that TERT reactivation proceeds via mono-allelic TERT expression exclusive to 
the promoter mutation phased chromosome. Upon displacement of minimally 
activating ELF1 or ELF2, GABP binding induces a robust transcriptional 
response driving TERT expression. This study suggests a model where binding 
of heterotetrameric, transcriptionally active GABP at novel and native ETS 
motifs effectively precludes ELF1 occupancy at the TERT promoter mutations 
(Fig. 4). 
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Figure 2. Heterotetrameric GABP excludes ELF1 from TERT promoter mutation 
binding
A Oligos were designed as before, but encompassing the C228T mutation plus two additional 
upstream ETS motifs. 
B  AP-MS/MS analysis of the C228T+ETS interactors. ELF1 and ELF2 were not significant at a 3 
IQR cutoff, but were noted specifically for comparison to GABPA and previous binding ratios.
C Band-shift experiments with the C228T+ETS TERT promoter mutation oligo. The grey line in 
the ELF1 band-shift indicates re-positioning of lanes; all lanes were run on the same gel, and 
exposures were kept uniform.  
D Competitive binding experiments between recombinant human ELF1 and GABP at the C228T 
TERT promoter mutation oligo. 
E Competitive binding experiments between recombinant human ELF1 and GABP at the 
C228T+ETS TERT promoter mutation oligo. 
F Western blot analysis of GABPA and ELF1 for each oligo used in this study. All lanes are taken 
from the same gel at the same exposure.
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UACC2331 <0.01 C - +
Figure 3. GABP activates mono-allelic TERT expression via promoter mutations
A TERT expression is mono-allelic and correlates with promoter mutation status. Mono-allelic 
TERT expression was assayed at rs2736098. Expression of only one allele was observed. The 
expressed allele correlated with a phased TERT promoter mutation as observed by PCR-based 
Sanger sequencing. 
B In the UACC903 melanoma cell line, GABPA knockdown substantially reduces TERT 
expression, while combined ELF1/2 knockdown minimally reduces TERT expression. 
Experiments were performed in triplicate and repeated three times. Error bars represent standard 
error of the mean. 
C In the UACC1113 melanoma cell line, GABPA knockdown substantially reduces TERT 
expression, while combined ELF1/2 knockdown minimally reduces TERT expression.
Identification of SDHD promoter mutations in multiple melanoma 
sequencing studies
Like TERT, though at much lower frequency, SDHD promoter mutations 
have previously been reported to show an ETS-family specific mutational 
signature in melanoma. In order to investigate SDHD promoter mutations in 
publicly available melanoma sequencing data, we downloaded WES data for 
the three largest melanoma sequencing studies (TCGA SKCM=470, Broad=122 
and Yale=213), high coverage WGS data for TCGA SKCM data (n=40) from 
CGHub and dbGaP, and supplemented with WES data generated from a panel 
of melanoma cell lines (n=99). This sample size here (n=904) was considerably 
larger than the original SDHD promoter mutation study reported by Weinhold 
and colleagues (17 whole-genomes, 128 whole-exomes; TCGA). We searched 
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this larger dataset for somatic mutations within the SDHD promoter and 
5’UTR (hg19 Chr11:111,957,493-111,957,631). Within the TCGA dataset, 
five recurrent mutations were identified, including the three (C523T, C541T, 
C544T) reported by Weinhold and colleagues, as well as two additional 
mutations (C532A, C548T; Fig. 5). Analysis of the larger combined dataset 
identified a total of ten mutations observed in more than one melanoma sample, 
with all but one (C532A) found in multiple datasets; mutations observed in 
cell lines (seven mutations in eight cell lines) were all confirmed via Sanger 
sequencing (Supplementary Fig. S1 and data not shown). The overall frequency 
of all SDHD promoter mutations was 5% (46/904, Supplementary Table S1), 
consistent with previous reports. The most frequently observed mutations 
(C523T, C544T, C541T, C524T) all are predicted to disrupt consensus ETS 
transcription factor binding sites, and were thus chosen to further investigate 
the mutational consequence in melanoma. 
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A
Figure 4. A model for ELF1 exclusion by heterotetrameric GABP at TERT promoter 
mutations
ELF1 binds in vitro at novel ETS motifs created by TERT promoter mutations. However, GABP 
binds with high affinity at novel and native ETS motifs and excludes ELF1 from binding.
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TGCACCGCCTCTCGAC TTCC GGTTCACCCAGCAT TTCC TCTTCC CTGTTTTCTTTCG...TGGTTCCGGGT...GAACGAG ATG...
TGCACCGCCTCTCGAC TTCC GGTTCACCCAGCAT TTCC TCTTCC CTGTTTTCTTTCG...TGGTTCCGGGT...GAACGAG ATG...
TGCACCGCCTCTCGAC TTCC GGTTCACCCAGCAT TTCC TCTTCC CTGTTTTCTTTCG...TGGTTCCGGGT...GAACGAG ATG...
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TGCACCGCCTCTCGAC TTCC GGTTCACCCAGCAT TTCC TCTTCC CTGTTTTCTTTCG...TGGTTCCGGGT...GAACGAG ATG...
Figure 5
Figure 5. SDHD promoter mutation identification in multiple melanoma tumors datasets 
and cell lines.
The frequencies of SDHD promoter mutations are identified from whole-genome and –exome 
sequencing data of 470 TCGA SKCM, 213 Yale, and 122 Broad melanoma tumors, as well as 
99 melanoma cell lines. Most recurrent mutations (colored in red) within each dataset are located 
within or adjacent to three consensus ETS transcription binding motifs (“TTCC”, colored in green).
Allele-specific gene regulatory potential for SDHD hotspot promoter 
mutations
To investigate the correlation between SDHD promoter mutations and SDHD 
mRNA expression in melanoma, we downloaded mRNA expression data for 
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TCGA SKCM samples from cBioPortal (RNA-Seq V2 RSEM, n=470). Several 
of the hotspot SDHD promoter mutations found in this dataset are predicted 
to disrupt consensus ETS transcription factor binding sites, and thus might be 
expected to result in reduced SDHD gene expression.  Considering samples that 
are copy-neutral at the SDHD locus, we observed significantly lower SDHD 
expression in those harboring the most common (C523T) mutation relative to 
wild-type samples (one-tailed student’s t-test, P = 5.97 x 10-4, Benjamini & 
Hochberg adjusted P = 0.002, Fig. 2A). Despite small sample numbers, we 
also observed decreased expression for C541T (P = 0.013; adjusted P = 0.026), 
however differences for C548T (P = 0.050; adjusted P = 0.066) and C544T 
(adjusted and unadjusted P = 0.050) were not significant after adjusting for 
multiple testing (C532A was unassessable, n=1). Considering all samples 
without regard to copy number, we also observed significantly lower expression 
in samples with the C523T mutation relative to wild-type (one-tailed student’s 
t-test, P = 0.014, adjusted P = 0.041; Supplementary Fig. S2). 
To further evaluate the functional consequences of SDHD promoter 
mutations on SDHD expression, we next performed luciferase reporter assays. 
We cloned the four most common hotspot promoter mutations occurring within 
or immediately adjacent to conserved ETS motifs (“TTCC”; C523T, C524T, 
C541T, and C544T) and wild-type promoter sequence into a luciferase vector. 
We tested these constructs in multiple cell lines that varied in terms of both 
SDHD promoter mutation status (C021, C541T and C517T; C077, C541T 
and C544T; UACC1113, WT; and UACC903, WT) and relative endogenous 
expression of SDHD (higher expression in C021 and UACC1113; relatively low 
levels in C077 and UACC903). Compared to the promoterless vector, the wild-
type vectors exhibited strongly increased luciferase activity in all four cell lines 
(Fig. 6B and Supplementary Fig. S3). C523T and C524T resulted in significant 
reductions of reporter expression across all four cell lines (two-tailed student’s 
t-test P-value ranged from 4.35 x 10-11 to 9.37 x 10-07 and 4.17 x 10-10 to 3.60 
x 10-04, respectively. Fig. 6B). The C544T mutation, which occurs directly 
adjacent to a “TTCC” sequence (CTTCC>TTTCC), resulted in a significant 
reduction of reporter expression in three cell lines (two-tailed student’s t-test: 
UACC1113, P = 0.043; C021, P = 6.30 x 10-06; UACC903, P = 0.01), whereas 
C541T showed significant reductions in two of the four cell lines tested 
(two-tailed student’s t-test: UACC1113, P = 0.0053; C021, P = 2.86 x 10-05). 
15609_M-Makowski_BNW.indd   56 11-06-18   14:29
Chapter 2
56
TCGA SKCM samples from cBioPortal (RNA-Seq V2 RSEM, n=470). Several 
of the hotspot SDHD promoter mutations found in this dataset are predicted 
to disrupt consensus ETS transcription factor binding sites, and thus might be 
expected to result in reduced SDHD gene expression.  Considering samples that 
are copy-neutral at the SDHD locus, we observed significantly lower SDHD 
expression in those harboring the most common (C523T) mutation relative to 
wild-type samples (one-tailed student’s t-test, P = 5.97 x 10-4, Benjamini & 
Hochberg adjusted P = 0.002, Fig. 2A). Despite small sample numbers, we 
also observed decreased expression for C541T (P = 0.013; adjusted P = 0.026), 
however differences for C548T (P = 0.050; adjusted P = 0.066) and C544T 
(adjusted and unadjusted P = 0.050) were not significant after adjusting for 
multiple testing (C532A was unassessable, n=1). Considering all samples 
without regard to copy number, we also observed significantly lower expression 
in samples with the C523T mutation relative to wild-type (one-tailed student’s 
t-test, P = 0.014, adjusted P = 0.041; Supplementary Fig. S2). 
To further evaluate the functional consequences of SDHD promoter 
mutations on SDHD expression, we next performed luciferase reporter assays. 
We cloned the four most common hotspot promoter mutations occurring within 
or immediately adjacent to conserved ETS motifs (“TTCC”; C523T, C524T, 
C541T, and C544T) and wild-type promoter sequence into a luciferase vector. 
We tested these constructs in multiple cell lines that varied in terms of both 
SDHD promoter mutation status (C021, C541T and C517T; C077, C541T 
and C544T; UACC1113, WT; and UACC903, WT) and relative endogenous 
expression of SDHD (higher expression in C021 and UACC1113; relatively low 
levels in C077 and UACC903). Compared to the promoterless vector, the wild-
type vectors exhibited strongly increased luciferase activity in all four cell lines 
(Fig. 6B and Supplementary Fig. S3). C523T and C524T resulted in significant 
reductions of reporter expression across all four cell lines (two-tailed student’s 
t-test P-value ranged from 4.35 x 10-11 to 9.37 x 10-07 and 4.17 x 10-10 to 3.60 
x 10-04, respectively. Fig. 6B). The C544T mutation, which occurs directly 
adjacent to a “TTCC” sequence (CTTCC>TTTCC), resulted in a significant 
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UACC1113, P = 0.043; C021, P = 6.30 x 10-06; UACC903, P = 0.01), whereas 
C541T showed significant reductions in two of the four cell lines tested 
(two-tailed student’s t-test: UACC1113, P = 0.0053; C021, P = 2.86 x 10-05). 
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Figure 6. SDHD expression difference in SDHD copy-neutral melanomas harboring 
promoter mutations compared to wild-type samples. 
A SDHD mRNA expression is significantly decreased in TCGA SKCM samples harboring the 
C523T and C541T mutations relative to wild-type samples. 
B SDHD promoter activity is significantly decreased by SDHD hotspot mutation (C523T and 
C524T). A 163-bp fragment from the wild-type SDHD promoter sequence surrounding hotspot 
mutations significantly enhance luciferase reporter expression relative to vector control, 
whereas the same fragment containing hotspot mutations decrease promoter activity relative 
to the wild-type sequence. Fold change over minimal promoter control (vector only) is plotted 
as relative luciferase activity. The experiment was performed four times with triplicates for 
each. Stars denote significant differences in luciferase activity by two-tailed student’s t-test (*: 
P-value <0.05; **: P-value <0.01; ***: P-value <0.001).
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Figure 6. SDHD expression difference in SDHD copy-neutral melanomas harboring 
promoter mutations compared to wild-type samples. 
A SDHD mRNA expression is significantly decreased in TCGA SKCM samples harboring the 
C523T and C541T mutations relative to wild-type samples. 
B SDHD promoter activity is significantly decreased by SDHD hotspot mutation (C523T and 
C524T). A 163-bp fragment from the wild-type SDHD promoter sequence surrounding hotspot 
mutations significantly enhance luciferase reporter expression relative to vector control, 
whereas the same fragment containing hotspot mutations decrease promoter activity relative 
to the wild-type sequence. Fold change over minimal promoter control (vector only) is plotted 
as relative luciferase activity. The experiment was performed four times with triplicates for 
each. Stars denote significant differences in luciferase activity by two-tailed student’s t-test (*: 
P-value <0.05; **: P-value <0.01; ***: P-value <0.001).
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These data are consistent with an interpretation that these mutations result in 
reduced levels of SDHD gene expression, while suggesting a potentially larger 
effect for the more commonly observed C523T mutation as well as the adjacent 
C524T mutation.
Effects of SDHD promoter mutations on ETS transcription factor 
binding
To predict mutational effects on transcription factor binding sites in the SDHD 
promoter, we performed motif analyses for the four most common recurrent 
mutations that occurred within or directly adjacent to a “TTCC” motif: C523T, 
C524T, C541T and C544T. As expected, the C523T mutation was predicted to 
disrupt multiple transcription factor binding sites, 13/16 of which were ETS 
transcription factor binding sties (TTCC >TTTC). We observed the same effect 
for the C524T mutation. These mutations were predicted to have the strongest 
effect on GABPA binding (Altscore-Refscore -2.0 and P-value increased from 
6.68 x 10-6 to 4.25 x 10-3 for both C523T and C524T, Fig. 7 and Supplementary 
Table S2), as well as a weaker effect on binding of ELF1 (Altscore-Refscore 
-1.88 and P-value increased from 3.35 x 10-6 to 7.43 x 10-4 for both C523T and 
C524T). In contrast, the C541T mutation both created and altered consensus 
motifs with strongest effect on PRDM1 binding (Supplementary Fig. S4A), 
while C544T was predicted to only create new motifs with strongest effect on 
IRF4 binding (Supplementary Fig. S4B). 
We subsequently used the TCGA SKCM gene expression dataset to evaluate 
the correlation between gene expression of predicted ETS transcription factors 
and SDHD, in both SDHD wild-type samples and samples bearing SDHD 
promoter mutations. Of the 13 ETS transcription factors for which binding 
sites are predicted to be altered by the C523T mutation, only expression 
levels of ELF1, GABPA, GABPB1, and GABPB2 were significantly positively 
correlated with SDHD mRNA levels in the subset of samples wild-type for the 
SDHD promoter (Fig. 8A and Supplementary Fig. S5). Among them, ELF1 
and GABPA were the two most significantly correlated transcription factors, 
with Pearson correlation coefficients of 0.46 (P = 4.40 x 10-8) and 0.42 (P = 
8.57 x 10-7), respectively (Fig. 8B and 8C); there was a non-significant trend 
towards correlation between expression levels of GABPA and SDHD in samples 
harboring the C523T mutation (Pearson correlation coefficient 0.45, P = 0.17) 
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with Pearson correlation coefficients of 0.46 (P = 4.40 x 10-8) and 0.42 (P = 
8.57 x 10-7), respectively (Fig. 8B and 8C); there was a non-significant trend 
towards correlation between expression levels of GABPA and SDHD in samples 
harboring the C523T mutation (Pearson correlation coefficient 0.45, P = 0.17) 
15609_M-Makowski_BNW.indd   58 11-06-18   14:29
        
2Recurrent promoter mutations at TERT and SDHD
59
but not ELF1 (Pearson correlation coefficient -0.03, P = 0.92). Significant 
correlations were not identified between the expression of SDHD and other 
transcription factors whose binding sites were predicted to be disrupted 
specifically by the C541T, C544T, as well as several other mutations in SDHD 
promoter wild-type TCGA SKCM samples (data not shown). In summary, 
these data are consistent with a potential role for GABPA, ELF1 and/or other 
ETS transcription factors in mediating SDHD expression. 
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Figure 7. Predicting SDHD promoter mutation effects on transcription factor binding 
sites. 
Data are shown for A) the C523T mutation and B) the C524T mutation. Genomic sequence and 
coordinates are at the bottom of the display; the positions of the matches represented (light blue 
boxes). The position of the mutation within the motif is indicated by a red-bounding box, with the 
alternate allele below in red font as on the motif logo position bar above. The motif logos generated 
from motifstack are shown above using the color conventions of the genomic sequence below. 
Predicted transcription factor name and change score (Alterscore-Refscore) are shown to the right of 
each motif, and the transcription factor with the strongest score is highlighted in red font. Mutations 
leading to predicted disruption of transcription factor binding have negative change scores, while 
those creating new transcription factor binding sites will have a positive change scores. 
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Figure 7. Predicting SDHD promoter mutation effects on transcription factor binding 
sites. 
Data are shown for A) the C523T mutation and B) the C524T mutation. Genomic sequence and 
coordinates are at the bottom of the display; the positions of the matches represented (light blue 
boxes). The position of the mutation within the motif is indicated by a red-bounding box, with the 
alternate allele below in red font as on the motif logo position bar above. The motif logos generated 
from motifstack are shown above using the color conventions of the genomic sequence below. 
Predicted transcription factor name and change score (Alterscore-Refscore) are shown to the right of 
each motif, and the transcription factor with the strongest score is highlighted in red font. Mutations 
leading to predicted disruption of transcription factor binding have negative change scores, while 
those creating new transcription factor binding sites will have a positive change scores. 
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Figure 8. mRNA expression correlation between SDHD and multiple ETS transcription 
factors in SDHD promoter wild-type TCGA SKCM samples. 
A Pearson correlation of mRNA expression between SDHD and 16 ETS transcription factors 
predicted by motifbreakR. Significant Pearson correlations are denoted with one or more star 
(*: P-value <0.05; **: P-value <0.01; ***: P-value <0.001). 
B-C SDHD mRNA expression is highly correlated with B) GABPA and C) ELF1 mRNA expression 
specifically in SDHD promoter wild-type SKCM samples. 
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Figure 8. mRNA expression correlation between SDHD and multiple ETS transcription 
factors in SDHD promoter wild-type TCGA SKCM samples. 
A Pearson correlation of mRNA expression between SDHD and 16 ETS transcription factors 
predicted by motifbreakR. Significant Pearson correlations are denoted with one or more star 
(*: P-value <0.05; **: P-value <0.01; ***: P-value <0.001). 
B-C SDHD mRNA expression is highly correlated with B) GABPA and C) ELF1 mRNA expression 
specifically in SDHD promoter wild-type SKCM samples. 
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Identification of GABPA and GABPB1 as proteins preferentially binding 
the wild-type SDHD promoter by quantitative mass spectrometry 
To perform an unbiased search for protein-DNA interactions specifically 
altered by SDHD promoter mutations, we used previously established workflows 
for AP-MS/MS based identification of sequence specific protein-DNA binding 
on a proteome-wide scale. Oligonucleotide baits were designed to encompass 
four mutation sites (C523T, C524T, C541T, and C544T) concurrently, and each 
oligo contained a mutation at one of these sites (Supplementary Table S3). All 
these mutations were located within the core motif of multiple ETS transcription 
factors as predicted by motifbreakR in silico. AP-MS/MS analysis of DNA 
pulldowns was performed using the metastatic melanoma-derived cell line 
UACC903. Interestingly, we identified components of the GABP transcription 
factor complex, GABPA and GABPB1, as wild-type specific interactors of the 
recurrent (C523T and C524T) SDHD promoter sites (Fig. 9A and 9B). GABP is 
unique amongst the ETS factors in that it alone is an obligate multimeric protein 
complex58-60, where GABPA contains a DNA binding domain, yet the transcriptional 
activation domain is encoded by GABPB genes58,61. In addition, transcription 
factor ETS1 might also specifically interact with the wild-type sequence of both 
C523T and C524T sites, albeit to a lesser degree than GABPA and GABPB1. We 
did not identify any transcription factors specifically interacting with the wild-
type or mutant sequence at mutation sites C541T and C544T (Fig. 9C and 9D). 
To further confirm specific GABPA/GABPB1 binding at wild-type SDHD 
promoter mutation sites, we performed band-shift analysis of recombinant 
protein-DNA interactions using the same oligos previously used for AP-MS/
MS analysis and recombinant human GABP or ELF1. Consistent with our 
results from AP-MS/MS analysis, we observed a specific and robust interaction 
of GABP (GABPA/B1 combined) at both the melanoma-specific C523T and 
C524T mutation sites via band-shift with recombinant protein (Fig. 9E and 9F). 
Intriguingly, band-shift experiments also revealed a present but relatively lower 
preference for the wild-type over the C541T and C544T mutated sequence (Fig. 
9G and 9H). In addition, the band-shift experiments using recombinant ELF1 
also suggested a slight preference for the wild-type sequence at C523T and 
C524T, especially at lower concentration (Supplementary Fig. S6). These data 
suggest that the transcription factors GABPA and GABPB1 specifically bind to 
the wild-type SDHD promoter sequence at the C523 and C524 sites, with this 
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Figure 9. AP-MS/MS identifies allele-specific protein-DNA interactions for hotspot 
SDHD promoter mutations. 
Custom oligos were 5’-biotinylated and designed to cover all analyzed mutation sites in the 
SDHD promoter as indicated in (Supplemental Table S3). Each mutation site was analyzed by 
two independent label-swapped experiments. ELF1, GABPA, and GABPB1, if not observed as 
significant interactors, are colored in yellow in the background cloud and noted by name. 
A AP-MS/MS analysis of the C523T SDHD promoter mutation interactors. Interactors with 
a ratio of at least 3 IQR (inter-quartile range) in both replicate experiments are colored in 
red. Ratios are shown after log2 transformation. Labels were swapped between replicates to 
avoid labeling bias, hence specific interactors show a high ratio in one experiment and a low 
ratio in the other. 
B AP-MS/MS analysis of the C524T SDHD promoter mutation interactors. 
C AP-MS/MS analysis of the C541T SDHD promoter mutation interactors. 
D AP-MS/MS analysis of the C544T SDHD promoter mutation interactors. E-H) band-shift 
experiments confirm SDHD WT-specific GABP binding at C523T and C524T mutation 
sites, but not C541T or C544T. Oligos were shifted using recombinant human protein as 
described in the materials and methods. 
E band-shift analysis with the C523T SDHD promoter mutation oligo and recombinant human 
GABP (GABPA and GABPB1) protein. Band-shift experiments for each protein-oligo 
combination were resolved on the same gel at the same exposure. The grey line indicates 
where a single lane was cropped out for clarity. 
F-H band-shift analysis with F) C524T G) C541T and H) C544T SDHD promoter mutation 
oligonucleotides and recombinant human GABP protein.
Regulation of SDHD expression by GABPA and GABPB1 
To validate the potential regulation of SDHD expression by the ETS 
transcription factors GABPA, GABPB1, and ELF1, we knocked down 
the expression of these factors via siRNA in multiple melanoma cell lines 
(UACC903, UACC1113 and C021). Consistent with a role for GABPA in 
regulating SDHD expression, we observed that depletion of GABPA resulted 
in significantly lower mRNA expression of SDHD in all three of the cell 
lines tested five days following siRNA transfection, with average normalized 
expression of 0.50 relative to a scrambled siRNA control (range 0.37 - 0.71; Fig. 
10A). In contrast, we did not detect a consistent effect of GABPB1 depletion 
on levels of SDHD mRNA (Fig. 10B); while depletion of GABPB1 resulted in 
a subtle reduction of SDHD expression in UACC903, GABPB1 knockdown 
had the opposite effect in UACC1113. These data suggest that although 
GABPB1 was identified as a protein binding preferentially to the wild-type 
SDHD promoter, other proteins may compensate for the loss of GABPB1, 
and a GABP complex specifically composed of both GABPA and GABPB1 
may not be the sole GABP complex regulating SDHD. Intriguingly, we found
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Figure 10
Figure 10. siRNA-mediated knockdown of GABPA and GABPB1 deregulates SDHD 
expression in melanoma cells. 
A GABPA depletion decreases SDHD and increases GABPB1 expression in three melanoma cell 
lines (UACC1113, UACC903, and C021).
B GABPB1 depletion increases GABPA expression in three melanoma cell lines (UACC1113, 
UACC903 and C021), but has little effect on SDHD levels. 
C concomitant depletion of both GABPA and GABPB1 decreases SDHD expression in both 
UACC1113 and UACC903 cell lines.
that depletion of either GABPA or GABPB1 resulted in an increase in mRNA 
levels of the other (Fig. 10A and 10B), raising the possibility that any effect of 
GABPB1 depletion on SDHD expression could have been masked by increased 
levels of GABPA. Further, concomitant depletion of both transcription factors 
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result in a consistent decrease of SDHD at both the mRNA (Fig. 10C). In 
contrast, depletion of ELF1 had no effect when tested in multiple cell lines 
(Supplementary Fig. S7). Knockdown of PRDM1 and IRF4, whose motifs are 
created by C541T and C544T mutations, respectively, resulted in varied but 
considerably lesser effects on SDHD expression across multiple cell lines than 
did depletion of GABPA (Supplementary Fig. S8A); luciferase reporter assays 
following knockdown of both genes suggested no change in expression for 
either mutation relative to that of wild-type (Supplementary Fig. S8B). Taken 
together, these data establish GABP as a major transcriptional regulator of 
SDHD.
Discussion
Understanding dynamic, specific interactions between transcription factors 
and the cognate DNA motifs they bind is crucial towards elucidating their 
mechanisms of transcriptional regulation. For TERT promoter mutations, 
understanding these dynamic binding specificities is of particular importance 
as transcriptional activation is directly correlated with oncogenic outcomes. 
This study utilizes an unbiased proteome-wide approach to identify dynamic 
interplay between GABP and ELF1 via their specific interactions with the 
TERT promoter mutations. This study also highlights the importance of 
considering both native motifs and the spatial architecture of DNA baits when 
performing DNA-protein AP-MS/MS experiments. The combinatorial nature 
of transcription factor binding is often difficult to predict, and this study offers a 
cautionary note that oligo baits of different lengths or different sequence/motif 
compositions might produce discrepant results even for the same locus. Indeed, 
as this study indicates, when using oligos designed to minimally cover a SNP 
or a cancer mutation, biologically important interactions may be overlooked. 
On the other hand, the importance of the super-structure (in terms of motif 
co-occurrence and spatial architecture) of promoter and enhancer elements is 
of growing interest in the study of gene regulatory mechanisms. This study 
shows that in vitro, MS-based approaches can shed light into combinatorial 
interactions between transcription factors that depend intrinsically not only on 
the motif interrupted or created by a variant but also on the presence of local (or 
distal) co-regulatory motifs.
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Although most ETS-transcription factors are reported to bind monomerically, 
cooperative, antagonistic, and combinatorial effects are common62. For example, 
Bell et al. use an elegant bioinformatics analysis to indicate that strong GABPA 
binding sites from ENCODE ChIP-seq tracks correlates with multiple motifs 
spaced in a manner suggesting dimerization29,63. This periodic feature is unique 
to GABPA and was not seen in ELF1 ChIP-seq tracks, suggesting that ELF1 in 
contrast indeed binds monomerically. Indeed, GABP is known to be the only 
obligate multimer among ETS-family transcription factors31,33,34. Intriguingly, 
competitive binding between GABP and another ETS factor, PU.1, has been 
seen at the CD18 promoter, yet this competition cooperatively drives CD18 
expression56. Recent reports have indicated that diverse combinatorial effects are 
crucial in the activating function of the TERT promoter mutations, specifically 
in cooperation with native ETS-motif binding factors29,57. Although our data 
indicates that ELF1 knockdown has only a mild effect on downstream TERT 
expression  (which seems to be driven predominantly by GABP), we cannot 
exclude the possibility of combinatorial effects with ELF1 or other natively 
binding factors in the TERT core promoter. 
This study highlights the dynamic nature of transcription factor binding at 
the recurrent TERT promoter mutations and points towards a complex picture 
of oncogenic transcriptional regulation at this locus. We present a model where 
stable, heterotetrameric, transcriptionally active GABP excludes monomeric 
ELF1 (Fig. 4). In doing so, we confirm the identification of GABP as a TERT 
mutation-specific interactor in melanoma and contribute to our knowledge of 
regulatory mechanisms at this important locus.
Searching for recurrent mutations occurring in a similar ETS-family 
signature context, Weinhold and colleagues reported recurrent SDHD promoter 
mutations in melanoma and reported a correlation between mRNA levels of the 
ETS transcription factor ELF1 and SDHD, suggesting ELF1 as a potential key 
mediator of SDHD expression. By analyzing expression data for multiple ETS 
factors in the updated TCGA SKCM dataset, we observed a positive correlation 
between the levels of SDHD and multiple ETS transcription factors including 
GABPA and ELF1. Consistent with a potential role for GABPA in regulation of 
SDHD, motif analysis of the relatively common C523T and C524T mutations 
revealed that while these mutations indeed alter consensus sequences for 
numerous ETS factors, including ELF1, these mutations are predicted to most 
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strongly disrupt binding of GABPA. Taken together, these data suggest GABPA 
as a potential transcriptional regulator of the SDHD promoter. 
We applied a mass spectrometry-based approach to identify proteins that 
preferentially bind to the wild-type SDHD promoter sequence as compared to 
several of the most commonly recurring promoter mutations (C523T, C524T, 
C541T, and C544T). Consistent with the motif analysis, GABPA was identified 
as a wild-type promoter interacting protein with binding disrupted specifically 
by the C523T and C524T mutations, in addition to GABPB1 and ETS1. In 
contrast, ELF1 did not show significant allele-preferential binding for either 
of these mutations. Nonetheless, both recombinant GABPA/B1 and ELF1 
alone showed considerably decreased binding to oligos containing either of 
these two mutations. Analysis of the C541T and C544T mutations, which 
occur adjacent to or within a different “TTCC” motif, on the other hand, did 
not reveal statistically significant allele-specific binding proteins. Still, both 
mutations exhibited an allelic preference for both recombinant GABPA/
B1 and ELF1, albeit more subtle than that observed for C523T/C524T. The 
differences observed between binding of recombinant proteins and those within 
crude lysates suggest that while both GABPA/B1 and ELF1 show an allelic 
preference for all four mutations, the situation is likely to be considerably more 
complex in melanoma cells. The observed differences may be attributable to 
cooperative and or competitive effects between ETS factors. 
Consistent with a potential role for GABPA in regulation of SDHD, depletion 
of GABPA in melanoma cell lines resulted in decreased SDHD transcription. 
Depletion of GABPB1, on the other hand, did not consistently reduce SDHD 
levels, suggesting that another protein, likely GABPB2, may compensate for 
the loss of GABPB1. In contrast to GABPA, depletion of ELF1 had no effect on 
SDHD levels. In all, these data point to GABPA, but not ELF1, as a key regulator 
of SDHD. Together with recent data supporting a role for GABPA in activating 
TERT in conjunction with recurrent promoter mutations in melanoma, these 
data raise the possibility that creation or alteration of GABPA binding motifs 
may be a more common mutational mechanism with functional consequences 
in melanoma. 
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Supplementary Figure 1. Confirmation of the recurrent C524, C541 and C544 SDHD 
promoter mutations in melanoma cell lines.
Sanger sequencing traces for both forward and reverse reads verify all three recurrent SDHD 
promoter mutation in melanoma cell lines UACC952, C021 and C077.
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Fig	S2
Supplementary Figure 2. SDHD expression difference in melanomas harboring 
promoter mutations compared to SDHD wild-type samples.
SDHD promoter-mutant samples are grouped according to mutation. SDHD expression 
was significantly decreased in the set of tumors harboring the SDHD C523T promoter 
mutation (onetailed student’s t test, P = 0.0135) compared to wild-type samples. “Other 
Hotspot Mutation” includes the SDHD promoter mutations C532A, C541T, C544T and 
C548T, while “Non- Hotspot Mutation” includes SDHD promoter mutations C515T, 
A530G, C531T, C547T and C549T. Copy number for each sample as predicted by 
GISTIC is denoted with different coloring (Purple/-2: homozygous deletion; Red/-1: 
shallow deletion; Green/0: copy-neutral; Blue/1: copy gain; Black/NA: not assessable).
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C548T, while “Non- Hotspot Mutation” includes SDHD promoter mutations C515T, 
A530G, C531T, C547T and C549T. Copy number for each sample as predicted by 
GISTIC is denoted with different coloring (Purple/-2: homozygous deletion; Red/-1: 
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Supplementary Figure 3. SDHD promoter activity is significantly decreased by the 
C541T and C544T SDHD hotspot mutations in multiple melanoma cell lines.
A 163 bp fragment from the wild-type SDHD promoter sequence surrounding hotspot mutations 
significantly enhance luciferase reporter expression relative to vector control, whereas the same 
fragment containing hotspot mutations decrease enhancer activity relative to the wild-type 
sequence. Luciferase activity was measured 24hr after transfection and normalized to Renilla 
luciferase readings. Fold change over minimal promoter control (vector only) is plotted as relative 
luciferase activity. The experiment was performed four times with triplicates for each. Stars denote 
significant differences in luciferase activity by two-tailed student’s t-test (*: P-value <0.05; **: 
P-value <0.01; ***: P-value <0.001).
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luciferase activity. The experiment was performed four times with triplicates for each. Stars denote 
significant differences in luciferase activity by two-tailed student’s t-test (*: P-value <0.05; **: 
P-value <0.01; ***: P-value <0.001).
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Supplementary Figure 4. Predicting SDHD promoter mutation effects on transcription 
factor binding sites.
Data are shown for (A) C541T and (B) C544T. Genomic sequence and coordinates are at the 
bottom of the display; the positions of the matches represented (light blue boxes). The position of 
the mutations within the motif is indicated by a red-bounded box, with the alternate allele below 
in red font as on the motif logo position bar above. The motif logos generated from motfstack are 
shown above using the color conventions of the genomic sequence below. Predicted transcription 
factor name and change score (Alterscore-Refscore) are shown to the right of each motif, and the 
transcription factor with the strongest score is highlighted in red. Mutations leading to disruption 
of transcription factor binding sites have negative change scores, while those creating new 
transcription factor binding sites have positive change scores.
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Supplementary Figure 5. mRNA expression correlation between SDHD and multiple 
ETS transcription factors in TCGA SKCM samples harboring the SDHD C523T 
promoter mutation.
Pearson correlation of mRNA expression between SDHD and 16 transcription factors with 
consensus motifs altered by the C523T mutation as predicted by motifbreakR. Significant Pearson 
correlations are highlighted with one or more star (*: Pvalue <0.05; **: P-value <0.01; ***: P-value 
<0.001).
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Supplementary Figure 5. mRNA expression correlation between SDHD and multiple 
ETS transcription factors in TCGA SKCM samples harboring the SDHD C523T 
promoter mutation.
Pearson correlation of mRNA expression between SDHD and 16 transcription factors with 
consensus motifs altered by the C523T mutation as predicted by motifbreakR. Significant Pearson 
correlations are highlighted with one or more star (*: Pvalue <0.05; **: P-value <0.01; ***: P-value 
<0.001).
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Supplementary Figure 6. Band-shift experiments indicate wild-type specific binding 
of ELF1 to the SDHD promoter.
A Band-shift analysis with the C523T SDHD promoter mutation oligo and recombinant human 
ELF1 protein. 
B Band-shift analysis with the C524T SDHD promoter mutation oligo and recombinant human 
ELF1 protein. 
C Band-shift analysis with the C541T SDHD promoter mutation oligo and recombinant human 
ELF1 protein. 
D Band-shift analysis with the C544T SDHD promoter mutation oligo and recombinant human 
ELF1 protein.
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ELF1 protein. 
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ELF1 protein. 
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ELF1 protein.
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Supplementary Figure 7. siRNA-mediated knockdown of ELF1 does not lead to 
decreased SDHD expression in melanoma cells.
Control siRNA or siRNAs targeting ELF1 were transfected into cells, and expression of ELF1 and 
SDHD were assayed by Taqman assays at day 5 following transfection. Data are shown for two 
melanoma cell lines, A) UACC903 and B) UACC1113.
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decreased SDHD expression in melanoma cells.
Control siRNA or siRNAs targeting ELF1 were transfected into cells, and expression of ELF1 and 
SDHD were assayed by Taqman assays at day 5 following transfection. Data are shown for two 
melanoma cell lines, A) UACC903 and B) UACC1113.
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Supplementary Figure 8. Effects of siRNA-mediated knockdown of PRDM1 or IRF4 
on SDHD expression and SDHD promoter activity in melanoma cells.
A Depletion of PRDM1 or IRF4 resulted in varied levels of reduction in SDHD expression across 
melanoma cell lines (UACC903, UACC1113, and C021). Control siRNA or siRNAs targeting 
PRDM1 or IRF4 were transfected into cells, and expression of PRDM1, IRF4 and SDHD were 
assayed by Taqman assays at day five following transfection. 
B siRNA-mediated depletion of PRDM1 or IRF4 do not dramatically alter wild-type or mutant 
SDHD promoter activity in an allele-specific manner. A 163-bp fragment from the wild-type 
SDHD promoter sequence surrounding hotspot mutations significantly enhances luciferase 
reporter expression relative to vector control. The same fragment containing hotspot mutations 
results in decreased promoter activity relative to the wildtype sequence. While depletion of 
PRDM1 or IRF4 do broadly result in small alterations in reporter activity, neither alters reporter 
expression of these constructs in an allele specific manner. Fold change over minimal promoter 
control (vector only) is plotted as relative luciferase activity. The experiment was performed 
four times with triplicates for each.
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on SDHD expression and SDHD promoter activity in melanoma cells.
A Depletion of PRDM1 or IRF4 resulted in varied levels of reduction in SDHD expression across 
melanoma cell lines (UACC903, UACC1113, and C021). Control siRNA or siRNAs targeting 
PRDM1 or IRF4 were transfected into cells, and expression of PRDM1, IRF4 and SDHD were 
assayed by Taqman assays at day five following transfection. 
B siRNA-mediated depletion of PRDM1 or IRF4 do not dramatically alter wild-type or mutant 
SDHD promoter activity in an allele-specific manner. A 163-bp fragment from the wild-type 
SDHD promoter sequence surrounding hotspot mutations significantly enhances luciferase 
reporter expression relative to vector control. The same fragment containing hotspot mutations 
results in decreased promoter activity relative to the wildtype sequence. While depletion of 
PRDM1 or IRF4 do broadly result in small alterations in reporter activity, neither alters reporter 
expression of these constructs in an allele specific manner. Fold change over minimal promoter 
control (vector only) is plotted as relative luciferase activity. The experiment was performed 
four times with triplicates for each.
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Supplementary Table 1. SDHD promoter mutations identified in melanoma tumors 
datasets (TCGA, Broad and Yale) and melanoma cell lines.
Chromosome Location Ref Alt Sample Source Ref_bases_num Alt_bases_num
11 111957518 G A Ma-Mel-114 Broad 24 16
11 111957527 T C Ma-Mel-35 Broad 12 3
11 111957529 C T JWCI-WGS-21 Broad 0 7
11 111957547 C T ME014 Broad 20 13
11 111957515 C T UACC257 Cell lines 257 12
11 111957517 C T C021 Cell lines 59 53
11 111957524 C T UACC1451 Cell lines 181 5
11 111957524 C T UACC2528 Cell lines 138 5
11 111957524 C T UACC952 Cell lines 78 83
11 111957541 C T C021 Cell lines 54 50
11 111957541 C T C077 Cell lines 35 11
11 111957544 C T C077 Cell lines 20 12
11 111957549 C T C025 Cell lines 8 19
11 111957556 C T C088 Cell lines 61 37
11 111957515 C T TCGA-EE-A29M TCGA 8 10
11 111957523 C T TCGA-D3-A51G TCGA 16 5
11 111957523 C T TCGA-D3-A8GI TCGA 13 3
11 111957523 C T TCGA-D9-A1JW TCGA 11 7
11 111957523 C T TCGA-DA-A1IC TCGA 1 6
11 111957523 C T TCGA-EE-A29D TCGA 6 3
11 111957523 C T TCGA-EE-A2GO TCGA 13 8
11 111957523 C T TCGA-EE-A3J5 TCGA 8 3
11 111957523 C T TCGA-HR-A2OG TCGA 5 6
11 111957523 C T TCGA-IH-A3EA TCGA 4 4
11 111957523 C T TCGA-W3-AA1V TCGA 7 4
11 111957523 C T TCGA-YD-A9TA TCGA 3 6
11 111957530 A G TCGA-EB-A5UL TCGA 18 3
11 111957531 C T TCGA-EE-A2GU TCGA 8 5
11 111957532 C A TCGA-D3-A2JC TCGA 12 3
11 111957532 C A TCGA-EE-A2A2 TCGA 165 3
11 111957532 C A TCGA-ER-A19B TCGA 8 3
11 111957541 C T TCGA-EE-A2MD TCGA 7 6
11 111957541 C T TCGA-EE-A2MI TCGA 11 6
11 111957541 C T TCGA-FS-A1ZK TCGA 0 8
11 111957544 C T TCGA-EE-A185 TCGA 6 7
11 111957544 C T TCGA-GN-A26C TCGA 7 10
11 111957544 C T TCGA-W3-AA1Q TCGA 12 8
11 111957547 C T TCGA-GN-A266 TCGA 12 9
11 111957548 C T TCGA-D3-A2JE TCGA 21 8
11 111957548 C T TCGA-FR-A8YC TCGA 2 9
11 111957549 C T TCGA-GN-A26C TCGA 8 10
11 111957517 C T YUPADI Yale 13 18
11 111957523 C T YUGEN8 Yale 0 43
11 111957523 C T YURIF Yale 15 18
11 111957524 C T YUROO Yale 16 23
11 111957535 G T YUFOLD Yale 92 4
11 111957544 C T YUKLAB Yale 60 29
11 111957544 C T YURUS Yale 40 6
11 111957548 C T YUZEAL Yale 14 28
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86
Abstract
Prior genome-wide association studies have identified a melanoma-
associated locus on chr1q42.1 that encompasses a ~100 kb region spanning 
the PARP1 gene. eQTL analysis in multiple cell types of melanocytic lineage 
consistently demonstrated that the 1q42.1 melanoma risk allele (rs3219090, G) 
is correlated with higher PARP1 levels. In silico fine-mapping and functional 
validation identified a common intronic indel, rs144361550 (-/GGGCCC, r2 
=0.947 with rs3219090) as displaying allele-specific transcriptional activity. 
A proteomic screen identified RECQL as utilizing an unusual sequence-
independent binding mode to interact with rs144361550 in an allele-preferential 
manner. This study thus highlights a new role for RECQL-mediated allele-
specific transcription of PARP1 in melanomagenesis.
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87
Introduction
To date, genome-wide association studies (GWAS) have identified twenty 
common, genome-wide significant melanoma susceptibility loci1-9, most of 
which do not appear to be explained by protein-coding variants.  A subset of 
these loci harbor known pigmentation genes that mediate melanoma-associated 
phenotypes such as eye, hair, and skin color.  While several loci harbor genes 
implicated in cancer, evidence directly linking common risk variants within 
most of these loci to altered function of specific genes is lacking.
MacGregor and colleagues initially identified a melanoma risk locus 
tagged by rs3219090 on chromosome band 1q42.1 in an Australian case-
control study at a near genome-wide level of significance (P = 9.3 x 10-8 , OR 
= 0.87, protective allele A)8.  The association has since been replicated by 
multiple other studies3,10, including most recently by a meta-analysis of 12,874 
melanoma cases (rs1858550, P = 1.7 x 10-13)7.  Notably, the locus at 1q42.1 
has also been associated with melanoma survival11, where the melanoma risk 
allele correlates with increased survival, an association that has since been 
replicated12. The region of association spans from 226.52 Mb to 226.63 Mb 
(hg19) of chromosome 1, encompassing the entirety of the poly(ADP-ribose) 
(PAR) polymerase-1 (PARP1) (OMIM: 173870) gene, and fine-mapping 
suggests that the association is best explained by a single-SNP model3.  
While a number of other genes are located in the vicinity of the association 
peak, PARP1 has the most well-established role in cancer.  PARP1 is best 
known for its role as a DNA repair enzyme and genotoxic sensor that functions 
in base excision repair (BER), single-strand break repair, and double-strand 
break repair13.  Once PARP1 binds to damaged DNA, its enzymatic function 
is activated, and it covalently attaches PAR polymers to acceptor proteins, 
including histones and PARP1 itself14. PARP1 amplifies DNA damage signals, 
modifies chromatin structures to accommodate DNA damage response proteins, 
and further recruits DNA repair proteins13,15,16.  While PARP1 is not directly 
involved in repair of UV signature mutations via nucleotide excision repair, its 
role in the repair of DNA lesions induced by reactive oxygen species (ROS) is 
well-established17. ROS are generated by UVA exposure18, are a byproduct of 
melanin production19, and appear to play a role in oncogene-induced senescence 
(OIS)20,21.  Aside from DNA repair, PARP1 functions in regulating gene 
expression by modifying chromatin structure, associating with promoters and 
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enhancers, and acting as a transcriptional co-regulator22,23.  While many of these 
roles rely on PARP1 catalytic activity, some are also PARylation-independent, 
as in the transcriptional co-regulator function for NF-kB and B-MYB24,25.
In this study, we functionally characterized the 1q41.2 melanoma risk 
locus, demonstrating a consistent correlation of the risk genotype with levels 
of PARP1 gene expression in tissues of melanocytic origin, identifying a gene 
regulatory variant within the first intron of PARP1, and elucidating a role for 
PARP1 in melanocyte OIS via regulation of the melanocyte master regulatory 
transcription factor, MITF.
Materials and Methods
Early passage melanoma cell line eQTL analysis
Early passage melanoma cell lines were obtained from the University 
of Arizona Cancer Center (UACC), and eQTL analysis was performed by 
combining gene expression profiling and SNP genotyping data. The use of cell 
lines was approved by National Institutes of Health Office of Human Subject 
Research. Early passage melanoma cell lines were grown in the medium 
containing RPMI1640, 10% FBS, 20 mM HEPES, and penicillin/streptomycin 
until ~70% confluent. All cell lines were tested negative for mycoplasma 
contamination. For RNA isolation, cells were washed twice with cold PBS on 
ice and lysed with Trizol.  Trizol was heated to 65ºC for 5 min to maximize 
melanin removal.  Following heating, 1 mL chloroform was added per 5 mL 
of Trizol, vortexed, cooled on ice for 5 min, and centrifuged.  The aqueous 
phase was removed, and equal volume of 70% EtOH was added dropwise while 
vortexing at low speed.  Ethanol /supernatant mixtures were added to Qiagen 
RNeasy midi columns, with the flow-through reapplied once.  Samples were 
then processed per manufacturer’s protocol.  RNA quantity and integrity were 
assessed using Bioanalyzer, which yielded RIN>7 for all samples.  Total RNA 
were expression profiled on Affymetrix U133Plus2 expression microarrays, 
with labeling, hybridization, washing, and scanning performed according to 
manufacturer’s protocol. Background correction and quantile normalization 
of gene expression data were performed using Robust Multi-array Average 
(RMA) algorithm with the default settings (Affymetrix). For genomic DNA 
isolation, Qiagen DNeasy Blood and Tissue kit was used.   DNA quantity was 
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measured using NanoDrop and PicoGreen fluorescent assay. All samples were 
profiled using Applied Biosystems Identifiler STR panel prior to genotyping on 
Illumina OmniExpress arrays. After quality assessment of genotypes samples 
with >0.1 missing rate were excluded from the analysis. Loci with > 0.1 
missing rate, MAF < 0.01, or Hardy-Weinberg Equilbrium P- value < 5E-5 
were also excluded. The genomic region encompassing 6Mb around the GWAS 
lead SNP rs3219090 (which was directly genotyped on the array) was imputed 
using IMPUTE2.2.226 and 1KG phase1 v3 April 2012 (build 37) as a reference 
data. After assigning imputed genotypes for 2 samples that were missing direct 
genotype for rs3219090 (recoded as 0.333 probability of each genotype), 
59 total samples were qualified for eQTL analysis with gene expression and 
genotype data available. Affymetrix U133Plus2 annotates 17 genes and 11 other 
transcripts in the 2 Mb region centering at rs3219090. Among these, probes for 
12 genes and 2 other transcripts passed QC, including PARP1. eQTL analysis 
was then performed for these samples and gene/transcripts using SNPTEST 
v2.5 (see URL section) considering an additive model for genotypes.
 Allele discrimination qPCR 
cDNA from early passage melanoma cell lines heterozygous for both 
rs3219090 and coding surrogate SNP rs1805414 as well as of normal genomic 
copy were assayed using custom-designed Taqman genotyping probe sets that 
do not recognize genomic DNA.  To act as a standard, the same amplicon 
was PCR-amplified for each allele from cDNA and subsequently cloned into 
the pCR2.1 TOPO vector (Invitrogen) and sequence verified. A standard 
curve was then generated using known amounts of cloned amplicons by 
plotting 11 different points of allelic ratio against VIC/FAM signal ratio. 
Allele discrimination qPCR was performed in triplicate, and allelic ratio was 
calculated from the average ratio of VIC/FAM signal using the standard curve. 
Departure from expected allelic ratio (major/minor allele) of 1 was assessed 
using two-tailed Wilcoxon signed rank test.
Nomination of candidate functional variants
All LD r2 values used for candidate variant nomination were from 1KG 
phase 3 data. r2 values based on both the EUR and CEU populations were 
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considered to extract the maximum r2 of each variant with the lead SNPs, 
rs3219090 and rs1858550. Meta-analysis P-values were obtained from the 
previously published work of Law and colleagues7; all samples used in the 
meta-analysis were collected with informed consent and ethics committee 
approvals as previously described.  DHS peaks for the primary human 
melanocyte culture “melano” (ENCODE/Duke) were obtained from ENCODE 
database27 through UCSC Genome browser (see URL section).  DNase-seq 
data for penis foreskin melanocyte primary cell cultures “skin 01” and “skin 
02” (shown as Melanocyte_1 and Melanocyte_2 in Fig 2 and Supplementary 
Fig 2) were obtained from Roadmap database (03/09/2015) and DHS peaks 
were called using MACS28(see URL section) using the default settings and FDR 
1% cutoff.  DHS peak intervals were overlaid with the genomic position of 
each candidate variant to determine whether each candidate localizes within 
a DHS peak.  Experimental duplicates for skin 01 (DS18590, DS18601) and 
skin 02 (DS19662, DS18668), and analytical duplicates for melano were 
used for our analysis.  To call a variant to be within DHS in one sample, DHS 
overlapping the variant in either of the duplicates were counted.  DHS peaks 
from DNase-seq data for two melanoma cell lines Mel2183 (ENCODE/Duke) 
and RPMI-7951 (ENCODE/UW) were obtained from the ENCODE database. 
Peaks from FAIREseq data for 11 melanoma culture samples were obtained 
from GEO (accession number: GSE60666). Histone mark annotation was 
performed in the same way. Primary melanocyte histone marks were taken 
from subsets of three individuals through Roadmap database (skin 01, skin 
02, and skin 03; shown as Melanocyte_1, Melanocyte_2, and Melanocyte_3 
in Fig 2 and Supplementary Fig 2). Source of each track visualized on UCSC 
genome browser is as follows: Melanocyte track names used for Fig 2 (Track 1: 
UCSF-UBC-USC Penis Foreskin Melanocyte primary Cells Histone H3K27ac 
Donor skin03 Library A15584 EA Release 9, Track 2: UCSF-UBC-USC Penis 
Foreskin Melanocyte primary Cells Histone H3K4me1 Donor skin03 Library 
A15579 EA Release 8, Track 3: UCSF-UBC-USC Penis Foreskin Melanocyte 
primary Cells Histone H3K4me3 Donor skin03 Library A15580 EA Release 
8, Track 4: Melano DNaseI HS Density Signal from ENCODE/Duke, Track 
5: Penis Foreskin Melanocyte Primary Cells Donor skin 01 DNase Uniformly 
Signal from Roadmap, Track 6: UW Penis Foreskin Melanocyte Primary Cells 
DNase Hypersensitivity Donor skin02 Library DNase DS19662 EA Release 
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9.), Melanoma track names used for Supplementary Fig 2 (Track 1 through 11: 
H3K27ac ChIP-seq signal from F-seq, Track 12 through 22: FAIRE-seq signal 
from F-seq, Track 23: Mel2183 DNaseI HS Density Signal from ENCODE/
Duke, Track 24: RPMI-7951 DNaseI HS Raw Signal Rep 1 from ENCODE/
UW.).
Luciferase reporter assays
Luciferase constructs were generated to include the DHS region encompassing 
each SNP.  Sequences encompassing each variant were amplified from genomic 
DNA of HapMap CEU panel samples using the primers listed in Supplementary 
Table 14, cloned into pCR2.1TOPO vector, and subsequently cloned into 
pGL4.23 vector using EcoRV and HindIII enzymes or directly into pGL4.23 
vector using primers with HindIII and XhoI sequence overhangs.  Sequence-
verified pGL4.23 constructs were then co-transfected with pGL4.74 (Renilla 
luciferase) into a melanoma cell lines UACC2331, UACC457, or UACC1308 
using Lipofectamine 2000 reagent (Thermo Fisher) or electroporation with 
Lonza Amaxa SE kit and DS-150 protocol on 4D-Nucleofector system. 
Electoporation of primary human melanocytes (HEMn-LP, Invitrogen) was 
performed using the Lonza Amaxa P2 kit and protocol CA-137 (Lonza). 
When luciferase assays were combined with RECQL over-expression, empty 
pCMV6-Entry vector or human RECQL cDNA clone (Origene, RC200427) 
were co-transfected with luciferase constructs into HEK293FT cells using 
Lipofectamine 2000 reagent.  Cells were collected 24hr following transfection 
and luciferase activity was measured using Dual-Luciferase reporter system 
(Promega) on GLOMAX multi detection system (Promega). All cell lines and 
primary cultures used here and onward were tested negative for mycoplasma 
contamination.
EMSA and antibody supershift  
Nuclear extracts were prepared from actively growing normal human 
melanocytes (HEMn-LP, Invitrogen or melanoma cell lines (UACC) using NE-
PER nuclear and cytoplasmic extraction kit (Thermo Scientific). DNA oligos for 
each variant were synthesized with 5’ biotin labeling, and HPLC-purified (Life 
Technologies; probe sequences are listed in Supplementary Table 14).  Forward 
and reverse strands were then annealed to make double stranded DNA probes. 
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Probes were bound to 0.5-4µg nuclear extracts pre-incubated with 1µg poly 
d(I-C) in binding buffer containing 10mM Tris (pH 7.5), 50 mM KCl, 1 mM 
DTT, 10 mM MgCl2, with or without 5% glycerol at 4ºC for 30min.  Unlabeled 
competitor oligos were added to the reaction mixture 5min prior to the addition 
of probes.  Completed reactions were run on 5% or 4-20% native acrylamide 
gel and transferred blots were developed using LightShift Chemiluminescent 
EMSA kit (Thermo Scientific) and exposed on film.  Supershift antibodies 
(RecQL, sc-25547, Santa Cruz) or rabbit normal IgG (sc-2027, Santa Cruz) 
were bound to nuclear extract prior to poly d(I-C) incubation at 4 ºC for 1hr. 
EMSAs with purified recombinant protein were performed using RECQL 
(TP300427, Origene), where purified recombinant proteins were used in place 
of nuclear extract and poly d(I-C). Additional antibodies and recombinant 
proteins for validations are as follows. Antibodies are from Santa Cruz unless 
otherwise specified: anti-NCL (sc-8031), anti-SRSF3 (sc-13510), anti-CIRP 
(sc-161012), anti-BLM (sc-7790), anti-hnRNPD (sc-22368), anti-RBM3 (sc-
162080), anti-TOP3A (sc-11257), anti-RPA1 (sc-14696), anti-DHX36 (A300-
525A, Bethyl), anti-RPA3 (ab167593, Abcam). Recombinant proteins are from 
Origene: NCL (TP319082), CIRP (TP301639), RPA1(TP302066), hnRNPD 
(TP300660), RBM3 (TP760298).
Mass-spectrometry
Quantitative AP-MS/MS following SNP DNA pulldown and in-solution 
dimethyl chemical labeling was performed based on procedures described 
previously29,30.  Nuclear extract from the melanoma cell line UACC2331 was 
collected as described previously using the Dignam lysis protocol31. For DNA 
pulldowns, 500 pmol of annealed, forward strand 5’-biotinylated oligo probes 
were coupled to streptavidin sepharose beads (GE Healthcare). Insertion and 
deletion allele probe sequences are listed in Supplementary Table 14. Beads 
were incubated with 450 µg of nuclear extract for 90 minutes plus 10 µg of 
non-specific competitor DNA (either 10 µg of poly-dAdT or 5 µg of poly-dAdT 
plus 5 µg poly-dIdC). After washes, beads were resuspended in 100mM TEAB 
buffer, proteins were reduced with 5mM TCEP, alkylated with 10 mM MMTS, 
and digested overnight with 0.25 µg trypsin. Digested peptides were labelled 
using in-solution dimethyl chemical labelling as described previously32. All 
experiments were performed in duplicate, and labels were swapped between 
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replicate pairs to prevent labeling bias. Heavy and light labelled peptides were 
mixed and prepared using C18-StageTips. Peptides were loaded on a column 
packed with 1.8 µm Reprosil-Pur C18-AQ beads (gift from Dr. Maisch) and 
eluted using a 120 minute gradient from 7%-32% buffer B (80% acetonitrile, 
0.1% formic acid) at a flow rate of 250nL/min. Peptides were sprayed directly 
onto a Thermo QExactive mass spectrometer. Data was collected in top10 data-
dependent acquisition mode. Thermo RAW files were analyzed with MaxQuant 
(version 1.3.0.5) by searching against the Uniprot curated human proteome. 
Methionine oxidation and N-terminal acetylation were considered as variable 
modifications and cysteine-dithiomethane was set as a fixed modification. 
Protein ratios normalized by median ratio shifting as described previously33 
were used for outlier calling. An outlier cutoff of 1.5 IQRs (inter-quartile 
ranges) in two out of two biological replicates was used. 
For TMT experiments, DNA pulldowns were performed as described  first 
by Hubner et al30. NaCl was replaced with LiCl in protein binding buffer for 
LiCl samples, and PhenDC3 or NC-Bis was added to the noted samples at a 
concentration of 20uM. After washes, samples were eluted into a 20% methanol 
buffer for reduction, alkylation, and digestion. Peptides were labelled using the 
10-plex tandem mass tag (TMT) system (Thermo)34 and measured on a Thermo 
Tribrid Fusion mass spectrometer using a 240 minute chromatography gradient 
essentially as described above. Thermo Proteome Discoverer (version 2.1) was 
used for peptide identification and reporter ion quantification. 
Chromatin immunoprecipitation of RECQL 
UACC2331 melanoma cells or primary human melanocytes (HEMn-
LP, Invitrogen) were fixed with 1% formaldehyde when 80-90% confluent, 
following the instructions of Active Motif ChIP-ITexpress kit or ChIP-IT 
high sensitivity kit.  7.5 x 106 cells were then sheared by sonication using a 
Bioruptor (Diagenode) at high setting for 15min, with 30 sec on and 30 sec 
off cycles. Sheared chromatin from 1 to 4 x 106 cells were used for each 
immunoprecipitation with antibodies against RECQL, H110 (sd-25547; Santa 
Cruz), and A300 (A300-450A; Bethyl), or normal rabbit IgGs (sc-2027; Santa 
Cruz) following the manufacturer’s instructions.  Purified pulled-down DNA 
was assayed by SYBR Green qPCR for enrichment of target sites using primers 
listed in Supplementary Table 14. A commercial primer set (71001, Active 
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Motif) recognizing a gene desert on chromosome 12 was used for a negative 
control (Neg). 
Overexpression of RECQL in melanoma cell lines 
RECQL was cloned from a cDNA construct (RC200427, purchased from 
Origene) into lentiviral pLU-TCMV-FMCS-pPURO vector (a generous gift 
from Dr. Meenhard’s lab at Wistar) containing tetracycline-inducible promoter. 
Lentiviral vectors were co-transfected into 293 cells with packaging vectors 
psPAX2, pMD2-G, and pCAG4-RTR2.  Virus was collected two days after 
transfection and concentrated by Vivaspin.  Cells were incubated with virus 
for 24 hr, followed by puromycin (1-2 µg/ml) selection for 2-3 days. After 
drug selection cells were seeded and grown in the media containing varying 
amount of doxycycline (0,0.5, and 1 µg/ml). Cells were harvested after 48 hrs 
of doxycycline induction for RNA and protein isolation. cDNA was generated 
from total RNA and transcript levels were measured using Taqman qPCR. 
RECQL and PARP1 transcript levels normalized to the levels of B2M, and PCR 
triplicates were averaged and considered as one data point. Western blotting of 
RECQL and GAPDH was performed using the following antibodies: RecQL1, 
sc-25547, Santa Cruz, GAPDH, sc-51907, Santa Cruz. For western blot 
analysis, total cell lysates were generated with RIPA buffer (Thermo Scientific, 
Pittsburgh, PA) and subjected to water bath sonication.  Samples were resolved 
by 4-12% Bis-Tris ready gel (Invitrogen, Carlsbad, CA) electrophoresis.  
Statistical analyses
All cell-based experiments were repeated at least three times with separate 
cell cultures, except for Fig3a (repeated twice), Fig4d-e (six technical 
replicates). When a representative set was shown, replicate experiments 
displayed similar patterns. For all the plots, individual data points are shown 
with median or mean, range (maximum and minimum), and 25 & 75 percentile 
(where applicable). Statistical method, number of data points, and number and 
type of replicates are indicated in each figure legend. 
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Results
The rs3219090 risk allele is correlated with high PARP1
We performed expression quantitative trait locus (eQTL) analysis in 
order to identify genes for which expression levels are correlated with 1q42.1 
risk genotype in tissues of melanocytic lineage.  Initially we evaluated the 
correlation of rs3219090 with expression of genes within +/-1Mb in 59 early-
passage melanoma cell lines using expression microarray data. The results 
indicated that the rs3219090 risk allele is associated with higher levels of 
PARP1 expression (P = 1.4 x 10-3, linear regression; Fig. 1a). Notably, PARP1 
is the only gene in the region that passed a Bonferroni-corrected P-value 
threshold (corrected for 14 genes, P < 3.6 x 10-3; Supplementary Table 1), and 
this eQTL subsequently validated via qPCR assay (P = 0.031, linear regression; 
Supplementary Fig. 1a).  We then sought independent replication of PARP1 
and other nominally significant eQTL genes (P < 0.05) in publicly available 
RNA-sequencing datasets for melanoma-relevant tissues. When 409 melanoma 
tumors from The Cancer Genome Atlas (TCGA) project (dbGAP Accession: 
phs000178.v9.p8) were tested, the melanoma risk allele of rs3219090 was 
again significantly correlated with higher PARP1 expression levels (P = 3.9 x 
10-3, linear regression using copy number as a covariate; Supplementary Fig. 
1b) while no other genes were significantly correlated (Supplementary Table 
2). Similarly, the PARP1 eQTL was replicated in normal skin samples collected 
through the Genotype-Tissue Expression (GTEx) Project (dbGAP Accession: 
phs000424.v6.p1), including those derived from both sun-exposed skin (P 
= 2 x 10-4, linear regression, n = 302) and non-sun-exposed skin (P = 0.011, 
linear regression, n = 196) (Supplementary Fig 1c-d, Supplementary Table 
3-4). Together, these data identified PARP1 as the strongest eQTL gene in the 
chr1q42.1 locus whose expression displayed the most consistent correlation 
with genotypes of the lead SNP in sample panels of melanocytic lineage as well 
as human skin.   
To complement eQTL data and rule out the possibility of any sample-
specific confounding factors masking genotype effect, we performed allele-
specific expression (ASE) analysis for PARP1 in samples carrying both risk 
and protective alleles. Fourteen melanoma cell lines that are heterozygous 
for rs3219090 and harbor normal regional copy number were assayed using 
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Figure 1. The melanoma risk-associated G allele of rs3219090 is correlated with 
increased PARP1 expression.  
A eQTL analysis was performed for rs3219090 using expression microarray and SNP array 
genotypes derived from a panel of 59 early-passage melanoma cell lines.  A significant eQTL 
was observed for PARP1, and the result is plotted for rs3219090 genotype (P = 1.4 x 10-3; linear 
regression). G is the risk allele and A the protective allele of rs3219090. A.U.; arbitrary unit. 
B The allelic ratios of PARP1 transcripts were measured in 14 copy-neutral melanoma cell lines 
that were heterozygous for both rs3219090 and a synonymous mRNA-coding surrogate SNP 
(rs1805414, r2=0.98 with rs3219090) using Taqman genotyping assays.  Allelic ratios were 
inferred from a known amount of allelic standards and plotted as a ratio of PARP1 expression 
from the risk over protective allele (P = 1.2 x 10-4, two-tailed Wilcoxon signed rank test, average 
value of PCR triplicates were considered as a single data point). 
C Allelic ratios of PARP1 transcripts were measured using RNA sequencing data from 48 
copy-neutral TCGA skin melanoma samples that were heterozygous for both rs3219090 and 
rs1805414.  The mapped numbers of RNAseq reads encompassing each allele of rs1805414 
were used for calculating allelic ratios (P = 0.011, two-tailed Wilcoxon signed rank test).  Solid 
line marks 1:1 ratio, and dashed line represents median ratio. 
a quantitative allelic TaqMan assay for a synonymous coding surrogate SNP 
(rs1805414; r2 = 0.98 with rs3219090 in 1KG phase3 EUR), where allelic ratio 
was inferred from known ratios of allelic standards. The results demonstrated a 
significant allelic imbalance towards a higher proportion of PARP1 expressed 
from the risk allele in the majority of heterozygous cell lines (P = 1.2 x 10-4, 
two-tailed Wilcoxon signed rank test; Fig. 1b). Significant allelic imbalance was 
also observed when a subset of these cell lines were analyzed by RNAseq (data 
not shown). Subsequent PARP1 ASE analysis in TCGA and GTEx RNAseq 
datasets demonstrated that a higher allelic proportion of mapped reads was also 
observed for the risk allele across TCGA tumor samples (P = 0.011, two-tailed 
Wilcoxon signed rank test, n = 48, copy-neutral and heterozygous; Fig. 1c), 
as well as in sun-exposed and non-sun-exposed skin tissues (GTEx, P = 1.16 
x10-5, n = 139; P = 8.9 x 10-5, n = 69; respectively, two-tailed Wilcoxon signed 
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A eQTL analysis was performed for rs3219090 using expression microarray and SNP array 
genotypes derived from a panel of 59 early-passage melanoma cell lines.  A significant eQTL 
was observed for PARP1, and the result is plotted for rs3219090 genotype (P = 1.4 x 10-3; linear 
regression). G is the risk allele and A the protective allele of rs3219090. A.U.; arbitrary unit. 
B The allelic ratios of PARP1 transcripts were measured in 14 copy-neutral melanoma cell lines 
that were heterozygous for both rs3219090 and a synonymous mRNA-coding surrogate SNP 
(rs1805414, r2=0.98 with rs3219090) using Taqman genotyping assays.  Allelic ratios were 
inferred from a known amount of allelic standards and plotted as a ratio of PARP1 expression 
from the risk over protective allele (P = 1.2 x 10-4, two-tailed Wilcoxon signed rank test, average 
value of PCR triplicates were considered as a single data point). 
C Allelic ratios of PARP1 transcripts were measured using RNA sequencing data from 48 
copy-neutral TCGA skin melanoma samples that were heterozygous for both rs3219090 and 
rs1805414.  The mapped numbers of RNAseq reads encompassing each allele of rs1805414 
were used for calculating allelic ratios (P = 0.011, two-tailed Wilcoxon signed rank test).  Solid 
line marks 1:1 ratio, and dashed line represents median ratio. 
a quantitative allelic TaqMan assay for a synonymous coding surrogate SNP 
(rs1805414; r2 = 0.98 with rs3219090 in 1KG phase3 EUR), where allelic ratio 
was inferred from known ratios of allelic standards. The results demonstrated a 
significant allelic imbalance towards a higher proportion of PARP1 expressed 
from the risk allele in the majority of heterozygous cell lines (P = 1.2 x 10-4, 
two-tailed Wilcoxon signed rank test; Fig. 1b). Significant allelic imbalance was 
also observed when a subset of these cell lines were analyzed by RNAseq (data 
not shown). Subsequent PARP1 ASE analysis in TCGA and GTEx RNAseq 
datasets demonstrated that a higher allelic proportion of mapped reads was also 
observed for the risk allele across TCGA tumor samples (P = 0.011, two-tailed 
Wilcoxon signed rank test, n = 48, copy-neutral and heterozygous; Fig. 1c), 
as well as in sun-exposed and non-sun-exposed skin tissues (GTEx, P = 1.16 
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rank test; Supplementary Fig. 1e-f). These data demonstrate that the melanoma 
risk allele of rs3219090 is significantly associated with increased PARP1 
expression in tissues of melanocytic origin and skin with striking consistency 
across multiple datasets. 
Fine-mapping and functional annotation of candidate SNPs
Given that high PARP1 levels are correlated with the melanoma risk allele 
of rs3219090, we next sought to identify functional risk variant(s) that may 
influence PARP1 expression.  Previously, fine-mapping of this locus in a large 
European population provided support for a model in which a single variant 
accounts for the association signal in this region3, a finding confirmed as part 
of the meta-analysis conducted by Law and colleagues7.  We prioritized 65 
variants that are highly correlated with the lead SNP as candidate functional 
variants (r2>0.6 with lead SNPs from the discovery or meta-analysis lead 
SNPs3,7, rs3219090 and rs1858550, respectively; LD based on 1KG phase3, 
EUR and CEU).  Given the absence of amino acid-changing PARP1 variants 
within this set of candidates, an absence of evidence for alternative splicing 
as a likely mechanism (Supplementary Note), and considerable evidence for 
allelic differences in PARP1 expression levels, we focused on those located 
within annotated melanocyte- or melanoma-specific cis-regulatory elements 
using data from the ENCODE27 and Roadmap projects35 (Supplementary 
Note, Supplementary Table 5-6, Supplementary Fig. 2-3). The four of the 
most strongly supported variants are situated at the center of melanocyte DHS 
peaks as well as within regions harboring promoter or enhancer histone marks 
(H3K4me1, H3K4me3, or H3K27ac) in the majority of melanocyte/melanoma 
cultures assayed (Supplementary Table 6).  Based on these data, we proceeded 
with functional characterization of these four candidates (Supplementary Table 
6, Supplementary Fig. 2). 
An intronic indel displays allelic transcriptional activity
We assessed all four candidate functional variants for gene regulatory 
potential using luciferase reporter assays, as well as for allelic patterns of protein 
binding via electrophoretic mobility shift assay (EMSA). For these assays, we 
sought to identify variants that display 1) transcriptional activation consistent 
with ENCODE annotation, 2) higher activity for the risk allele consistent with
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Figure 2. Functional annotation of a 3kb region encompassing rs144361550 in primary 
melanocytes.
Histone modifications (H3K4Me1, H3K4Me3, and H3K27Ac) and DNaseI hypersensitivity sites 
(DHS) in primary melanocytes are shown for a 3kb region encompassing rs144361550. The red 
dashed vertical line indicates the position of rs144361550, overlapping histone marks, DHS, and 
transcription factor binding sites. Genomic positions are based on hg19. Transcription factor 
binding sites are from UCSC genome browser track “Transcription Factor ChIP-seq (161 factors) 
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from ENCODE with Factorbook Motifs” representing multiple ENCODE cell types. “Chromatin 
Primary Core Marks Segmentation by HMM from Roadmap Project” track is also shown for 
three melanocyte samples. TssA: Active_TSS, TssF: Flanking_Active_TSS, Enh: Enhancers. For 
DHS, traces from two experimental replicates of Melanocyte 1 and 2 are displayed. The scale of 
each track is uniformly set throughout the region of the PARP1 gene to cover the highest peaks, 
with 0 as the baseline (see online methods for details of each track).
the eQTL data, and 3) allele-specific protein binding. Among four candidate 
variants, only rs144361550, a GGGCCC indel variant, met all these criteria 
(Fig. 2-3, Supplementary Figs. 4-6; summarized in Supplementary Table 7). 
Namely, luciferase assays conducted in a melanoma cell line demonstrated that 
the genomic region around rs144361550 exhibits strong transcriptional activity 
in both long (905bp covering the larger DHS region, ~17-20 fold higher than 
control levels) and short cloned fragments (22 or 28bp covering the GGGCCC 
repeats, ~1.7-2.5 fold higher than control levels; Fig. 3a), where the risk-
associated deletion allele exhibited higher reporter activity than the insertion 
allele (30-45% higher). In primary melanocytes, where transfection efficiency 
is considerably lower, allelic activity was not observed, but the long deletion 
and insertion fragments displayed weak but significant transcriptional activity 
(P = 1.2 x 10-3 and 5.9 x10-4, respectively, two-tailed, paired t-test; Fig. 3c). 
EMSAs using nuclear extract from melanoma cell lines or cultured primary 
human melanocytes displayed preferential binding of nuclear proteins to the 
insertion allele (Fig. 3b,d). Given the potential for miscalling genotype of this 
functional indel, we directly genotyped rs144361550 in a large reference set to 
confirm LD with the lead SNP (Supplementary Note, Supplementary Table 8-9, 
Supplementary Fig. 7-8). 
To identify proteins that bind rs144361550 in an allele-preferential 
manner, we utilized quantitative mass-spectrometry employing dimethyl 
label swapping30,32 29.  Mass-spectrometry using melanoma cell line extract 
identified exclusively insertion allele-preferential interactors, the majority of 
which are not conventional transcription factors, including the RECQL helicase 
(Fig. 4a). While two transcription factors previously found by the ENCODE 
Project to localize to the region overlapping rs144361550 via chromatin 
immunoprecipitation (ChIP) were found to bind rs144361550 probes (TFAP2A, 
ZBTB7A), neither did so in an allele-preferential manner (data not shown), in 
line with the observation that rs144361550 creates no new sequence motifs but 
rather extends a poly-G repeat stretch. We then performed a series of antibody
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variants, only rs144361550, a GGGCCC indel variant, met all these criteria 
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ZBTB7A), neither did so in an allele-preferential manner (data not shown), in 
line with the observation that rs144361550 creates no new sequence motifs but 
rather extends a poly-G repeat stretch. We then performed a series of antibody
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Figure 3. The melanoma-associated indel, rs144361550, drives allelic transcriptional 
activity and protein binding. 
A,C Luciferase assays for rs144361550 were conducted using the melanoma cell line UACC2331 
(A) or primary melanocytes (C). 905bp or 22/28bp encompassing rs144361550, respectively, 
were cloned 5’ of minimal promoter in pGL4.23 vector and transfected into the cells. 
Luciferase activity was measured 24hrs after transfection and was normalized against Renilla 
luciferase activity. Relative luciferase levels were plotted as percent of the minimal promoter 
control. P-values are shown or * P < 0.05 against Ctrl (two-tailed, paired t-test). Two (A) and 
three (C) independent cell cultures and transfections of n = 3 were combined to present the 
median with range, 75 & 25 percentiles, and each data point. Ctrl: minimal promoter control, 
Del: deletion/risk allele construct, Ins: insertion/protective allele construct.  
B, D EMSA was performed using biotin-labeled double stranded oligos for the deletion/risk (Del, 
D) or insertion/protective (Ins, I) alleles of rs144361550 and nuclear extracts from melanoma 
cell lines UACC2331 and UACC457 (B) or primary melanocytes (D). Sequences shown in 
panel b for the 22 bp deletion and 28 bp insertion probes were used for both b and d (bold and 
Italic bases highlight potential G4 structure forming nucleotides). 50X, 200X or 500X molar 
excess of unlabeled competitors were added in specified lanes. 
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were cloned 5’ of minimal promoter in pGL4.23 vector and transfected into the cells. 
Luciferase activity was measured 24hrs after transfection and was normalized against Renilla 
luciferase activity. Relative luciferase levels were plotted as percent of the minimal promoter 
control. P-values are shown or * P < 0.05 against Ctrl (two-tailed, paired t-test). Two (A) and 
three (C) independent cell cultures and transfections of n = 3 were combined to present the 
median with range, 75 & 25 percentiles, and each data point. Ctrl: minimal promoter control, 
Del: deletion/risk allele construct, Ins: insertion/protective allele construct.  
B, D EMSA was performed using biotin-labeled double stranded oligos for the deletion/risk (Del, 
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supershifts and EMSAs using purified recombinant proteins for multiple 
candidates and validated that RECQL is an unequivocal allele-preferential 
binder to rs144361550 (Fig. 4b, Supplementary Figs. 9, and Supplementary 
Table 10). ChIP assays indicated that RECQL indeed binds to the PARP1 indel 
region in melanoma cells and primary human melanocytes carrying an insertion 
allele (Fig. 4c, Supplementary Fig. 10). We also performed a series of in silico 
and in vivo assays testing for alternative DNA secondary structure formation 
(G-quadruplex or G4), with the results suggesting RECQL-specific allelic 
binding mechanism rather than the one through G4 (Supplementary Note, 
Supplementary Table 10-11, Supplementary Fig. 11-13). Intriguingly, chemical 
perturbation of potential ssDNA secondary structures either repelled proteins 
involved in (nucleotide excision repair) DNA damage associated processes or 
recruited proteins involved in RNA processing (Supplementary Fig. 14). These 
global effects were largely independent of allele, indicating a general structural 
mechanism. Yet, while RECQL prefers the insertion allele in a dsDNA context, 
RECQL prefers the deletion allele in a ssDNA, G4 permissive context, 
suggesting a complex and so-far uncharacterized DNA secondary structure.
Ectopic expression of RECQL in three melanoma cell lines carrying 
insertion or deletion alleles at a moderate level using lentiviral transduction 
resulted in a mild increase in PARP1 transcription (Fig. 4d). We then performed 
luciferase assays for rs144361550 with or without RECQL over-expression in 
cells with low baseline levels of RECQL relative to melanomas (HEK293FT 
cells). At a basal level, insertion and deletion alleles did not display differential 
luciferase activity, but upon RECQL over-expression, significant allele-specific 
transcriptional activity we previously observed in melanoma cell lines was 
recapitulated (Fig. 4e). Together, these data suggest that RECQL may play a 
role in PARP1 allelic expression in cells of melanocytic lineage through the 
melanoma risk-associated indel, rs144361550.
15609_M-Makowski_BNW.indd   101 11-06-18   14:29
3
PARP1 confers melanoma risk via regulation by RECQL of an allelic DNA structure
101
supershifts and EMSAs using purified recombinant proteins for multiple 
candidates and validated that RECQL is an unequivocal allele-preferential 
binder to rs144361550 (Fig. 4b, Supplementary Figs. 9, and Supplementary 
Table 10). ChIP assays indicated that RECQL indeed binds to the PARP1 indel 
region in melanoma cells and primary human melanocytes carrying an insertion 
allele (Fig. 4c, Supplementary Fig. 10). We also performed a series of in silico 
and in vivo assays testing for alternative DNA secondary structure formation 
(G-quadruplex or G4), with the results suggesting RECQL-specific allelic 
binding mechanism rather than the one through G4 (Supplementary Note, 
Supplementary Table 10-11, Supplementary Fig. 11-13). Intriguingly, chemical 
perturbation of potential ssDNA secondary structures either repelled proteins 
involved in (nucleotide excision repair) DNA damage associated processes or 
recruited proteins involved in RNA processing (Supplementary Fig. 14). These 
global effects were largely independent of allele, indicating a general structural 
mechanism. Yet, while RECQL prefers the insertion allele in a dsDNA context, 
RECQL prefers the deletion allele in a ssDNA, G4 permissive context, 
suggesting a complex and so-far uncharacterized DNA secondary structure.
Ectopic expression of RECQL in three melanoma cell lines carrying 
insertion or deletion alleles at a moderate level using lentiviral transduction 
resulted in a mild increase in PARP1 transcription (Fig. 4d). We then performed 
luciferase assays for rs144361550 with or without RECQL over-expression in 
cells with low baseline levels of RECQL relative to melanomas (HEK293FT 
cells). At a basal level, insertion and deletion alleles did not display differential 
luciferase activity, but upon RECQL over-expression, significant allele-specific 
transcriptional activity we previously observed in melanoma cell lines was 
recapitulated (Fig. 4e). Together, these data suggest that RECQL may play a 
role in PARP1 allelic expression in cells of melanocytic lineage through the 
melanoma risk-associated indel, rs144361550.
15609_M-Makowski_BNW.indd   101 11-06-18   14:29
        
Chapter 3
102
RECQLIgG
Probe D I  D  I  D  I  D  I  D I   D I   I  D  I  D I   D  I  
D
A
RECQL protein
Antibody
Nuclear extract
Insertion-specific
Deletion
-specific
R
at
io
 O
ve
r I
np
ut
Neg Pos Indel
IgG
anti-RECQL
R
el
at
iv
e 
Lu
ci
fe
ra
se
 A
ct
iv
ity
(%
 o
f c
on
tr
ol
)
Ctrl Del Ins Del Ins
Empty RECQL
Ctrl
P = 2.1 x 10-8
B
C
PA
R
P1
 m
R
N
A
 le
ve
ls
(F
ol
d 
ov
er
 E
m
pt
y 
ve
ct
or
 c
on
tr
ol
)
0.5 0.5 0.5 0.50 0 01 10.5 0.5Doxycycline
(µg/ml)
RECQLEmpty Empty Empty
UACC2534 (II) UACC2545 (II) UACC903 (DD)
E
RECQL
0
500
1000
1500
2000
0.0
0.5
1.0
1.5
2.0
0.0
0.5
1.0
1.5
2.0
2.5
   3.7 x 10-3
   1.7 x 10-2
   1.8 x 10-2
   2.9 x 10-5
   8.9 x 10-6
   1.1 x 10-4
RECQLRECQL
0
10
20
30
R
EC
Q
L 
m
R
N
A
 le
ve
ls
(F
ol
d 
ov
er
 E
m
pt
y 
ve
ct
or
)
RECQL
GAPDH
0.5 0.5 0.5 0.50 0 01 10.5 0.5Doxycycline
(µg/ml)
RECQLEmpty Empty Empty RECQLRECQL
* * * * *
* * *
* *
*
*
Deletion-bound/Insertion-bound Ratio
In
se
rti
on
-b
ou
nd
/D
el
et
io
n-
bo
un
d 
R
at
io
Supershift
Figure 4. RECQL binds to the insertion allele and mediates allelic expression.  
A Insertion allele-specific binding proteins were identified by mass-spectrometry using melanoma 
cell nuclear extract and biotinylated double-stranded oligos. The ratio of proteins bound to 
heavy/light-dimethyl labeled probes is plotted on x and y-axis for labeling swapping.  Red 
circles: enriched above the background in both directions. Circle sizes represent relative 
abundance.
B RECQL EMSA/supershift. D: deletion, I: insertion 
C ChIP was performed using anti-RECQL antibody or IgG and melanoma cell chromatin followed 
by qPCR. DNA quantity was normalized to input DNA for each IP (n=3). Neg: gene desert, 
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Figure 4. RECQL binds to the insertion allele and mediates allelic expression.  
A Insertion allele-specific binding proteins were identified by mass-spectrometry using melanoma 
cell nuclear extract and biotinylated double-stranded oligos. The ratio of proteins bound to 
heavy/light-dimethyl labeled probes is plotted on x and y-axis for labeling swapping.  Red 
circles: enriched above the background in both directions. Circle sizes represent relative 
abundance.
B RECQL EMSA/supershift. D: deletion, I: insertion 
C ChIP was performed using anti-RECQL antibody or IgG and melanoma cell chromatin followed 
by qPCR. DNA quantity was normalized to input DNA for each IP (n=3). Neg: gene desert, 
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 Pos: a known RECQL binding locus, Indel: rs144361550 region. A representative set from 
four independent experiments is shown.
D RECQL under tetracycline-inducible promoter was expressed in three melanoma cell lines. 
PARP1 levels (top) and RECQL RNA (middle) and protein (bottom) levels were measured at 
48hrs of doxycycline induction (blot images were cropped). Transcript levels are shown as 
fold over Empty vector after normalizing to B2M control (n = 6, 5, and 6 for each cell line).
E Luciferase assays were performed using 905bp deletion (Del) or insertion allele (Ins) 
constructs with RECQL or Empty vector co-transfection in HEK293FT cells. Renilla-
normalized relative luciferase activities were plotted as percent of the minimal promoter 
control (Ctrl) (n = 6). (C-E) Each graph shows median with range, 75 & 25 percentiles, and 
each data point. Two-tailed, t-test assuming unequal variance for all P-values shown. * P < 
0.05 against Ctrl (E) or Empty (D).
Discussion
In this study, eQTL and ASE analyses suggest PARP1 as the susceptibility 
gene underlying the melanoma risk locus on chromosome band 1q42.1. 
When we evaluated the set of genes in +/- 1Mb of the lead melanoma risk 
SNP (rs3219090) to account for potential long-range regulation, we observed 
a highly-reproducible eQTL with PARP1, but not with other nearby genes. 
The correlation between the risk allele and higher levels of PARP1 expression 
was highly reproducible across multiple melanoma-relevant tissues, including 
early-passage melanoma cell lines, melanoma tumors, and human skin biopsies 
in both eQTL and ASE analyses.  While eQTL and ASE analyses cannot 
completely rule out a potential role for other genes within the larger genomic 
region surrounding the GWAS peak, these data strongly implicate PARP1 as 
functionally mediating melanoma risk at this locus. 
While this region is relatively small in size, 65 variants are nonetheless 
strongly correlated (r2>0.6) with the lead GWAS SNP.  To efficiently prioritize 
functional candidates we took advantage of potential gene regulatory regions 
annotated in human melanocyte and melanoma samples by the ENCODE 
and Roadmap Projects.  We chose to focus on variants located in most 
consistently annotated regulatory elements across different individuals and 
cellular conditions because of the strikingly consistent eQTL and ASE data 
observed in both melanocytes and melanomas. Subsequent characterization of 
these candidate variants highlighted a single variant, rs144361550, as a strong 
functional candidate. Of the variants tested, only rs144361550 demonstrated 
both allele-specific transcriptional activity and protein binding pattern in a 
manner consistent with the observed pattern of genotype/expression correlation. 
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While these data provide support for rs144361550 as a functional melanoma 
risk variant influencing levels of PARP1 expression, they nonetheless cannot 
rule out other variants in this region as also contributing to the observed 
correlation between PARP1 levels and genotype.  
Our unbiased approach using quantitative mass-spectrometry identified 
RECQL as a protein binding allele-preferentially to rs144361550. Importantly, 
RECQL binding to rs144361550 does not appear to be driven by sequence 
specificity but rather by DNA secondary structure. While genomic sequence 
encompassing rs144361550 suggested G4-forming potential (Supplementary 
Table 11), which might explain a regulatory role36, our in vitro assays failed to 
provide definitive evidence for G4 structure either by insertion or deletion allele. 
However, formation of another differential structural motif, such as a transient 
hairpin structure (formed by single-stranded sequences, Supplementary Table 
13) or a locally perturbed double-helix structure at the hexanucleotide repeat 
domain37, inducing DNA bending and serving as a recognition motif for allele-
specific protein binding38, cannot be excluded.  As such, a more detailed 
molecular and structural analysis of the interaction between the rs144361550 
insertion and deletion alleles, in both a dsDNA and ssDNA context, will be an 
important topic for future research.
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SUPPLEMENTARY NOTE
Supplementary Results
Evaluation of alternative splicing as a potential mechanism of PARP1 
regulation
We considered other potential mechanisms by which the two alleles of 
rs144361550  may influence PARP1 levels. Given the location of rs144361550 
in an intron, approximately 100bp downstream of the first exon-intron junction, 
we investigated the possibility of allelic PARP1 regulation via alternative 
splicing. Sequence-based prediction suggested that neither the insertion nor 
deletion alleles create cryptic splice donor, branch point, or acceptor sites 
(http://splice.uwo.ca/)1,2. In addition, RNAseq data from 15 early-passage 
melanoma cell lines used in this study, as well as three independent primary 
melanocyte cultures, did not detect novel or cryptic splice forms of PARP1 
transcript including an unspliced first intron sequence, and a larger qPCR-based 
analysis of 57 early-passage melanoma cell lines and six primary melanocyte 
cultures did not show a statistically significant association between the 
melanoma risk SNP rs3219090 and any specific alternative PARP1 transcript 
(data not shown). Together, these data do not support altered splicing as a likely 
functional mechanism.
Prioritization of candidate functional variants
We prioritized 65 variants that are highly correlated with the lead SNP as 
candidate functional variants (r2>0.6 with lead SNPs from the discovery or 
meta-analysis lead SNPs3,4, rs3219090 and rs1858550, respectively; LD based 
on 1KG phase3, EUR and CEU). This set of 65 variants included all that were 
found to be associated with melanoma within four orders of magnitude P-value 
of the lead SNP from the latest meta-analysis4 (n = 51 SNPs, Supplementary 
Table 5-6). Given the absence of amino acid-changing PARP1 variants within 
this set of candidates as well as the considerable evidence for allelic differences 
in PARP1 expression levels, we focused on those located within annotated 
melanocyte- or melanoma specific cis-regulatory elements5,6. Considering 
that accessible chromatin regions annotated using DNase I hypersensitivity 
sequencing (DHS) data are one of the most inclusive predictors of different 
classes of tissue-specific cis-regulatory elements7, we turned to DHS data 
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generated from three independent cultures of primary human melanocytes, 
available through the ENCODE5 and Roadmap projects6, as a primary predictor 
(Supplementary Fig. 2). As a secondary predictor, we examined DHS from two 
melanoma cell lines, as well as recently published open chromatin data using 
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE-seq) from 11 
melanoma cultures and cell lines8 (Supplementary Fig. 3). We considered the 
strongest candidates to be those that are situated in regions of open chromatin 
in both primary melanocyte and melanoma cultures (open chromatin in all three 
melanocytes and >50% of melanoma cultures), and identified four such variants 
(Supplementary Figs. 2-3). All four of the most strongly supported variants 
are situated at the center of melanocyte DHS peaks as well as within regions 
harboring promoter or enhancer histone marks (H3K4me1, H3K4me3, or 
H3K27ac) in the majority of melanocyte/melanoma cultures (Supplementary 
Table 6). Based on these data, we proceeded with functional characterization 
of these four candidates (Supplementary Table 6, Supplementary Fig. 2).
Direct genotyping of rs144361550 and LD assessment
Notably, one of the top four candidates, rs144361550, is a six base-pair 
insertion/deletion (indel) within a string of GGGCCC repeat units at the beginning 
of the first intron of PARP1. This variant lies over prominent melanocyte 
epigenetic marks, including H3K27Ac, H3K4me3, and DNAseI hypersensitive 
peaks, as well as ENCODE ChIP-seq peaks for multiple transcription factors 
(Fig.2, Supplementary Fig. 4). Consistent with its annotation as an active 
transcriptional start site (TSS) by the Epigenome RoadMap Project, this region 
displays a chromatin modification signature consistent with a promoter region, 
where H3K4Me3 and H3K27Ac peaks are overlapping while H3K4me1 signal 
is diminished. LD estimates between rs144361550 and the lead SNP (rs3219090) 
within this locus varied between 1KG phase 1 (r2 = 0.67), which served as the 
imputation reference for meta-analysis datasets4, and 1KG phase 3 (r2 = 0.95). 
Given this disparity, we directly genotyped this indel for 85 HapMap CEU 
individuals using a fluorescence-based fragment length polymorphism assay 
on a capillary sequencer (Supplementary Fig. 7, Supplementary Table 8). Of 
35 individuals included in both HapMap and 1KG phase 1, three individuals 
showed discordant genotypes for rs144361550 (~9% estimated error rate); data 
from HapMap samples were consistent with Mendelian errors introduced only 
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from 1KG phase1 genotypes (Supplementary Fig. 8). We then further assessed 
LD between rs144361550 and rs3219090 by directly genotyping rs144361550 
in a set of 745 healthy individuals of European descent9; correlation between 
these two variants was consistent with that observed in 1KG phase 3 (r2=0.94; 
Supplementary Table 9), where the deletion allele is phased with the rs3219090 
risk allele G.
In silico and in vitro tests of G-quadruplex DNA structure formation on 
rs144361550
In an attempt to understand the seemingly unconventional mechanism of 
allele-specific binding of RECQL to rs144361550, we performed a set of in 
vitro assays assessing the nature of the DNA secondary structure driving the 
indel allelic difference. Based on the evidence that (i) RECQL is a helicase as 
opposed to transcription factor recognizing and binding DNA sequence motifs, 
(ii) 41% of insertion-binding proteins from the mass-spec including RECQL 
are also known to bind alternative nucleotide secondary structures including 
G-quadruplex (G4) (Supplementary Table 10)10-15, and (iii) sequence 
prediction analyses suggesting allelic differences in G4-forming potential 
for sequences encompassing rs144361550 (Supplementary Table 11), we 
tested if G4 structure can be formed by insertion or deletion alleles, in vitro. A 
series of biophysical studies including circular dichroism (CD) spectrometry 
(Supplementary Fig. 11 and 12) and thermal difference UV spectroscopy 
(TDS, Supplementary Fig. 13) suggested that a G4 structure could be induced 
in the presence of a strong G4 ligand, PhenDC3, for both insertion and deletion 
alleles but without allelic discrimination. These results failed to demonstrate 
a definitive G4 structure formed either by insertion or deletion allele in vitro 
and are also consistent with the lack of validation for the other six G4-binding 
proteins from mass-spec by antibody-supershifts, suggesting a RECQL-specific 
allelic binding mechanism.
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Supplementary Methods
qPCR analysis of PARP1 in early passage melanoma cell lines
The same RNA used for expression array analysis was used for cDNA 
generation for qPCR analysis. Expression levels of four control genes were 
measured in all 57 cell lines, and two most stable genes selected from Biogazelle 
qbasePLUS analysis (ACTB, PPIA) were used for duplex Taqman assays with 
VIC and FAM labeled probe sets (Taqman probe ID Hs00242302). Geometric 
means of control gene Ct values from four qPCR replicates (2 x ACTB and 2 x 
PPIA) were subtracted from geometric means of PARP1 Ct values to generate 
mean ΔCt values. Mean ΔCt from replicates were treated as single data points. 
After assessing normal distribution by Shapiro-Wilk test, analysis of covariance 
was performed for mean ΔCt using genotype as a category. Only the samples 
whose genotype (rs3219090) was directly typed by array (n=53) were included 
in the analysis.
eQTL and ASE analysis from TCGA and GTEx RNAseq datasets
For TCGA melanomas eQTL analysis, transcript levels, rs3219090 
genotypes, and Affymetrix SNP6 regional copy numbers were obtained 
from TCGA data version 2015_11_01 (dbGAP Accession: phs000178.v9.p8) 
through Firebrowse beta version (http://firebrowse.org/) and the TCGA data 
portal (https://tcga-data.nci.nih.gov/tcga/). RNAseq expression data was 
extracted as “RNA Seq V2 RSEM” from level 3 file “rem.genes.normalized_
results” and rs3219090 genotype data was generated from level 2 “birdseed.
data.txt” with filter set at confidence threshold <0.05. SNP6 copy numbers 
were averaged across the genomic region of each gene to obtain gene-based 
copy number. A total of 409 melanoma samples from unique individuals had 
direct genotype, expression, and copy number information available and were 
used for the analysis. A total of 16 genes, including PARP1, were located 
within the 2 Mb region surrounding rs3219090 had genotype, expression, and 
copy number data available and were used for the analysis. The Matrix eQTL 
package (http://www.bios.unc.edu/research/genomic_software/Matrix_eQTL/) 
was used for eQTL analysis, using a linear model considering an additive 
model for genotypes and using gene-specific copy number as a covariate. To 
incorporate gene-specific copy numbers as a covariate, Matrix eQTL analysis 
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was run separately for each gene. GTEx eQTL analysis was performed on 
GTEx portal (http://www.gtexportal.org/home/testyourown; 12/02/2015,data 
source: GTEx Analysis Release V6, dbGaP Accession phs000424.v6.p1) using 
the Test Your Own eQTL function for 20 genes within +/- 1Mb of rs3219090 
(RefSeq Genes, hg19) that had detectable expression data available. For ASE, 
we included 48 TCGA melanoma samples from unique individuals that are both 
heterozygous for rs1805414 and rs3219090, as well as copy-neutral for the 
PARP1 genomic region by GISTIC 2.0 (www.broadinstitute.org/cancer/cga/
gistic, obtained through cBio portal; http://www.cbioportal.org/). rs3219090 
genotypes were obtained from Affymetrix SNP6 genotype data, while allele-
specific reads for assessing rs1805414 genotype were obtained from exome 
sequencing data. Allele-specific PARP1 transcript levels were obtained from 
RNAseq reads (TCGA, dbGAP Accession: phs000178.v9.p8). For accurate 
genotype assignment, only the samples with >=5 reads for each allele were 
accepted as heterozygotes for rs1805414. The mapped numbers of RNAseq 
reads encompassing the variant for each allele were used to calculate an allelic 
ratio. Only those samples with >= 10 reads for each allele were used for the 
analysis. A two-tailed Wilcoxon signed rank test was used to assess allelic 
imbalance. GTEx ASE analysis was performed in a similar manner with the 
following difference. Samples included in the analysis were heterozygous for 
rs1805414 based on genotype imputation and also heterozygous for rs3219090 
by genotyping (n = 139, sun-exposed skin; n = 69, not sun-exposed; GTEx 
Analysis Release V6, dbGaP Accession phs000424.v6.p1,12/17/2015). All 
samples have >= 10 total reads and >= 3 reads for each allele.
Re-genotyping of rs144361550
Two different amplicons (156bp and 240bp) encompassing rs144361550 
were amplified from genomic DNA of 85 HapMap CEU individuals and 745 
healthy individuals of European descent from the NCI-DCEG imputation 
reference panel9 using respective primer sets labeled with different fluorescent 
dyes (6-FAM for 156 bp and VIC for 240 bp, primer sequences listed in 
Supplementary Table 14). PCR products were purified and subsequently 
injected into an ABI3730XL with the Gene Scan 500LIZ size standard. 
Genotypes were automatically called using GeneMapper (Applied Biosystems/
Thermo Fisher Scientific) and manually confirmed using PeakScanner v2. A 
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subset of samples with ambiguous calls were validated by Sanger sequencing 
followed by analysis using Mutation Analyzer (SoftGenetics, State College, 
PA) using strand separation function for mixed sequences of heterozygous 
samples.
Circular dichroism (CD) and thermal difference spectra (TDS)
Lyophilized, HPLC-purified oligonucleotides (sequences: cf. 
Supplementary Table 14) were purchased from MWG Eurofins and dissolved 
in milliQ water to a strand concentration of 200 μM. Single-stranded and 
double-stranded samples for CD and TDS were prepared to give final total strand 
concentration of 5 μM in 10 mM Li cacodylate buffer (pH 7.2) supplemented 
with 100 mM LiCl (Li+ conditions), 100 mM KCl (K+ conditions) or 100 mM 
KCl + 10 μM PhenDC3, a G4-stabilizing ligand16. Samples were heated to 
95 °C for 5 min, slowly cooled to ambient temperature, and kept at +4 °C 
overnight, in order to induce formation of thermodynamically stable secondary 
structures. CD spectra were recorded with a JASCO J-710 spectropolarimeter 
equipped with a Peltier temperature controller, using quartz cells with a path 
length of 10 mm; the scans were recorded at 20 °C from 210 to 330 nm using 
the following parameters: data pitch, 0.5 nm; bandwidth, 2 nm; response, 2 s; 
scan speed, 50 nm miní1; the scans are the result of four accumulations. The CD 
spectra were blank-subtracted and converted to molar dichroic absorption (Δε, 
cm -1 M-1) based on total nucleoside concentration (Equation S1):
      ΔεCD= Θ / 32980 x c x n x ℓ) (S1)
where Θ is the ellipticity (millidegrees), c  is the strand concentration in 
sample (M), n is oligonucleotide length (bases), and ℓ is the path length (cm).
Absorption spectra were obtained with an Agilent Cary 300 Bio 
spectrophotometer equipped with a temperature controller in quartz cells (path 
length: 1 cm), using samples containing 5 μM DNA (strand concentration) in 
K+-containing buffer as mentioned above. Absorption spectra were recorded 
at 20 °C and then at 90 °C, and molar extinction coefficient differences (TDS) 
were calculated using Equation S2:
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      ΔεTDS = [A(90 °C) – A(20 °C)] / (c × n × ℓ) (S2)
where A is absorbance at a given temperature, and c, n, and ℓ are as above.
Bisulfite sequencing
Genomic DNA were purified from melanocytes using the DNeasy Blood 
and Tissue Kit from Qiagen, and bisulfite conversion was performed using 
the EZ DNA methylation-Direct kit from ZYMO research Corp, following 
the manufacturer’s instructions. PCR-amplified bisulfite-converted DNAs 
were then sequenced on a 3730xl DNA Analyzer (ABI). The sequence of PCR 
primers are listed in Supplementary Table 14. Methylated CpG control DNA 
was provided by the kit.
Luciferase assays for MITF promoter
Three luciferase constructs were generated containing different lengths of 
the MITF-M promoter. Approximately 2.2 Kb 5’ region of MITF-M promoter 
was sub-cloned into pGL4.23 luciferase vector (Promega) from pMITF-2256 
(a gift from Dr.
 William Pavan, NHGRI)17 to make MITF.2200. A short 382bp region of 
the MITF-M promoter was sub-cloned into pGL4.23 from pMITF-382 (a gift 
from Dr. David Fisher, Dana-Farber Cancer Institute)17 to make MITF.382. A 
674bp fragment 5’ of MITF-M promoter was PCR amplified from pMITF-2256 
and cloned into pGL4.23 to make MITF.674. Primer sequences for sub-
cloning are listed in Supplementary Table 14. pGL4.23 constructs were then 
co-transfected with pGL4.74 (Renilla luciferase) into melanocytes infected 
with either PARP1shRNA or PARP1 expression vector by electroporation 
with Lonza Amaxa P2 kit and protocol CA-137 (Lonza). Cells were collected 
24hr following transfection and luciferase activity was measured using Dual-
Luciferase reporter system (Promega) on GLOMAX multi detection system 
(Promega).
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Prediction of PARP1 binding sites on MITF-M promoter
FASTA file of the MITF promoter sequence was downloaded from UCSC 
genome browser (hg19), and loaded to CLC Genomics Workbench (version 
7.5). We used the TRANSFAC TFBS (BIOBASE professional database) Plugin 
(version 1.1) on CLC Genome Workbench and filtered the result by setting 
“Set Matrix similarity cut-off” as “only high-quality matrices” (“set matrix 
similarity cut-off 0.95 and set core similarity cut-off 0.99”). Predicted PARP1 
binding sites were extracted from the result list.
Expression correlation analysis
PARP1 and MITF transcript levels, and rs3219090 genotypes of 409 cutaneous 
melanomas were obtained from TCGA (same set of samples that were used for 
eQTL). GISTIC copy numbers of MITF were accessed through cBioPortal18 
and 189 neutral copy samples were assessed separately for correlation. Pearson 
correlation analysis was performed to obtain correlation coefficient (r). For 59 
early passage melanoma cell lines, expression levels of PARP1, MITF, and five 
MITF target genes (CDK2, TBX2, RAB27A, EDNRB, and MC1R) were obtained 
from microarray data in the same way as PARP1 eQTL analysis. Normalized 
MITF levels of 59 cell lines were plotted, and cell lines were divided into high- 
and low-MITF subgroups based on a distinct delineation point. Genomic copy 
number of MITF region was also assessed using genotyping data, with no cell 
line displayed high-level amplification of the MITF gene. Pearson correlation 
analysis was performed to obtain correlation coefficient (r), or linear regression 
was used when MITF copy number was used as a covariate.
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Supplementary Figure 1. PARP1 eQTL and allele-specific expression analysis of 
melanoma cell lines, TCGA melanomas, and GTEx skin tissues. 
15609_M-Makowski_BNW.indd   116 11-06-18   14:29
Chapter 3
116
A B
R
el
at
iv
e
PA
R
P1
Le
ve
ls
 (A
.U
.)
0.1
1
10
100
AA GA GG
AA GA GG
R
an
k 
N
or
m
al
iz
ed
 P
A
R
P
1 
E
xp
re
ss
io
n 
(A
.U
.)
R
an
k 
N
or
m
al
iz
ed
 P
A
R
P
1 
E
xp
re
ss
io
n 
(A
.U
.)
AA GA GGAA GA GG
Skin Sun-Exposed (Lower Leg) Skin NOT Sun-Exposed (Suprapubic)
P = 2 x 10-3 P = 0.011
C D
P = 0.031
rs3219090 Genotype
PA
R
P1
Tr
an
sc
rip
tL
ev
el
s 
(A
.U
.)
0
5000
10000
15000
20000 P = 3.9 x 10-3
rs3219090 Genotype
rs3219090 Genotype rs3219090 Genotype
0 50 100 150
3e-01
5e-01
1
2
4
Skin Sun-Exposed
PA
R
P1
 rs
18
05
41
4
A
lle
lic
 R
at
io
(r
is
k/
pr
ot
ec
tiv
e)
0 20 40 60 80
3e-01
5e-01
1
2
4
Skin NOT Sun-Exposed
P = 1.16 x 10-5 P = 8.9 x 10-5
PA
R
P1
 rs
18
05
41
4
A
lle
lic
 R
at
io
(r
is
k/
pr
ot
ec
tiv
e)
E F
Supplementary Figure 1. PARP1 eQTL and allele-specific expression analysis of 
melanoma cell lines, TCGA melanomas, and GTEx skin tissues. 
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A PARP1 eQTL validation by qPCR in low passage human melanoma cell lines. PARP1 
transcript levels in 53 melanoma cell lines were measured by Taqman qPCR. PARP1 
levels were normalized against those of two control genes (ACTB and PPIA) and relative 
fold difference to the lowest sample is plotted using the ΔΔCt method ( P = 0.031, linear 
regression). G is the risk allele and A the protective allele of rs3219090. A.U. ; arbitrary unit, 
horizontal lines represent mean value and error bars s.e.m.
B PARP1 expression levels from RNA sequencing of 409 melanomas as a part of the TCGA 
skin melanoma project were plotted for each genotype of rs3219090 (P = 3.9 x 10-3, linear 
regression using gene-specific regional copy number as a covariate). Horizontal lines 
represent mean value and error bars s.e.m. 
C,D PARP1 eQTL analysis in GTEx skin tissues. eQTL analysis of PARP1 levels and genotype of 
rs3219090 was performed on 302 sun-exposed skin samples (P = 2 x 10-3, linear regression), 
as well as 196 skin samples from non-sun-exposed skin (P = 0.01, linear regression) using 
the GTEx portal (GTEx Analysis Release V6; dbGaP Accession: phs000424.v6.p1; http://
www.gtexportal.org/home/testyourown). 
E, F Allelic ratios of PARP1 transcripts were measured using data from (E) 139 sun-exposed 
or (F) 69 non-sun-exposed skin samples that are heterozygous for both rs3219090 and 
rs1805414 (coding surrogate SNP of rs3219090) from the GTEx database. The mapped 
numbers of RNAseq reads encompassing each allele of rs1805414 variant were used for 
calculating allelic ratios (P = 1.16 x10-5, sun-exposed; P = 8.9 x 10-5, non-sun-exposed; two-
tailed Wilcoxon signed rank test). Solid line marks 1:1 ratio, and dashed line represents the 
median ratio.
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Supplementary Figure 2. Functional annotation and prioritization of potentially gene-
regulatory candidate sequence variants based on melanocyte- and melanoma-specific 
epigenetic data.
Prioritization of candidate functional variants was based on LD with the lead GWAS SNPs 
(rs3219090 and rs1858550; r2 > 0.6) as well as location within potentially gene regulatory regions 
in human melanocyte and melanoma samples. All tracks for melanocyte DNaseI Hypersensitivity 
Site (DHS) and histone mark data were obtained from ENCODE and Roadmap Projects through 
UCSC genome browser. Histone mark ChIP-seq signals (H3K4Me1, H3K4Me3, and H3K27Ac) 
are shown for a representative individual (melanocyte_3) among three individuals analyzed by the 
Roadmap Project. DNaseI hypersensitivity signals are shown for one individual from ENCODE 
project (Melano) and two individuals from Roadmap project (Melanocyte_1, Melanocyte_2). The 
scale of each track is uniformly set throughout the region of the PARP1 gene to cover the highest 
peaks, with 0 as the baseline (see online methods for details of each track). Regions spanning 250bp 
upstream and downstream of each candidate SNP are enlarged in boxes. The genomic scale on 
chromosome 1 is following the hg19 human genome build and presented in bp unless it is shown 
as Mb. r2 of each SNP with rs3219090 was obtained from 1000 Genomes Phase 3 EUR (EUR, 
1KGph3) population. Recombination hotspots for 1000 genomes phase1 v3 CEU population are 
presented as log likelihood ratio.
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Supplementary Figure 3. Functional annotation of potentially gene- regulatory 
sequence variants at the PARP1 locus.
Annotations of four strong candidates are shown for both melanoma open chromatin and histone 
marks. All tracks were obtained from Melanoma Epigenome Project 8 and the ENCODE Project 
through the UCSC genome browser. Histone marks (H3K27Ac) are shown for 11 samples from 
Melanoma Epigenome. Scales of H3K27Ac ChIP-seq signal are uniformly set throughout the 
genome (0 to 0.3). Peaks are shown for 11 samples from Melanoma Epignome and two melanoma 
cell lines from ENCODE project (Mel2183 and RPMI7951). Open chromatin peaks from FAIRE-
seq are presented as interval of peaks except for Mel2183 and RPMI7951 for which uniform scale 
of DNaseI hypersensitivity signal was used throughout the PARP1 gene (0 to 0.1 and 0 to 100, 
respectively). See online method for details of each track. Regions spanning 250bp upstream and 
downstream of each candidate SNP are enlarged. Genomic scale on chromosome 1 follows the 
hg19 human genome build and presented in bp unless otherwise shown as Mb. r2 of each SNP with 
rs3219090 was obtained from 1000 Genomes Phase3 (1KGph3) EUR population. Recombination 
hotspots for 1000 Genomes Phase1 v3 CEU population are presented as log likelihood ratio.
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Annotations of four strong candidates are shown for both melanoma open chromatin and histone 
marks. All tracks were obtained from Melanoma Epigenome Project 8 and the ENCODE Project 
through the UCSC genome browser. Histone marks (H3K27Ac) are shown for 11 samples from 
Melanoma Epigenome. Scales of H3K27Ac ChIP-seq signal are uniformly set throughout the 
genome (0 to 0.3). Peaks are shown for 11 samples from Melanoma Epignome and two melanoma 
cell lines from ENCODE project (Mel2183 and RPMI7951). Open chromatin peaks from FAIRE-
seq are presented as interval of peaks except for Mel2183 and RPMI7951 for which uniform scale 
of DNaseI hypersensitivity signal was used throughout the PARP1 gene (0 to 0.1 and 0 to 100, 
respectively). See online method for details of each track. Regions spanning 250bp upstream and 
downstream of each candidate SNP are enlarged. Genomic scale on chromosome 1 follows the 
hg19 human genome build and presented in bp unless otherwise shown as Mb. r2 of each SNP with 
rs3219090 was obtained from 1000 Genomes Phase3 (1KGph3) EUR population. Recombination 
hotspots for 1000 Genomes Phase1 v3 CEU population are presented as log likelihood ratio.
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Supplementary Figure 4. Epigenetic annotation of the region encompassing PARP1 in 
primary melanocytes. 
A zoomed out view of histone modification and DNaseI hypersensitivity sites (DHS) in primary 
melanocytes are shown for PARP1 region. Red dashed vertical line indicates the position of 
rs144361550 overlapping histone marks and DHS. Genomic positions are based on hg19. 
Melanocyte DNaseI Hypersensitivity Sites are shown for two experimental replicates of two 
individuals. H3K4me1 and H3K4me3 signals are from three individuals, and H3K27ac traces are 
shown for two individuals including an experimental replicate. Melanocyte Chromatin States are 
from Chromatin Primary Core Marks Segmentation by HMM from Roadmap Project. Red: TSS; 
yellow: Enhancers; Green: Transcription. All tracks were obtained from ENCODE and Roadmap 
projects through UCSC Genome browser.
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Supplementary Figure 5. EMSAs of three top functional candidate SNPs rs1417765, 
rs2695240, and rs2570370. 
A-D EMSAs were performed using biotin-labeled double-stranded DNA probes encompassing 
10 bp to either side of each SNP with two different alleles. Nuclear extracts from melanoma 
cell lines UACC457, UACC1308, or UACC2331, and primary human melanocytes were 
used for each SNP. 50X, 100X or 500X molar excess of unlabeled competitors were added in 
specified lanes for competition. Risk alleles are shown first (T allele), in red, and protective 
alleles second (G or C allele) in green. 
E Since rs2695240 and rs2470370 are 50bp apart and in perfect LD, two SNPs were also tested 
as haplotypes using 186bp probes encompassing both SNPs. Probes were PCR-amplified 
using biotin labeled primers (primer sequences in Supplementary Table 14).
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cell lines UACC457, UACC1308, or UACC2331, and primary human melanocytes were 
used for each SNP. 50X, 100X or 500X molar excess of unlabeled competitors were added in 
specified lanes for competition. Risk alleles are shown first (T allele), in red, and protective 
alleles second (G or C allele) in green. 
E Since rs2695240 and rs2470370 are 50bp apart and in perfect LD, two SNPs were also tested 
as haplotypes using 186bp probes encompassing both SNPs. Probes were PCR-amplified 
using biotin labeled primers (primer sequences in Supplementary Table 14).
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Supplementary Figure 6. Luciferase assays for rs1417765 and rs2695240. 
Sequences encompassing rs1417765 (557bp) or rs2695240-rs2570370 (711bp) were cloned 5’ 
of minimal promoter of pGL4.23 vector and transfected into (A,C) primary melanocytes or (B) 
melanoma cell lines UACC1308 and (D) UACC2331. Luciferase activity was measured 24hrs after 
transfection and normalized against Renilla luciferase activity (shown as mean with s.e.m.). *P < 
0.05, **P < 0.01, ***P < 0.001 (n=6, two-tailed, t-test assuming unequal variance). Risk alleles are 
shown first (T allele), in red, and protective alleles second (G or C allele) in green. Since rs2695240 
and rs2570370 are 50bp apart and in perfect LD, two SNPs were tested as a haplotype.
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Sequences encompassing rs1417765 (557bp) or rs2695240-rs2570370 (711bp) were cloned 5’ 
of minimal promoter of pGL4.23 vector and transfected into (A,C) primary melanocytes or (B) 
melanoma cell lines UACC1308 and (D) UACC2331. Luciferase activity was measured 24hrs after 
transfection and normalized against Renilla luciferase activity (shown as mean with s.e.m.). *P < 
0.05, **P < 0.01, ***P < 0.001 (n=6, two-tailed, t-test assuming unequal variance). Risk alleles are 
shown first (T allele), in red, and protective alleles second (G or C allele) in green. Since rs2695240 
and rs2570370 are 50bp apart and in perfect LD, two SNPs were tested as a haplotype.
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Supplementary Figure 7. Representative capillary electrophoresis profiles of fragment 
analysis for rs144361550. 
Each panel shows an example trace for each of three genotypes (-/-: deletion/deletion, GGGCCC/
GGGCCC: insertion/insertion, and -/GGGCCC: deletion/insertion). Orange traces represent the 
sizing ladder, while blue and green peaks represent 6-FAM and VIC signal, respectively.
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Supplementary Figure 8. Hapmap CEU individuals with discordant genotypes between 
1KG Phases 1 and 3 were resolved by fragment analysis. 
Three individuals from three Hapmap CEU trios (families 1459, 1350, and 1454) with discordant 
genotypes of rs144361550 between 1000 Genomes Phase1 (1KG Phase1) and Phase 3 (1KG 
Phase3) are shown twice, with genotypes from each 1KG Phase. The remaining two members 
of the trios were genotyped by fragment analysis and resulting genotypes are shown in black. 
Fragment analysis genotypes and traces for discordant individuals are shown at the bottom and 
in the boxes: D, deletion allele; I, insertion allele. A red ‘X’ next to each progeny of trios denotes 
Mendelian error while green ‘O’ denotes no Mendelian error. All three discordant genotypes were 
resolved by fragment analysis and validated 1KG Phase3 genotypes. Trio structures and genotype 
comparisons are shown in Supplementary Table 8.
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Supplementary Figure 9. RECQL preferentially binds to the rs144361550 insertion 
allele. 
EMSA was performed using 100-800ng purified recombinant RECQL protein. Arrow indicates 
RECQL-probe complex. D: double-stranded 22bp deletion probe (risk), I: double-stranded 28bp 
insertion probe (protective). (A) long exposure, (B) short exposure.
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Supplementary Figure 10. RECQL binds the genomic region encompassing 
rs144361550 in primary melanocytes. 
Chromatin immunoprecipitation was performed using anti-RECQL antibody or normal IgG and 
sheared chromatin from 1% formaldehyde-fixed primary melanocytes. DNA was isolated from 
pulled-down chromatin and analyzed by qPCR. DNA quantity was normalized by taking ratio 
over input DNA for each IP. qPCR primers were designed to recognize either a known RECQL 
binding locus (Ctrl) or the region encompassing rs144361550 (indel). The average ratio from two 
independent experiments is presented (mean with s.e.m.).
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Supplementary Figure 11. Molar dichroic absorption spectra of single-stranded insertion and 
deletion alleles. Spectra recorded at 20 °C in 10 mM Li cacodylate buffer (pH 7.2) supplemented with 
100 mM LiCl (Li+ conditions, red curves), 100 mM KCl (K+ conditions, blue curves), or 100 mM KCl + 
10 μM PhenDC3 (black curves). (a–b) Reverse (transcribed, a) and forward (b) strands of deletion (Del) 
allele. (c–d) The same for insertion (Ins) allele. Oligonucleotide sequences are provided in 
Supplementary Table 14; Deletion: risk, Insertion: protective allele. (e) A 34-mer oligonucleotide 
UpsB-Q-�����-CAGGGTTAAGGGTATAACTTTAGGGGTTAGGGTT-���19 was used as a positive control: 
the difference between the spectra observed in K+ and Li+ conditions is indicative of formation of a G4 
structure in K+ conditions.
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the difference between the spectra observed in K+ and Li+ conditions is indicative of formation of a G4 
structure in K+ conditions.
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Supplementary Figure 12. Molar dichroic absorption spectra of double-stranded insertion and 
deletion alleles. Experimental conditions and plot designations as for Supplementary Figure 9 above. 
(a–b) Double-stranded probes, as used for mass-spec, corresponding to deletion (Del, a) and insertion 
(Ins, b) alleles. (c–d) Truncated probes corresponding to deletion (Del, c) and insertion (Ins, d) alleles.
Probe sequences are listed in Supplementary Table 14.
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(a–b) Double-stranded probes, as used for mass-spec, corresponding to deletion (Del, a) and insertion 
(Ins, b) alleles. (c–d) Truncated probes corresponding to deletion (Del, c) and insertion (Ins, d) alleles.
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Supplementary Figure 13. Molar thermal difference spectra ¨İTDS  İ95 °C – İ20 °C) of insertion and 
deletion alleles. (a) Single-stranded oligonucleotides. MS-R-Del or MS-R-Ins: reverse (transcribed) 
strands, MS-F-Del or MS-F-Ins: forward strands of deletion (Del) or insertion (Ins) alleles as used for 
mass-spectrometry. Oligonucleotide UpsB-Q-1 (sequence: cf. Supplementary Figure 9 above) was used 
as a positive control: negative peak labeled with an asterisk gives evidence of formation of a G4 structure. 
(
b) Double-stranded (F/R) oligonucleotides formed by annealing of reverse and forward probes used
above (MS-F/R-Del, MS-F/R-Ins) or truncated sequences (Sh-F/R-Del, Sh-F/R-Ins). Oligonucleotide
sequences are provided in Supplementary Table 14. Deletion: risk, Insertion: protective allele.
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A Single-stranded oligonucleotides. MS-R- Del or MS-R -Ins: reverse (tra scribed) strands, 
MS-F-Del or MS-F-Ins: forward strands of deletion (Del) or insertion (Ins) alleles as used 
for mass-spectrometry. Oligonucleotide UpsB-Q-1 (sequence: cf. Supplementary Figure 9 
above) was used as a positive control: negative peak labeled with an asterisk gives evidence of 
formation of a G4 structure.
B Double-stranded (F/R) oligonucleotides formed by annealing of reverse and forward probes 
used above (MS-F/R-Del, MS-F/R-Ins) or truncated sequences (Sh-F/R-Del, Sh-F/R-Ins). 
Oligonucleotide sequences are provided in Supplementary Table 14. Deletion: risk, Insertion: 
protective allele.
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Supplementary Figure 14. Chemical perturbation of PARP1 indel DNA secondary 
structure recruits and repels binding proteins with little allelic preference. 
Quantitative isobaric TMT labeling was used to identify preferential protein binders of the PARP1 
rs144361550 ssDNA insertion or deletion allele after chemical perturbation of possible DNA 
secondary structures. LiCl was used to distupt potential G-quadruplex structure, while PhenDC3 was 
used to stabilize G-quadruplex like structures. NC-Bis was used as a negative control compound. 
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A Heatmap of protein binding (based on a readout of row Z-score normalized normalized TMT 
reporter ion abundance) for rs144361550 insertion and deletion baits in different structure 
perturbing binding conditions. Two main clusters were identified, distiguished as either repelled 
(top cluster) or recruited (bottom cluster) by PhenDC3 ligand in a non-allele specific fashion. 
GO term enrichment per cluster is indicated on the right of the heatmap. 
B Two-dimensional interaction plot of data from (A) for the rs144361550 ssDNA insertion v 
deletion allele. For rs144361550 ssDNA, in contrast to dsDNA, RECQL prefers the deletion 
allele in KCl protein binding buffer conditions (minus PhenDC3 or NC-Bis). Outliers are called 
as before, using 1.5 IQRs in both replicates as an outlier calling criterion.
Supplementary Table 1 Chr1q42.1 locus eQTL genes for rs3219090 in UACC 
melanoma cell lines
Gene (probe)a P-Value Effect Size fore ach copy of risk allele, G Standard Error
PARP1 (208644_at) 0.0014 0.3653 0.1091
PYCR2 (231715_s_at) 0.0122 0.2567 0.0992
PYCR2 (224855_at) 0.0296 0.1997 0.0895
EPHX1 (228549_at) 0.0304 0.2761 0.1240
TMEM63A (202699_s_at) 0.0428 0.1811 0.0873
TMEM63A (215583_at) 0.0725 0.0975 0.0532
ACBD3 (202323_s_at) 0.1153 0.2055 0.1285
SRP9 (201273_s_at) 0.1454 0.1187 0.0804
TMEM63A (202700_s_at) 0.1482 0.0788 0.0537
ADCK3 (218168_s_at) 0.2477 0.1213 0.1039
C1orf55 (1553338_at) 0.2689 0.1309 0.1171
PSEN2 (204262_s_at) 0.2928 0.1479 0.1393
LBR (201795_at) 0.3122 0.1369 0.1342
PSEN2 (211373_s_at) 0.3624 0.1467 0.1597
CDC42BPA (203794_at) 0.4880 0.0980 0.1404
CDC42BPA (214464_at) 0.5098 0.1372 0.2067
ENAH (222434_at) 0.5539 -0.0939 0.1574
ACBD3 (202324_s_at) 0.5731 0.0615 0.1084
ENAH (217820_s_at) 0.6924 0.0729 0.1833
ENAH (222433_at) 0.7180 0.0594 0.1636
EPHX1 (202017_at) 0.7602 0.0648 0.2112
ENAH (228310_at) 0.9282 0.0184 0.2033
ITPKB (203723_at) 0.9994 0.0002 0.3233
a – Gene name followed by Affymetrix U133Plus2 expression microarray probe ID. PARP1 and 
other nominally significant ( P < 0.05) eQTL genes are in bold. Bonferroni-corrected P-value 
threshold for testing 14 genes is P < 3.6 x 10-3
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Supplementary Table 2. Chr1q42.1 locus eQTL genes for rs3219090 in TCGA 
melanomas
Genea P-Valueb Effect Size(risk allele, G)
PARP1 0.00392 393.63
ACBD3 0.35784 -39.02
CDC42BPA 0.35986 59.93
LIN9 0.40174 -4.89
LBR 0.41458 33.70
ENAH 0.44541 -96.02
ITPKB 0.53837 294.57
SDE2 0.63349 -9.43
DNAH14 0.63800 2.23
PSEN2 0.64290 -48.24
SRP9 0.72069 -25.43
TMEM63A 0.77179 11.79
LEFTY2 0.80346 1.27
ADCK3 0.81551 8.64
EPHX1 0.90889 56.79
H3F3A 0.97950 2.65
a – PARP1 and other nominally significant (P < 0.05) eQTL genes from the discovery set (UACC 
melanoma cell lines) are in bold.
b – Linear regression with gene-specific regional copy number as a covariate
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Supplementary Table 3. Chr1q42.1 locus eQTL genes for rs3219090 in GTEx skin 
tissues (Sun-exposed)
Genea P-Value Effect Size(risk allele, G)
PARP1 0.0002 0.1300
PYCR2 0.0170 -0.1000
DNAH14 0.0260 -0.1400
PSEN2 0.0770 0.0870
SDE2 0.3200 -0.0370
CDC42BPA 0.4500 -0.0400
LBR 0.4500 -0.0370
H3F3A 0.5800 0.0410
H3F3AP4 0.6000 0.0170
ADCK3 0.6300 -0.0200
LEFTY2 0.6500 -0.0300
LIN9 0.7600 -0.0130
ENAH 0.8100 -0.0085
ITPKB 0.8100 -0.0120
C1orf95 0.8300 0.0130
TMEM63A 0.8700 0.0050
ITPKB-IT1 0.9500 -0.0052
ACBD3 0.9700 0.0015
SRP9 0.9900 -0.0004
EPHX1 1.0000 0.0003
a – PARP1 and other nominally significant (P < 0.05) eQTL genes from the discovery set (UACC 
melanoma cell lines) are in bold.
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Supplementary Table 3. Chr1q42.1 locus eQTL genes for rs3219090 in GTEx skin 
tissues (Sun-exposed)
Genea P-Value Effect Size(risk allele, G)
PARP1 0.0002 0.1300
PYCR2 0.0170 -0.1000
DNAH14 0.0260 -0.1400
PSEN2 0.0770 0.0870
SDE2 0.3200 -0.0370
CDC42BPA 0.4500 -0.0400
LBR 0.4500 -0.0370
H3F3A 0.5800 0.0410
H3F3AP4 0.6000 0.0170
ADCK3 0.6300 -0.0200
LEFTY2 0.6500 -0.0300
LIN9 0.7600 -0.0130
ENAH 0.8100 -0.0085
ITPKB 0.8100 -0.0120
C1orf95 0.8300 0.0130
TMEM63A 0.8700 0.0050
ITPKB-IT1 0.9500 -0.0052
ACBD3 0.9700 0.0015
SRP9 0.9900 -0.0004
EPHX1 1.0000 0.0003
a – PARP1 and other nominally significant (P < 0.05) eQTL genes from the discovery set (UACC 
melanoma cell lines) are in bold.
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Supplementary Table 4. Chr1q42.1 locus eQTL genes for rs3219090 in GTEx skin 
tissues (NOT Sun-exposed)
Genea P-Value Effect Size(risk allele, G)
PARP1 0.0110 0.1200
PYCR2 0.0120 -0.1900
LEFTY2 0.0410 0.2100
PSEN2 0.0990 0.1100
LIN9 0.1300 0.0940
TMEM63A 0.1500 -0.0610
H3F3A 0.1600 0.1300
ADCK3 0.1700 -0.0670
SRP9 0.2000 0.0480
DNAH14 0.3500 -0.0750
ACBD3 0.3600 -0.0430
ENAH 0.4700 0.0360
ITPKB-IT1 0.4900 -0.0790
EPHX1 0.5000 0.0300
CDC42BPA 0.5700 -0.0480
C1orf95 0.6000 0.0390
LBR 0.6800 -0.0280
H3F3AP4 0.7600 0.0190
ITPKB 0.8300 0.0140
SDE2 0.9100 0.0051
a – PARP1 and other nominally significant (P < 0.05) eQTL genes from the discovery set (UACC 
melanoma cell lines) are in bold.
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Supplementary Table 4. Chr1q42.1 locus eQTL genes for rs3219090 in GTEx skin 
tissues (NOT Sun-exposed)
Genea P-Value Effect Size(risk allele, G)
PARP1 0.0110 0.1200
PYCR2 0.0120 -0.1900
LEFTY2 0.0410 0.2100
PSEN2 0.0990 0.1100
LIN9 0.1300 0.0940
TMEM63A 0.1500 -0.0610
H3F3A 0.1600 0.1300
ADCK3 0.1700 -0.0670
SRP9 0.2000 0.0480
DNAH14 0.3500 -0.0750
ACBD3 0.3600 -0.0430
ENAH 0.4700 0.0360
ITPKB-IT1 0.4900 -0.0790
EPHX1 0.5000 0.0300
CDC42BPA 0.5700 -0.0480
C1orf95 0.6000 0.0390
LBR 0.6800 -0.0280
H3F3AP4 0.7600 0.0190
ITPKB 0.8300 0.0140
SDE2 0.9100 0.0051
a – PARP1 and other nominally significant (P < 0.05) eQTL genes from the discovery set (UACC 
melanoma cell lines) are in bold.
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Supplementary Table 6. Nomination of PARP1 functional risk variants
SNP ID Maxa r2 P-value(meta-analysis)b
Melanocyte
DHS 
(n=3)c
Melanoma 
DHS 
(n=13)d
Assignment
Candidate 
for 
validation
rs144361550 1 4.85E-11 100% 62%
Strong supported
Yes
Open Chromatin
rs1417765 1 4.73E-12 100% 69%
Strong supported
Yes
Open Chromatin
rs2695240 1 3.28E-13 100% 62%
Strong supported
Yes
Open Chromatin
rs2570370 1 3.48E-13 100% 69%
Strong supported
Yes
Open Chromatin
rs1341336 1 8.32E-13 67% 23%
Weak supported
Open Chromatin
rs2793657 1 1.53E-12 67% 23%
Weak supported
Open Chromatin
rs1858548 1 3.56E-13 67% 0%
Weak supported
Open Chromatin
rs35380305 1 2.25E-10 67% 0%
Weak supported
Open Chromatin
rs1858549 1 3.59E-13 67% 0%
Weak supported
Open Chromatin
rs2666428 1 5.27E-12 33% 0%
Weak supported
Open Chromatin
rs2048426 1 7.82E-13 33% 31%
Weak supported
Open Chromatin
rs2136875 1 3.18E-13 33% 8%
Weak supported
Open Chromatin
rs878366 0.634 33% 8%
Weak supported
Open Chromatin
rs577289790 0.826 33% 0%
Weak supported
Open Chromatin
rs35242305 0.996 33% 8%
Weak supported
Open Chromatin
a -  Max r 2 is the highest r2 value for each SNP among (1) r2 with GWAS lead SNP rs3219090 in 1KG EUR, (2) 
1KG CEU, (3) r2 with meta-analysis 4 lead SNP rs1858550 in 1KG EUR, or (4)1KG CEU.
b - P-value for melanoma association from meta- analysis4. Blank: P-value is higher than 1 x 10-8 
c - Percentage of individual melanocyte samples with evidence of open chromatin for the region encompassing 
each SNP in ENCODE/Roadmap data5
d -Percentage of melanoma short-term cultures or cell lines with evidence of open chromatin for the region 
encompassing each SNP5,8
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Supplementary Table 7. Summary of experimental validation for PARP1 gene-regulatory 
candidate functional variants
rs1417765 rs144361550 rs2695240 rs2570370
EMSA (p)
Specific bindinga
Protective allele Protective allele Risk allele Not specific
EMSA (m)
Specific bindingb
Protective allele Protective allele Risk allele Not specific
Luc (p) 
Higher activityc Protective allele No difference Risk allele NA
Luc (m)
Higher activityd Protective allele Risk allele Risk allele NA
Transcriptional 
activity (p)e Weak Weak Weak NA
Transcriptional 
activity (m)f Weak Strong Negative NA
Direction (allele)g Not consistent Consistent Consistent NA
a - alleles that display specific or favorable binding to nuclear proteins from primary melanocytes 
b - alleles that display specific or favorable binding to nuclear proteins from melanoma cell lines
c - alleles that display significantly higher luciferase activity when transfected to primary melanocytes 
d - alleles that display significantly higher luciferase activity when transfected to melanoma cell lines 
e - luciferase activity of the DHS region encompassing each SNP in primary melanocytes compared to the 
minimal promoter control
f - luciferase activity of the DHS region encompassing each SNP in melanoma cell lines compared to the minimal 
promoter control
g - denotes whether if the risk allele displays higher luciferase activity consistent with expression data (eQTL 
and allelic imbalance)
Supplementary Table 9. Validation of rs144361550 genotype and re-assessment of LD 
with rs3219090
r2 with rs3219090a rs1417765 rs144361550 rs2695240 rs2570370
1KG, phase1 EUR
(n=379) 1.00 0.667 0.905 0.905
1KG, phase1 CEU
(n=85) 1.00 0.770 0.869 0.869
1KG, phase3 EUR
(n=503) 1.00 0.947 0.910 0.910
1KG, phase3 CEU
(n=99) 1.00 1.00 0.873 0.873
DCEG reference set 
(healthy, EUR, n=745)c
0.94 b
Hapmap CEU
(58 founders)d 1.00 
b
a - r2 values were calculated using PLINK with 1000 genomes (1KG) genotypes obtained from 1KG, phase1 and 
phase3 databases.
b - rs144361550 was genotyped for 30 Hapmap CEU trios and a 745 sample imputation reference panel European 
decent 9 using fragment analysis on CE with two different dyes (6-FAM and VIC) and two different fragment 
sizes.
c - rs3219090 genotypes for 745 reference individuals were determined by direct genotyping using Taqman 
genotyping assay.
d - rs3219090 genotypes for 58 founders were obtained from Hapmap Rel28 PhaseII+III, Aug10, b36
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Supplementary Table 10. Insertion-specific binding protein identified by mass 
spectrometry
Protein 
names
Mean Ins/
Del Ratio in 
Mass-speca
Putative G4-related 
function Reference
Antibody
super-shift
EMSA with 
purified protein
CIRBP 28.1 No super-shift No allelic binding
NCL 20.6 G4 binding (stabilizing) Gonzalez et al10 No super-shift Allelic binding
HNRNPD 20.3 G4 binding Dempsey et al11 No super-shift No allelic binding
SRSF3 19.7 No super-shift
SRSF7 16.9
SUB1 12.8
RBM39 10.9
PDCD11 9.6
PCBP1 9.5
RBM14 7.7
ZC3HAV1 7.7
RPA1 7.6 G4 unwinding helicase Safa et al12 No super-shift No allelic binding
TOP3A 7.6 G4 unwinding helicase Temime-Smaali et al13 No super-shift
DHX36 6.7 G4 unwinding helicase Chen et al14 No super-shift
RPA3 6.2 G4 unwinding helicase Safa et al12 No super-shift
RFC3 6.4
RECQL 4.7 G4 unwinding helicase Huber et al15 Super-shift Allelic binding
a - mean ratio of heavy/light-labeled peptides from two experiments by label swapping
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Supplementary Table 11. G-quadruplex forming potential prediction
A)  Intramolecular G4 structures
Query Name Deletion allele Insertion allele
Query Sequencea
GAGCGAGCGGGCCCGGGCCC
TCGGAGCGGCACTTGGGGCC
GAGCGAGCGGGCCCGGGCCC
GGGCCCTCGGAGCGCACTT
GGGGCC
Length (number of nucleotide) 40 46
QGRS foundb 0 1
G-Scorec NA 58
QGRS Mapper (http://bioinformatics.ramapo.edu/QGRS/analyze.php)20 was used with the following search 
parameters: QGRS Max Length: 45, Min G-Group Size: 3, Loop size: from 0 to 36.
a - Query sequence is the same as the probe sequences used for mass-spectrometry. Sequence from the reverse 
(transcribed) strand was used for both alleles. Predicted G-quadruplex strings are underlined and highlighted.
b - Number of non-overlapping QGRS (putative Quadruplex forming G-Rich Sequences) found in the query 
sequence
c - Likelihood score for forming a stable G-quadruplex. NA: score not available
B)  Intermolecular G4 structures
Querya Sequence (5ƍ–3ƍ)b
Putative
G4 
topologyc
Del allele (F) GGCCCCAAGTGCCGCTCCGAGGGCCCGGGCCCGCTCGCTC ABAB
(R) GAGCGAGCGGGCCCGGGCCCTCGGAGCGGCACTTGGGGCC
Ins allele (F) GGCCCCAAGTGCCGCTCCGAGGGCCCGGGCCCGGGCCCGCTCGCTC ABAB, 
ABBB, or 
AAAB
(R) GAGCGAGCGGGCCCGGGCCCGGGCCCTCGGAGCGGCACTTGGGGCC
Sequences were analyzed according to algorithms described by Kudlicki21.
a - Query is the double-stranded sequence corresponding to probes described above. G runs which can participate 
in formation of G-quartets are underlined and highlighted.
b - Truncated sequences used for a biophysical study are typed in bold (cf. Supplementary Table 14 below).
c - Topological description of putative G4 structures using notation from Kudlicki21.
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Supplementary Table 12. PARP1 and MITF target gene expression correlation in melanoma cell 
lines
Gene
Symbola Probe ID
b
vs MITF
Pearson
r (n=59)
P-valuec
vs
PARP1
Pearson
r (n=59)
P-valuec
vs PARP1
Pearson r
(n=23,
MITF-high)
P-
valuec
CDK2   211804_s_at 0.85 1.67E-17 0.25 0.0588 0.37 0.0827
TBX2 40560_at 0.70 5.09E-10 0.23 0.0779 0.32 0.1420
RAB27A  209514_s_at 0.69 1.60E-09 0.19 0.1487 0.15 0.4940
EDNRB  204271_s_at 0.68 1.40E-08 0.11 0.4436 0.43 0.0394
MC1R 205458_at 0.42 1.04E-03 -0.01 0.9298 -0.07 0.7443
a – MITF target genes were selected based on 13 melanocyte-specific target genes that were validated by Hoek et 
al22. Five of those thirteen genes are expressed above background levels in our 59 early-passage melanoma cell 
lines and used for testing correlation with PARP1 levels.
b – probe ID from Affymetrix U133Plus2 expression microarray
c – Correlation analyses were performed regardless of genomic copy number.
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Supplementary Table 13. Mfolda-predicted lowest-energy secondary structures of oligonucleotides 
used for G4 analyses.
Oligonucleotide Structure ǻG / kcal molí1
EMSA-R-Del í3.94
MS-R-Del í6.12
EMSA-R-Ins í9.79
MS-R-Ins í11.97
a- http://unafold.rna.albany.edu/?q=mfold 23a - http://unafold.rna.albany.edu/?q=mfold 23
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Supplementary Table 14. Oligonucleotide sequences
rs144361550 Oligo probes Forward (5’-3’) Reverse (5’-3’)
Deletion EMSA and luciferase 
construct (22bp)
GCCGCTCCGAGGGCCCGGG
CCC GGGCCCGGGCCCTCGGAGCGGC
Insertion EMSA and luciferase 
construct (28bp)
GCCGCTCCGAGGGCCCGGG
CCCGGGCCC
GGGCCCGGGCCCGGGCCCTC
GGAGCGGC
Deletion mass spec, CD and TDS 
(40bp)
GGCCCCAAGTGCCGCTCCG
AGGGCCCGGGCCCGCTC
GCTC
GAGCGAGCGGGCCCGGG
CCCTCGGAGCGGCACTT
GGGGCC
Insertion mass spec, CD and TDS 
(46bp)
GGCCCCAAGTGCCGCTC
CGAGG GCCCGGGCCCGGG
CCCGCTCGCTC
GAGCGAGCGGGCCCGGG
CCCGGGCCCTCGGAGCGG
CACTTGGGGCC
Truncated deletion CD and TDS 
(14bp) AGGGCCCGGGCCCG CGGGCCCGGGCCCT
Truncated insertion CD and TDS 
(20 bp)
AGGGCCCGGGCCCGGG
CCCG CGGGCCCGGGCCCGGGCCCT
PCR primers for re-genotyping 
rs144361550 Forward (5’-3’) Reverse (5’-3’)
156bp amplicon (6-FAM) GCAACATCAGCAAAACCTTC CCCGGGTTAACTGTGTCC
240bp amplicon (VIC) CCACCCAGAAAGGAGAAGAG GTTAACTGTGTCCGGGAAGG
PCR primers for rs144361550 
ChIP qPCR Forward (5’-3’) Reverse (5’-3’)
RECQL positive control (Pos) CTCCACCCCCAAGGAAAAAG GGCAGGGTCCCATGCA
rs144361550 locus (Indel) GAAGAGGCTCCTCGTTTTCAC TTCCGGAAGGTTTTGCTG
EMSA probes Forward (5’-3’) Reverse (5’-3’)
rs1417765 (21bp) ATGTAGTGTG[T/G]GTCCCTGCTC
GAGCAGGGAC[A/C]
CACACTACAT
rs2695240 (21bp) GGGGCTGATG[T/C]GGGAGCCTCG
CGAGGCTCCC[A/G]
CATCAGCCCC
rs2570370 (21bp) GACAGCAAAG[T/C]CATGAGAAAT
ATTTCTCATG[A/G]
CTTTGCTGTC
primers for rs2695240-rs2570370 
haplotype probe (186bp amplicon)
CAGTCATTAAGAAAA
CAAGGACAAAG
ATGAGACACCCTGG
AAATAAATG
PCR primers for luciferase 
constructs Forward (5’-3’) Reverse (5’-3’)
rs144361550 (905bp) CTGGGACAGAACAATCAAAGG GTCGCCACCATCCATGTAG
rs1417765 (557bp) TTCCAGAGTATTTTCCCTGTCC TTAGTAGCAATGGGGCTTCAC
rs2695240-rs2570370 (711bp) TCAGGAAATCTGCACTCTGG GTCAGGGCAAGTCCATTAGG
MITF-M promoter ChIP primers Forward (5’-3’) Reverse (5’-3’)
Primer1 AACATGAATCTCTTTTCTTTTTAAGTG
CAATCTCATATTGTTTC
AAATGACTG
Primer2 TGCATTATCCTGGGCATTTAG
TTGTGAACAAACAG
ATATAGTTTCCAG
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rs1417765 (21bp) ATGTAGTGTG[T/G]GTCCCTGCTC
GAGCAGGGAC[A/C]
CACACTACAT
rs2695240 (21bp) GGGGCTGATG[T/C]GGGAGCCTCG
CGAGGCTCCC[A/G]
CATCAGCCCC
rs2570370 (21bp) GACAGCAAAG[T/C]CATGAGAAAT
ATTTCTCATG[A/G]
CTTTGCTGTC
primers for rs2695240-rs2570370 
haplotype probe (186bp amplicon)
CAGTCATTAAGAAAA
CAAGGACAAAG
ATGAGACACCCTGG
AAATAAATG
PCR primers for luciferase 
constructs Forward (5’-3’) Reverse (5’-3’)
rs144361550 (905bp) CTGGGACAGAACAATCAAAGG GTCGCCACCATCCATGTAG
rs1417765 (557bp) TTCCAGAGTATTTTCCCTGTCC TTAGTAGCAATGGGGCTTCAC
rs2695240-rs2570370 (711bp) TCAGGAAATCTGCACTCTGG GTCAGGGCAAGTCCATTAGG
MITF-M promoter ChIP primers Forward (5’-3’) Reverse (5’-3’)
Primer1 AACATGAATCTCTTTTCTTTTTAAGTG
CAATCTCATATTGTTTC
AAATGACTG
Primer2 TGCATTATCCTGGGCATTTAG
TTGTGAACAAACAG
ATATAGTTTCCAG
15609_M-Makowski_BNW.indd   142 11-06-18   14:30
        
3PARP1 confers melanoma risk via regulation by RECQL of an allelic DNA structure
143
Supplementary Table 14. Oligonucleotide sequences (Continued)
MITF-M promoter ChIP primers Forward (5’-3’) Reverse (5’-3’)
Primer3 ATGCTTTGTACAGTGTTTAGCAC AAAGCATGAGCATTTTTGCTGAG
Primer4 CCACTTCTGTGTGTGCTATGTTC TCCGACTGCAGGATGACTATC
Primer5 GGGGCATTCTGCTATTAACC ATTTTTCCCCCTGGCTTG
Primer6 AAAAGGCCCTTATGTGAACG GGTAGACTATCCCTCCCTCTAC
Primer7 TGGTGTCTCGGGATACCTTG TGAGTCAGAATAAATCTCACCTGATAG
Primer8 TGCTCTTTTAATGCTGTTTATTATTTG TGAGCAATGAACAGGAGCTG
Primer9 CATCAGCTCCTGTTCATTGC TTTCAAATGCATAACACTTACACG
Primer10 CAGGGAAATAAAATAGGGCAAAG TTTCAGACGGCTCTTCCTTC
Primer11 GGGCAGGCAGTTTAGCATAG CATTGGGTTCGAGGATTTTC
Primer12 GGGCTATA-AGCTTTTTCAACTGG CGTGGGGGATACCTAGTGAG
Bisulfite sequencing primers Forward (5’-3’) Reverse (5’-3’)
Cg06640206 (F3 and R3) TTTTTTAAAGGGGTATTTTGTTATT AATTTATTGTTG
AAACACCACCRAAAACTTT
ATCAC AAAAACCCTAC
Cg11038507 (F7 and R7) ATGTAGTTAAGAATAAGGTGTATA TTAAGATTAGGATG
AAATAACRAACTATCAAAA
TCAAACTCACTATC
Primers for MITF-M promoter 
luciferase construct
Forward (5’-3’) with KpnI 
overhang (lower case) Reverse (5’-3’)
MITF.674 construct actgaactggtaccATTCTCAGCAAAAATGCTCATGC CCAAGCTTACTTAGATCTCGAG
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Abstract
Interaction proteomics studies have provided fundamental insights into 
multimeric biomolecular assemblies and cell-scale molecular networks. 
Significant recent developments in mass spectrometry-based interaction 
proteomics have been fueled by rapid advances in label-free, isotopic, and 
isobaric quantitation workflows. Here, we report a quantitative protein-DNA 
and protein-nucleosome binding assay that uses affinity purifications from 
nuclear extracts coupled with isobaric chemical labeling and mass spectrometry 
to quantify apparent binding affinities proteome-wide. We use this assay with 
a variety of DNA and nucleosome baits to quantify apparent binding affinities 
of monomeric and multimeric transcription factors and chromatin remodeling 
complexes. 
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Introduction
Interaction proteomics, via mass spectrometry, has contributed invaluably 
to the identification of physical associations between biological molecules and 
the translation thereof into cellular protein networks1-3. Interaction proteomics 
methodologies are generally semi-quantitative and use label-free or chemical 
labeling based relative quantification to call interactions as “outliers” from a 
background of non-specific identifications4,5. Thus, interactions are regularly 
reported in a binary “on/off” manner, though semi-quantitative stoichiometric 
information is beginning to add a quantitative dimension to interaction studies. 
Nevertheless, a complete characterization of a functioning cell requires 
knowledge not only of specificity of biomolecular interactions (i.e., does an 
interaction occur, or not) but also of affinity (i.e., how strong, in absolute terms, 
is some given interaction)6. Typical affinity quantitation methods, such as ITC, 
SPR, Fluorescence Polarization, FRET, or EMSA, have been performed on 
a single interaction, case-by-case basis and require laborious expression and 
purification of recombinant proteins. Importantly, chemoproteomic approaches 
studying protein-small molecule interactions established the possibility of 
designing absolutely quantitative binding assays using semi-quantitative isobaric 
labeling and mass spectrometry7,8. Similarly, thermal proteome profiling is an 
innovative mass spectrometry approach that uses thermal stability shifts upon 
small molecule binding to estimate apparent dissociation constants proteome-
wide, again with a semi-quantitative isobaric labeling strategy9,10. Other 
protein-centric studies have focused on measuring the DNA binding landscape 
of a single, or a few, transcription factors11,12. However, the inverse problem 
of interrogating the quantitative protein binding landscape of DNA sequences 
of interest has received considerably less attention and is still dominated by 
semi-quantitative workflows13,14. Here, we present a method for determining, 
proteome-wide, tens to hundreds of apparent dissociation constants (Kd
app) of 
nuclear proteins for DNA and nucleosome ligands simultaneously using affinity 
purification from nuclear lysates and isobaric 10-plex TMT labeling coupled 
with mass spectrometry.
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Methods
Cell culture and nuclear lysate preparation
Wild-type HeLa Kyoto cells (received from Anthony Hyman and Ina Poser, 
Human HeLa BAC database, Dresden, Germany) were cultured in DMEM 
supplemented with 10% FBS and 100 U/mL penicillin and streptomycin. Cells 
were periodically tested for mycoplasma contamination. Nuclear lysates were 
isolated as described previously14. Briefly, cells were lysed by swelling and 
mechanical force in buffer A (10 mM HEPES (pH 7.9), 1.5 mM MgCl2, 10 
mM KCl and 0.15% NP40). Then, nuclei were collected by centrifugation and 
chemically lysed in buffer C (420 mM NaCl2, 20 mM Hepes (pH 7.9), 20% 
(v/v) glycerol, 2 mM MgCl2, 0.2 mM EDTA, 0.1% NP40, EDTA-free complete 
protease inhibitors (CPIs, Roche), and 0.5 mM DTT). Protein concentrations 
were assessed by Bradford assay. 
Affinity purification and sample preparation
Oligonucleotides for affinity purification were ordered as custom synthesized 
oligos from Integrated DNA Technologies (IDT, Supplementary Table 1). DNA 
and nucleosome affinity purifications were performed using a filter plate based 
workflow described first by Hubner et al15. The essential protocol is described 
below. 
First, all dsDNA oligos were annealed by heating to 95C for 10 minutes 
before cooling to room temperature. Each oligo was then diluted to a working 
stock of 3 μM, which represented the highest concentration “reference” titration 
point in this study. A series of nine three-fold dilutions was then prepared, 
resulting in a titration series of 10 oligo concentrations ranging from 0.15 nM 
to 3 μM. We prepared 200 uL of oligo per titration point per replicate in this 
fashion. Dilutions were performed in DNA binding buffer (DBB: 1 M NaCl, 10 
mM Tris pH 8, 1 mM EDTA, 0.05% NP-40).
Filter plates were first prepared with 50 uL of ethanol per well (96-well filter 
plate, 1.2 μM pore, Millipore/Merck MSBVS1210). Wells were then washed 
twice with DBB. 20 uL streptavidin-sepharose bead slurry was added to each 
well (GE, 10 uL beads, 3 nmol binding capacity). Wells were washed twice 
with DBB. 150 uL of the corresponding oligo titration point was added to each 
well, and oligos were immobilized to the streptavidin-conjugated beads over a 
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1 hour incubation at 4C while shaking on a tabletop microplate shaker.  Samples 
were then washed once with DBB and twice with protein binding buffer (PBB: 
150 mM NaCl, 50 mM Tris pH 8, 0.25% NP-40, 1 mM TCEP, and CPIs). 100 
μg of HeLa nuclear lysate was then diluted to 150 uL final volume in PBB and 
added to each well. Samples were incubated for 2 hours at 4C while shaking on 
a microplate shaker, then washed six times with washing buffer (150 mM NaCl, 
100 mM Triethylammonium bicarbonate, TEAB). 
For competition experiments using SP/KLF wild-type and mutated 
oligonucleotides, beads were pre-washed as described and pre-incubated in 96-
well plate format with 200 nM biotinylated SP/KLF wild-type oligonucleotide 
diluted in DBB for 1 hour at 4C while shaking on a tabletop microplate shaker. 
Free (unbiotinylated) wild-type or mutated SP/KLF oligonucleotide were 
prepared at three-fold diluted concentrations in PBB from 0.3 nM to 6 μM 
as described above. 100 μg of HeLa nuclear lysate was prepared in PBB and 
oligonucleotides were mixed with HeLa nuclear lysates at a ratio of 1:1 in a final 
volume of 150 uL, with free oligonucleotides at a final concentration of 0.15 
nM to 3 μM. Samples were then washed once with DBB and twice with PBB. 
HeLa lysates plus free oligonucleotides were added to the beads containing 
200 nM immobilized SP/KLF oligonucleotide. Proteins were incubated for 2 
hours at 4C while shaking while shaking on a microplate shaker, then washed 
six times with washing buffer. Sample preparation for mass spectrometry was 
continued as described below. 
For the LiCl mycG4 experiment, the oligos were heated for 10 minutes 
at 95C and afterwards snap-cooled on ice for 3-5 minutes before they were 
immobilized on the beads. The NaCl in the PBB was replaced with 150 mM LiCl 
for the oligo titration, protein incubation, and washing steps (PBB composition: 
150 mM LiCl, 50 mM Tris pH 8, 0.25% NP-40, 1 mM TCEP, and CPIs). For the 
PhenDC3 mycG4 experiment, 20 μM PhenDC3, final concentration, was added 
to the PBB for oligo titration, protein incubation, and washing steps (PBB 
composition: 150 mM NaCl, 50 mM Tris pH 8, 0.25% NP-40, 1 mM TCEP, 
CPIs, and 20 μM PhenDC3). For the nucleosome experiments, nucleosome 
titration and immobilization was performed in PBB instead of DBB. All other 
experimental conditions were the same as described above.
Sample preparation for mass spectrometry was performed by first adding 
50 uL of elution buffer (20% methanol, 80 mM TEAB, 10mM TCEP). Proteins 
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were incubated for 30 minutes at room temperature, alkylated with 50 mM 
iodoacetamide, and digested with 0.25 μg trypsin overnight while shaking on a 
tabletop shaker at room temperature. 
For formaldehye cross-linking experiments using the mycG4 ssDNA 
oligonucleotide, 500 μg of HeLa nuclear lysate was prepared in a volume of 
600 uL borate buffered saline (50 mM boric acid pH 8.4, 150 mM NaCl, 0.25% 
NP-40, 1 mM DTT, and CPIs). 500 pmols of mycG4 ssDNA oligonucleotide 
was added to each reaction (no DNA was added to duplicate control reactions). 
Reactions were incubated for 90 minutes at 4C while rotating end-over-end. 
Formaldehyde was added to a 1% final concentration, and reactions were 
incubated for 10 mins at 30C. Cross-linking was quenched by adding glycine 
to a final concentration of 12.5 mM and incubating for 5 minutes at 30C. 20 
uL of streptavidin-sepharose bead slurry was added to each reaction, and bead 
reactions were incubated for 30 minutes at 4C with rotation. Each reaction was 
washed three times with 8 M urea prepared in 50 mM ammonium bicarbonate. 
Each reaction was resuspended in 100 uL of 2 M urea with 50 mM ammonium 
bicarbonate and 10 mM DTT. Samples were incubated for 30 minutes at room 
temperature with shaking on a tabletop shaker. IAA was added to each reaction 
to 50 mM and incubated for 10 minutes in the dark while shaking. 2.5 μg 
trypsin was added to each sample, and reactions were incubated overnight at 
room temperature while shaking. Digested samples were washed three times 
with 8 M urea plus 50 mM ammonium bicarbonate and three times with 50 mM 
ammonium bicarbonate to remove digested peptides not cross-linked to DNA 
oligonucleotides. 100 uL of 50 mM ammonium bicarbonate was added to each 
sample, and cross-links were reversed by incubating at 70C for 90 minutes. The 
supernatant was collected and transferred to a new tube. 0.25 ug fresh trypsin 
was added to each sample. Samples were incubated at room temperature for 4 
hours with shaking, prepared on stageTips, and labelled by dimethyl chemical 
labelling on stageTips as described previously16,17. 
Isobaric labeling was performed using the 10-plex tandem mass tag (TMT) 
system (Thermo)18. 0.8 mg TMT reagent for each reporter mass was resuspended 
in 100 uL anhydrous acetonitrile. 10 ul resuspended TMT reagent was then 
added to the corresponding sample. Reactions were incubated for 1 hour in 
the dark before quenching for 30 minutes with 100 mM Tris pH 8.0. All ten 
pulldowns corresponding to all ten oligonucleotide titration points labelled by 
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the corresponding TMT reagent were pooled into one Eppendorf tube, acidified 
with trifluoroacetic acid, and desalted for mass spectrometry analysis by the 
C18 StageTip method19. 
Preparation of modified nucleosomes
Recombinant human core histone proteins were expressed in E. coli 
BL21(DE3)/RIL cells from pET21b(+) (Novagen) vectors and purified by 
denaturing gel filtration and ion exchange chromatography essentially as 
described20. Truncated human H3.1Δ1-31T32C protein for native chemical 
ligation of modified histone H3 variants was expressed in BL21(DE3)/RIL 
cells and purified as described21. Native chemical ligations were carried out in 
550 µl of degassed NCL buffer (200 mM KPO4, 2 mM EDTA, 6 M Guanidine 
HCl) containing 1 mg of modified H3.1 aa’s 1-31 thioester peptide (Cambridge 
Peptides), 4 mg of truncated H3.1Δ1-31T32C, 12.5 mg 4-Mercaptophenylacetic 
acid (MPAA) and 10 mg TCEP as reducing agent at a pH of 7.5.  The reactions 
were incubated over night at 40C and quenched by addition of 60 µl of 1 
M DTT and 700 µl 0.5% acetic acid. After a centrifugation step to remove 
precipitates the ligation reactions were directly loaded and purified on a 
reversed phase chromatography column (Perkin Elmer Aquapore RP-300 C8 
250x4.6 mm i.d.) using a gradient of 45-55% B (Buffer A: 0.1% TFA  in water; 
B: 90% acetonitrile, 0.1% TFA) over 10 column volumes. Positive fractions 
containing ligated full-length histone H3.1 were then combined and lyophilized. 
Histone octamers were refolded from the purified histones and assembled into 
nucleosomes with biotinylated DNA via salt deposition dialysis as described20. 
Biotinylated nucleosomal DNAs containing either one (mono-nucleosomes) or 
two 601 nucleosome positioning sequences22 separated by a 50 bp linker (di-
nucleosomes) were prepared as described21. Di-nucleosomes were assembled in 
the presence of MMTV A competitor DNA and a slight excess of octamers as 
described for longer chromatin arrays to ensure saturation of the 601 repeats23. 
The reconstituted nucleosomes were then immobilized on magnetic streptavidin 
beads (Dynabeads MyOne Steptavidin T1) via the biotinylated DNA, washed to 
remove MMTV A competitor DNA and MMTV A nucleosomes (in the case of 
di-nucleosomes), and directly used for affinity pull down reactions as described 
above. Nucleosome quality control checks are shown in Supplementary Fig. 9.
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Mass spectrometry analysis
Samples containing labelled peptides were eluted from StageTips with 
buffer B (80% acetonitrile, 0.1% formic acid), concentrated to 5 uL by SpeedVac 
centrifugation at room temperature, and resuspended to 12 uL in buffer A (0.1% 
formic acid). Samples were separated by liquid chromatography using an Easy-
nLC 1000 system (Thermo). For our first SP/KLF replicate, we used a modified 
gradient from 7-15% buffer B over 5 minutes, from 15%-35% buffer B over 
174 minutes, from 35-50% buffer B over 5 minutes, and finally from 50-95% 
buffer B in 1 minute followed by 5 minutes hold at 95% buffer B. For all other 
replicates and experiments, the gradient was the same with the exception of the 
15-35% buffer B gradient extending over 214 minutes.
Mass spectrometry analysis was performed on a Thermo Fusion Tribrid 
instrument using the built-in Thermo synchronous precursor selection (SPS) 
MS3 method, with a modified nano-HPLC gradient as described above24,25. 
Briefly, full MS scans were collected in the orbitrap at 120,000 resolution in a 
scan range from 380-1500 m/z. We used an AGC target of 2.0e5, and a maximum 
injection time of 50 ms. Peaks were selected for MS2 based on selection criteria 
of charge state 2-7 and an intensity threshold of 5.0e3. Dynamic exclusion was 
enabled, with peaks excluded after 1 scan for a duration of 70 seconds in a 
±10 ppm window. MS2 was conducted in top speed data dependant acquisition 
mode, with precursor priority given based on highest intensity. MS2 scans were 
performed after isolation in the quadrupole using an isolation window of 0.7 m/z 
units.  We used CID activation at a collision energy of 35% for fragmentation. 
MS2 detection was performed in the ion trap with an AGC target of 1.0e4 and a 
maximum injection time of 50 ms. MS2 precursors in the mass range 400-1200 
m/z were selected for MS3 analysis using the Thermo TMT reagent isobaric 
tag loss exclusion property and excluding MS2 precursor ions 18 m/z units low 
and 5 m/z units high. MS3 selection was conducted in top 10 data dependent 
acquisition mode giving the most intense ions the highest precursor priority. 
MS3 ions were selected with synchronous precursor selection activated for 10 
precursors. MS and MS2 isolation windows were set to 2 m/z. HCD activation 
was used at a collision energy of 65%. Fragment ions were detected in the 
orbitrap with 60,000 resolution in the scan range 120-500 m/z. For MS3, we 
used an AGC target of 1.0e5 and a maximum injection time of 120 ms. 
Mass spectrometry analysis of formaldehyde cross-linking experiments 
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was performed using a 2 hour gradient with chromatography and instrument 
settings as reported previously17. 
Computational identification and quantification of proteins
Spectral matching to peptides, grouping of peptide identifications into 
proteins, and isobaric label quantification were performed using Proteome 
Discoverer 2.1 (Thermo). We used the built-in processing workflow “PWF_
Fusion_Reporter_Based_Quan_SPS_MS3_SequestHT_Percolator” and the 
built-in consensus workflow “CWF_Comprehensive_Enhanced Annotation_
Quan_Results”, both with default settings. We used the TMT 10-plex 
quantification method with the 131 mass set as the control channel. In our 
workflow, the 131 reporter mass always corresponded to the titration point with 
the highest bait concentration (3 μM), with each sequentially lighter reporter 
tag corresponding to a threefold dilution of the next highest bait concentration. 
For the Sequest HT search, database parameters were enzymatic digestion 
with trypsin allowing two missed cleavages, a minimum peptide length of 6 
amino acids and a maximum peptide length of 144 amino acids. Our search was 
performed against the uniprot curated human proteome (downloaded December 
2015). We used a precursor mass tolerance of 10 ppm and a fragment mass 
tolerance of 0.6 Da. Cysteine carbamidomethylation was included as a static 
modification (57.021 Da), while methionine oxidation (15.995 Da) and protein 
N-terminal acetylation (42.011 Da) were included as dynamic modifications. We 
included the 6-plex TMT reagent mass (229.163 Da) as a dynamic modification 
on lysine, histidine, serine, and threonine, as well as the peptide N-terminus. 
FDR filtering was performed via percolator with a strict target FDR of 0.01 and 
a relaxed FDR of 0.0526. Strict parsimony was applied for protein grouping, and 
unique plus razor peptides were used for quantification. Peptide quantification 
normalization was applied based on total peptide amount.
For peptide searching taking into account peptide phosphorylation, we 
considered serine, threonine, and tyrosine (STY) phosphorylation events 
(79.966 Da) as possible dynamic modifications. All other parameters were 
unchanged. 
Peptide identification and quantification of dimethyl chemical labels for 
formaldehyde cross-linking experiments was performed using the MaxQuant 
software package27 v1.6.0.1 searching against the UniProt curated human 
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proteome (released June 2017). Carbamidomethylation was included as a fixed 
modification and methionine oxidation and protein N-terminal acetylation 
were included as variable modifications. Requantification was selected as a 
quantification parameter. Normalized peptide ratios were transformed to log2, 
and replicates were plotted against each other in two dimensions. Outliers were 
called based on inter-quartile ranges using an inter-quartile range of 1.5 in each 
replicate as a cutoff value. 
HeLa nuclear lysate absolute proteome quantification
Absolute abundances of proteins in HeLa nuclear lysate were reported 
previously (Supplementary Data 2)28. Quantification was based on the iBAQ 
method as described previously using MaxQuant version 1.2.2.527,29-31. 
Fitting of binding parameters and statistical analysis
To calculate protein binding parameters, we fit a Hill-like curve of the form:
                 𝛩𝛩 =  1
�
𝐾𝐾dApp[𝐿𝐿] �𝑛𝑛+1  Eq. 1
where θ represents the fraction of protein bound, [L] represents the 
concentration of bait, Kd
App represents the apparent dissociation constant at 
which half the protein is bound to a bait molecule, and n is the Hill coefficient 
describing the rate at which binding saturates. Θ was observed by calculating the 
normalized ratio of each titration point to the 131 reporter ion signal (representing 
a 3 μM bait concentration), implicitly assuming that for each protein that shows 
Kd
App values in the nanomolar range we would essentially saturate binding at 
this titration point. Then, the signal from the 131 reporter ion represented the 
complete bait binding population of the entire sample, so the signal from each 
titration point relative to the 131 reporter ion represented the “fraction bound” 
of the total binding population. [L] was known from the experimental design. 
We fit the parameters Kd
App and n using non-linear least squares using the mean 
θ of each triplicate (SP/KLF oligo experiments and nucleosome experiments) 
or duplicate (motif survey experiments including mycG4 experiments). 
Proteins were considered for further analysis only if θ was measured for each 
titration point of each replicate. θ values from MS3 quantification in Proteome 
Discoverer were normalized by min-max scaling between 0 and 1.  We used 
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initial parameter estimates of Kd
App=100 and n=1. After fitting, our data was 
filtered first based on the goodness of fit of the Hill-like curve. We required a 
r-squared value of 0.95 (0.9 in nucleosome experiments) for a linear regression 
between the fit binding model and the measured data, as well as a predicted 
fraction bound of < 0.25 for the lowest titration point and > 0.75 for the highest 
titration point. In other words, fit binding curves should match the data well 
to avoid spurious fitting, and the binding curve should nearly saturate on both 
sides based on the assumptions in the workflow described above. For SP/KLF 
competition experiments, binding parameters were fit using a Hill-Like curve 
essentially as described above, using an r-squared cutoff of 0.95, to estimate 
IC50 values. These IC50 values were then converted to Kd
App values using the 
Cheng-Prusoff correction:8 
𝐾𝐾dApp_Free =  𝐼𝐼𝐼𝐼50
1+
200
𝐾𝐾dApp Immobilized
                              Eq. 2
where Kd
App_Free is the calculated Kd
App for either the wild-type or the 
mutated SP/KLF oligonucleotide, IC50 is the fit IC50 value from the competition 
experiment, and Kd
App_Immobilized is the Kd
App value calculated from the immobilized 
SP/KLF wild-type oligonucleotide experiment. Kd
App values identified in this 
study are listed in Supplementary Data 1. Binding curves were plotted as 
the mean of replicates plus and minus error bars representing the standard 
error of the mean calculated using bootstrapping in the python package 
seaborn. Clustering of protein binding profiles was performed by hierarchical 
agglomerative clustering, and the mean Kd
App value of each sample-cluster 
combination was plotted in a heatmap. The number of clusters was selected by 
manual inspection. For statistical comparisons between multiple members of a 
complex or complexes, we performed a two-sided t-test treating all measured 
Kd
App values for that complex or paralog group as sample populations as 
described in the main text and figure legends. 
Comparison of KdApp and motif score
To compare fitted Kd
App values with motif scores from genome-wide binding 
models, we first collected all vertebrate JASPAR motifs for factors both with 
measured Kd
App values and identified in control experiments with mutated SP/
KLF oligonucleotide as  sequence-specific. To account for intrinsic differences 
in length and information content of the different motifs, we calculated the 
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sides based on the assumptions in the workflow described above. For SP/KLF 
competition experiments, binding parameters were fit using a Hill-Like curve 
essentially as described above, using an r-squared cutoff of 0.95, to estimate 
IC50 values. These IC50 values were then converted to Kd
App values using the 
Cheng-Prusoff correction:8 
𝐾𝐾dApp_Free =  𝐼𝐼𝐼𝐼50
1+
200
𝐾𝐾dApp Immobilized
                              Eq. 2
where Kd
App_Free is the calculated Kd
App for either the wild-type or the 
mutated SP/KLF oligonucleotide, IC50 is the fit IC50 value from the competition 
experiment, and Kd
App_Immobilized is the Kd
App value calculated from the immobilized 
SP/KLF wild-type oligonucleotide experiment. Kd
App values identified in this 
study are listed in Supplementary Data 1. Binding curves were plotted as 
the mean of replicates plus and minus error bars representing the standard 
error of the mean calculated using bootstrapping in the python package 
seaborn. Clustering of protein binding profiles was performed by hierarchical 
agglomerative clustering, and the mean Kd
App value of each sample-cluster 
combination was plotted in a heatmap. The number of clusters was selected by 
manual inspection. For statistical comparisons between multiple members of a 
complex or complexes, we performed a two-sided t-test treating all measured 
Kd
App values for that complex or paralog group as sample populations as 
described in the main text and figure legends. 
Comparison of KdApp and motif score
To compare fitted Kd
App values with motif scores from genome-wide binding 
models, we first collected all vertebrate JASPAR motifs for factors both with 
measured Kd
App values and identified in control experiments with mutated SP/
KLF oligonucleotide as  sequence-specific. To account for intrinsic differences 
in length and information content of the different motifs, we calculated the 
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normalized motif score, defined here as the maximum motif score for the oligo 
sequence used divided by the patser motif significance threshold in biopython32. 
G-quadruplex enrichment in PRC2 and NuRD ChIP-Seq peaks
We compared publically available ChIP-sequencing data for SWI/SNF, 
PRC2 and NuRD subunits33,34 with publically available G4-sequencing data35 
(Supplementary Table 3). All sequencing datasets were mapped to the human 
genome build hg38 using the UCSC genome browser liftOver tool36. All G4 
peaks from the plus and minus strand with overlapping coordinates were 
combined using bedtools37. We used automated permutation based testing with 
pybedtools38 to look for significant correlation between ChIP-seq peaks and 
G4-seq peaks. We randomized ChIP-seq peaks 1000 times over the genome and 
each time measured the peak intersection with G4-sequencing peaks. We then 
calculated an empirical p-value by comparing the number of true intersected 
peaks between SWI/SNF, PRC2, or NuRD subunits and G4-seq peaks with 
these 1000 randomized intersections. 
Protein cloning, expression, and western blotting
DNA pulldowns were performed as described above for western blotting. 
For the recombinant SP3 and SP3+HeLa spike-in pulldowns, 50 ng SP3 protein/
pulldown was used, and the protein binding step was performed in protein 
binding buffer supplemented with 10 ng/uL BSA (final concentration), 10 μM 
ZnCl2, and 10% glycerol.  After washing steps, 20 uL sample buffer (1X laemmli 
buffer diluted from 4X in 8 M urea) was added to each sample. Samples were 
incubated for 30 minutes at 37C and resolved by denaturing polyacrylamide 
gel electrophoresis. Proteins were transferred to either nitrocellulose or PVDF 
membranes by semi-dry transfer using the Bio-Rad Trans-Blot Turbo transfer 
system. Membranes were blocked in 5% milk for 30 minutes, and proteins 
were imaged by immuno-blotting using the Thermo Super Signal Pico PLUS 
chemiluminescent substrate. 
The recombinant N-terminally GST-tagged KLF4-ZF domain was expressed 
in BL21 
Rosetta (DE3) bacterial cells using 1 mM IPTG induction performed 
overnight at 16C. 200 mL cell culture was collected and incubated in 10 mL 
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lysis buffer (PBS, 0.1% NP-40, 1 mM DTT, CPIs, 10 μM ZnCl2, 2.5 μM MgCl2, 
0.25 mg/ml lysozyme,  2 uL benzonase [>500 U]) on ice for ten minutes. Cells 
were lysed by 30 second rounds of sonication followed by thirty seconds 
incubation on ice until the lysate cleared. Lysates were centrifuged at 4600 g for 
thirty minutes at 4C and the soluble supernatant was immediately added to 150 
uL glutathione-agarose beads that had been prewashed 1X with DBB (Pierce). 
Ethidium bromide was added to the supernatant to a final concentration of 20 
μg/mL, and lysates were incubated with beads for 1 hour while rotating end-
over-end at 4C. Beads were washed six times with DBB (1 M NaCl) and three 
times with PBS. GST-tagged proteins were eluted from the beads with 50 mM 
reduced glutathione in PBS. Eluted proteins were dialyzed into PBS (+10 μM 
ZnCl2) twice over two hours at 4C before a final dialysis overnight into PBS 
(+10 μM ZnCl2) at 4C using Slide-A-Lyzer dialysis cassettes (10,000 MWCO, 
0.1-0.5mL volume, Thermo). NP-40 was added to 0.1% and DDT was added 
to 1mM, while NaCl was adjusted to 400 mM in PBS for storage. Protein 
concentration was measured by UV absorbance at 280 nM and by Bradford 
assay. KLF4-ZF experiments were repeated after dialyzing GST-KLF4-ZF into 
PBS with no additions, and similar results were observed. 
The PHF10 C-terminal double PHD finger domain and the SMARCB1 
N-terminal winged-helix domain (WHD) were N-terminally GST-tagged during 
ligation-based cloning, expressed in BL21 Rosetta (DE3) bacteria, and used for 
H3 peptide pulldowns as described previously39. Antibodies and dilutions used 
in this study are listed in Supplementary Table 2, and raw gel images are shown 
in Supplementary Fig. 11.
Electrophoretic mobility shift assays (EMSA)
For EMSA experiments probing for endogenous protein from HeLa lysates, 
only PBB was used as the incubation buffer. DNA oligos were diluted in PBB 
as described above and incubated with ~0.75 μg/uL HeLa nuclear lysate for 
15 minutes at room temperature. Binding reactions were then resolved by 
native polyacrylamide gel electrophoresis in 0.5X TBE running buffer. Protein 
transfer and immunoblotting was performed as described above. For EMSAs 
using purified recombinant SP3, the oligo dilution and protein binding steps 
were performed in protein binding buffer supplemented with 10 ng/uL BSA 
(final concentration), 10 μM ZnCl2, and 10% glycerol. 100 ng SP3 protein per 
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reaction was used for the recombinant SP3 EMSA. Recombinant proteins used 
in this study are listed in Supplementary Table 2.
For KLF4-ZF EMSA experiments, proteins were prepared with DNA based 
on molar concentration as shown in Supplementary Fig. 3C in PBS. Binding 
reactions were incubated for 15 minutes at room temperature and resolved on a 
1% agarose gel using 0.5X TAE running buffer. The agarose gel was washed for 
5 minutes in distilled water, stained for thirty minutes with 0.5 μg/mL ethidium 
bromide, and destained for 5 minutes in distilled water before imaging. 
Fluorescence polarization and fluorescence intensity assays
Fluorescence polarization and intensity experiments were performed largely 
as described previously40,41. SP/KLF wild-type oligonucleotides were ordered 
with a 5’ Cy5 fluorescent label on each strand (IDT). Labelled oligonucleotides 
were annealed as described above and diluted to 2 nM in PBS. Recombinant 
KLF4-ZF was diluted using PBS to a three-fold dilution series of ten 
concentrations from 0.3 nM to 6 μM in a Greiner black, 96-well non-binding 
microplate. Recombinant KLF4-ZF and labelled oligonucleotides were mixed 
at a ratio of 1:1 in a final volume of 200 uL, with labelled oligonucleotides at a 
final concentration of 1 nM and recombinant KLF4-ZF at a final concentration 
range of 0.15 nM to 3 μM. Binding reactions were incubated for 20 minutes at 
room temperature, and fluorescence polarization and intensity were measured 
at 25C on a Tecan Spark 10M microplate reader. Baseline polarization was 
calibrated based on protein-free reference samples to 50 mP. Wells were 
measured with 200 flashes per well and a 1 second settling time per sample. 
Binding assays were performed in triplicate, and binding parameters were 
calculated and plotted as described above using a Hill-like function.
Data availability
The mass spectrometry proteomics data have been deposited to the 
ProteomeXchange Consortium via the PRIDE partner repository42 with the 
dataset identifier PXD007132. All other relevant data are available from the 
authors. 
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Results
Benchmarking Kdapp  measurements with the SP/KLF motif
We first affinity purified nuclear proteins from isolated nuclear lysates using 
a series of ten pulldowns with different concentrations of oligonucleotide baits 
coupled to streptavidin-sepharose beads. Proteins binding at each titration point 
were digested to tryptic peptides and isobarically labelled with the 10-plex 
TMT system18. Labelled peptides were combined and measured in a single SPS-
MS3 mass spectrometry run24,25 (Fig. 1A). Critically, the highest titration point 
(labelled with TMT131) represented a pulldown at micromolar concentration. 
We assumed that proteins with nanomolar range apparent dissociation constants 
(Kd
app~1-500 nM) would exhibit saturated binding at this concentration. Thus, 
for each DNA concentration we calculated the bound fraction for each individual 
protein compared to the TMT131 reporter ion signal (Fig 1B, Supplementary 
Fig. 1). Kd
app values were determined independently for each protein by fitting 
the parameters of a Hill-like curve using the known DNA concentrations and the 
observed fraction bound (Fig. 1A). We filtered out background or non-specific 
proteins based on the quality of fit of the Hill curve, under the assumption 
that background proteins would show randomly distributed ratios near 1:1 
for all titration points. As such, only proteins fitting a Hill-like curve with an 
r-squared value greater than 0.95 were kept for downstream analysis. As each 
bait profiled required a set of ten pulldowns conducted in triplicate or duplicate 
for fitting, we utilized a filter plate system to increase throughput15. We note that 
this system is amenable to automation in future high-throughput studies. 
As a benchmark case, we quantitatively profiled the nuclear protein binding 
landscape of the well-characterized SP/KLF consensus GC-box15. Oligo 
depletion was essentially complete after bead immobilization (Supplementary 
Fig. 2A). Binding of canonical SP/KLF factors was strongly specific for the 
designed SP/KLF motif oligonucleotide, with essentially no background 
binding observed for a mutated SP/KLF motif (Supplementary Fig. 2B). Using 
an r-squared value of 0.95 as a filtering criterion, we observed low coefficients 
of variation for fitted Kd
app values (Fig. 1C). We estimated the Kd
app value for 
canonical SP/KLF binding factor SP1 as ~38 nM and confirmed this result in 
lysates with gel-based assays  (Fig. 1D, Supplementary Fig. 2C). Furthermore, 
we estimated Kd
app values for a number of other SP/KLF family factors including 
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Figure 1. Benchmarking protein-DNA KdApp measurements with the SP/KLF consensus 
motif
A A titration series of a known concentration of bait is used for affinity purification of proteins 
from nuclear lysates. Bound proteins are digested with trypsin, isobarically labelled with TMT 
reagent, and analyzed by mass spectrometry. Quantification of binding interactions yields a 
Hill-like curve, as described in the Methods, which can be used to calculate the Kd
App.  
B SPS-MS3 TMT reporter ion spectrum of an example SP1 peptide. Only the low m/z range of 
the MS3 spectrum, where the TMT reporter ions are observed,  is displayed for clarity. Plotted 
on the y-axis are signal-to-noise values measured in the orbitrap at 60,000 resolution.
C Boxplot analysis of all coefficients of variation for fitted Kd
App values identified using the SP/
KLF consensus motif with r-squared values > 0.95. The box represents the quartiles of the 
data, while the whiskers represent the range of 1.5 IQRs. The center line is the median of the 
distribution. 
D Hill-like curve identified for SP1 binding to the consensus SP/KLF GC-box motif. Binding 
curves were generated by fitting the parameters of the Hill equation including Kd
App. Each data 
point is the mean of three experiments (n=3), and the error bars represent the standard error of 
the mean. 
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Figure 2. A motif survey identifies SWI/SNF and ISWI factors binding to G4-quadruplex 
structures
A Heatmap analysis Kd
App binding profiles for all dsDNA and ssDNA sequences and experiments. 
Proteins were clustered (15 clusters) using hierarchical agglomerative clustering. The 
heatmap is colored by the average log10(Kd
App) value of the cluster per bait. Cluster labels 
and number of proteins per cluster (n) are listed in columns to the left of the heatmap. 
B-G Kd
App binding curves for canonical and unreported binding proteins for some example dsDNA 
and ssDNA motifs. 
B Kd
App binding curve for AP-1 dsDNA motif and dimeric binding factors JUNB (Cluster 15) 
and JUND (Cluster 3).
C Kd
App binding curve for E-box dsDNA motif and dimeric binding factor MAX (Cluster 2).
D Kd
App binding curve for TEAD dsDNA motif and dimeric binding factors TEAD4 (Cluster 4) 
and YAP1 (Cluster 4).
E Kd
App binding curve for the telomere ssDNA motif (four repeats) and binding factor POT1 
(Cluster 11).
F Kd
App binding curve for the mycG4 ssDNA motif in NaCl (G4-permissive), LiCl (G4-
nonpermissive), and PhenDC3 (G4-ligand) binding conditions and SWI/SNF binding factor 
SMARCA4 (Cluster 7).
G Kd
App binding curve for the mycG4 ssDNA motif in NaCl, LiCl, and PhenDC3 binding 
conditions and ISWI binding factor SMARCA5 (Cluster 7).
For B-G), binding curves were generated by fitting the parameters of the Hill equation including 
Kd
App. Each data point is the mean of two experiments (n=2), and the error bars represent the 
standard error of the mean.
SP3 and KLF4. Interestingly, purified recombinant SP3 exhibited a substantially 
lower Kd in gel-shift assays indicating a higher affinity compared to mass 
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A Schematic representation of Kd
App di-nucleosome and modified di-nucleosome study design.
B Heatmap analysis of Kd
App binding profiles for all nucleosome, di-nucleosome, and modified 
di-nucleosome experiments. Proteins were clustered (5 clusters) using hierarchical 
agglomerative clustering. The heatmap is colored by the average log10(Kd
App) value of the 
cluster per bait. Cluster labels and number of proteins per cluster (n) are listed in columns to 
the left of the heatmap. 
C Boxplot analysis of all coefficients of variation for fitted Kd
App values identified in nucleosome 
experiments with r-squared values > 0.90. The box represents the quartiles of the data, while 
the whiskers represent the range of 1.5 IQRs. The center line is the median of the distribution. 
D-E  Example Kd
App binding curves for binding proteins of H3K4me3 and H3K9AcK14Ac di-
nucleosomes. 
D Kd
App binding curve for H3K4me3 modified di-nucleosomes and binding factor C17orf49 
(Cluster 1).
E Kd
App binding curve for H3K9AcK14Ac modified di-nucleosomes and binding factor PHF10 
(Cluster 3).
Binding curves were generated by fitting the parameters of the Hill equation including Kd
App. Each 
data point is the mean of three experiments (n=3), and the error bars represent the standard error 
of the mean.
spectrometry-based measurements from nuclear lysates (Supplementary Fig. 
2D). However, this shift was abrogated when recombinant SP3 was spiked into 
nuclear lysates, where recombinant and endogenous SP3 showed comparable 
binding curves. Similarly, we observed a lower Kd value for the SP/KLF motif 
and purified recombinant KLF4-ZF domain using fluorescence polarization and 
fluorescence de-quenching assays compared to those measured for endogenous 
KLF4 in lysates by mass spectrometry and gel-based assays (Supplementary 
Fig. 3)40,41. This clearly suggests competitive inhibition between proteins in 
the nuclear environment as has been reported for SP1-KLF4 and SP1-KLF16 
among other SP/KLF factors43. As such, this complex interplay between DNA 
binding proteins indicates Kd
app measurements will be useful information for 
uncovering interactions within transcriptional networks as they exist in the in 
vivo nuclear environment. 
To further characterize the specificity and sensitivity of this assay, we 
conducted a series of competition experiments with free (unbiotinylated) 
wild-type and mutated SP/KLF oligonucleotides. In agreement with western 
blot analysis (Supplementary Fig. 2B), known sequence-specific SP/KLF 
transcription factors showed no measurable binding to the mutated SP/KLF 
oligonucleotide (Supplementary Fig. 4A). In competition experiments, these 
sequence-specific factors were similarly not competed away from immobilized 
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spectrometry-based measurements from nuclear lysates (Supplementary Fig. 
2D). However, this shift was abrogated when recombinant SP3 was spiked into 
nuclear lysates, where recombinant and endogenous SP3 showed comparable 
binding curves. Similarly, we observed a lower Kd value for the SP/KLF motif 
and purified recombinant KLF4-ZF domain using fluorescence polarization and 
fluorescence de-quenching assays compared to those measured for endogenous 
KLF4 in lysates by mass spectrometry and gel-based assays (Supplementary 
Fig. 3)40,41. This clearly suggests competitive inhibition between proteins in 
the nuclear environment as has been reported for SP1-KLF4 and SP1-KLF16 
among other SP/KLF factors43. As such, this complex interplay between DNA 
binding proteins indicates Kd
app measurements will be useful information for 
uncovering interactions within transcriptional networks as they exist in the in 
vivo nuclear environment. 
To further characterize the specificity and sensitivity of this assay, we 
conducted a series of competition experiments with free (unbiotinylated) 
wild-type and mutated SP/KLF oligonucleotides. In agreement with western 
blot analysis (Supplementary Fig. 2B), known sequence-specific SP/KLF 
transcription factors showed no measurable binding to the mutated SP/KLF 
oligonucleotide (Supplementary Fig. 4A). In competition experiments, these 
sequence-specific factors were similarly not competed away from immobilized 
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wild-type oligonucleotides by free mutated oligonucleotides (Supplementary 
Fig. 4A). Yet, importantly, Kd
app values for sequence-specific proteins estimated 
by applying the Cheng-Prusoff correction to IC50 values from competition 
experiments (Supplementary Fig. 4B) were highly correlated to Kd
app values 
estimated with immobilized oligonucleotides at a near 1:1 ratio (Supplementary 
Fig. 4C). In contrast, non-sequence specific proteins bound to immobilized wild-
type or mutated SP/KLF oligos with high correlation (Supplementary Fig. 4A). 
Non-sequence specific proteins were also competed from immobilized wild-type 
oligonucleotides by either wild-type of mutated free oligonucleotide. However, 
non-sequence specific proteins displayed lower Kd
app values on average to either 
free oligonucleotide compared to immobilized oligonucleotides in competition 
experiments (Supplementary Fig. 4C). We attribute this to free oligonucleotides 
having two available blunt ends acting as substrates for some non-sequence 
specific proteins, while immobilized oligonucleotides only have one sterically 
free blunt end. This is an important consideration for future studies comparing 
free v. immobilized oligonucleotides and sequence-specific v. non-specific 
DNA binding factors. 
The Kd
app values we measured did not significantly correlate with absolute 
protein abundance, demonstrating that the Kd
app values we measured were 
not biased by protein abundance (Supplementary Fig. 4D, Supplementary 
Data 2)28,44. An additional analysis taking possible phospho-post-translational 
modifications into account also showed practically no difference with our 
original result, suggesting such phospho-modifications, even if stoichiometric 
in vivo, may not be easily identified without specific enrichment methods 
(Supplementary Fig. 4E)45. Finally, we calculated JASPAR transcription factor 
binding profile motif scores for sequence-specific proteins with JASPAR motifs 
and correlated them with the Kd
app values we measured (Supplementary Fig. 
5). We observed significant correlation, demonstrating that our assay produced 
results consistent with motif-based binding landscape models. Summarily, on 
these bases we concluded that our assay generated reliable Kd
app measurements 
for protein-DNA interactions in this SP/KLF benchmark case.
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Chromatin remodelers quantitatively prefer G-quadruplexes
Next, we conducted a larger assay of eight different dsDNA or ssDNA 
(Fig. 2A, Supplementary Table 1) sequences representing canonical, well-
characterized biological motifs (AP-1, CTCF, E-box, NF-Y, TATA, TEAD, the 
human ssDNA telomere repeat, and the c-Myc promoter Pu27 G4-quadruplex 
forming ssDNA sequence [mycG4]46). We observed numerous homo- and 
hetero-multimeric transcription factors and DNA-binding proteins binding 
to their canonical motif in readily distinguishable clusters, including JUNB/
JUND, MAX, POT1, and TEAD/YAP (Fig. 2A-E). More specifically, we were 
surprised and intrigued to see subunits of many chromatin modifying complexes 
binding to the mycG4 sequence in G4-permissive NaCl-based binding buffer, 
including SWItch/Sucrose Non-Fermentable (SWI/SNF) and Imitation SWI 
(ISWI) subunits (Fig. 2F-G). This immediately suggested the possibility that 
some chromatin remodeling and modifying enzymes specifically recognize 
DNA G4 structures. To further characterize these interactions, we performed 
an additional set of assays using either 150 mM LiCl buffer, which destabilizes 
G-quadruplex structures, or 150 mM NaCl binding buffer supplemented with 
20 μM PhenDC3, which stabilizes G4-structures (Fig. 2A). Both LiCl and 
G-quadruplex stabilizing small molecules were shown previously to inhibit G4-
RNA binding of Polycomb repressive complex 2 (PRC2) 47, which binds RNA 
G-quadruplexes through interfaces on EZH2 and EED subunits and an RNA 
recognition motif in the SUZ12 subunit48,49. Here, we observed that Kd
app values 
measured for the mycG4 sequence in LiCl and PhenDC3 binding conditions 
were indeed positively correlated (Supplementary Fig. 6A). LiCl or PhenDC3 
treatment quantitatively and significantly increased Kd
app values for both SWI/
SNF and ISWI subunits and for PRC2 and Nucleosome remodeling and 
deacetylase (NuRD) subunits (Fig. 2F-G, Supplementary Fig. 6B-C). Among 
these, PRC2 and NuRD subunits bound with ~100 nM Kd
apps to the mycG4 
sequence, similar to the recently reported binding affinity of PRC2 to RNA 
G-quadruplexes47,48. Further supporting this finding, we detected enrichment 
of induced G-quadruplex structures in both SWI/SNF, PRC2, and NuRD 
subunit binding sites in a variety of ENCODE ChIP-seq datasets, consistent 
with our in vitro binding data (Supplementary Fig. 6D)33-35. We also verified 
this finding by western blot (Supplementary Fig. 7A-C). Finally, we were 
interested in identifying potential direct G4 DNA-binding subunits from these 
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chromatin remodeling and modifying complexes. We adapted a formaldehyde 
cross-linking approach to identify individual peptides immediately proximal 
to the mycG4 DNA bait (Supplementary Fig. 8A)50. Identified peptides from 
a known DNA-binding complex were proximal to the DNA-binding channel, 
indicating the reliability of the approach (Supplementary Fig. 8B, PDB: 1JEY 
[http://dx.doi.org/10.2210/pdb1JEY/pdb])51. We identified a peptide from 
the N-terminal winged helix-like domain (WHD) of SMARCB1 as the most 
significantly enriched for direct G4 binding of SWI/SNF, ISWI, PRC2, and 
NuRD subunits (Supplementary Fig. 8C-E). Affinity purification experiments 
with the recombinant SMARCB1-WHD verified that the SMARCB1-WHD 
specifically recognizes the mycG4 bait compared to a variety of control baits 
while the double PHD finger of PHF10, another SWI/SNF accessory subunit, 
does not (Supplementary Fig. 8F)52. Overall, these in vitro analyses provide 
biochemical support for the hypothesis that some chromatin remodelers and 
modifiers can bind G4 DNA sequences in a G-quadruplex preferential manner. 
Kdapp estimation using nucleosome substrates
Finally, to show that this binding assay is compatible not only with 
nucleic acids but also with nucleoprotein complexes, we performed a set of 
experiments using mono-nucleosomes, di-nucleosomes, and modified di-
nucleosomes  (Fig. 3A, Supplementary Fig. 9A-D). We identified a number of 
protein-di-nucleosome interactions that were either specific to or modulated 
by either H3K4me3 or H3K9AcK14Ac (Fig 3B, Fig. 3D-E). Across all baits, 
coefficients of variation were reasonably low indicating good data quality 
(Fig 3C). We observed SWI/SNF and ISWI binding with significantly lower 
Kd
app to H3K9AcK14Ac-containing di-nucleosomes compared to unmodified 
di-nucleosomes (Supplementary Fig. 10A/D). Indeed, many accessory SWI/
SNF subunits were uniquely identified with the H3K9AcK14Ac di-nucleosome 
bait. We identified one SWI/SNF subunit, PHF10, which harbors a C-terminal 
double PHD finger (DPF) and may preferentially interact with H3K9AcK14Ac 
compared to unmodified H3 or H3K4me3 as has been reported for another DPF 
domain53. PHF10 shows one of the lowest Kd
app values of all identified SWI/
SNF subunits (~35 nM, Fig 3E) for H3K9AcK14Ac di-nucleosomes and was 
similarly identified exclusively with the H3K9AcK14Ac di-nucleosome. To 
further investigate the H3K9AcK14Ac specificity of PHF10, we used bacterial 
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Finally, to show that this binding assay is compatible not only with 
nucleic acids but also with nucleoprotein complexes, we performed a set of 
experiments using mono-nucleosomes, di-nucleosomes, and modified di-
nucleosomes  (Fig. 3A, Supplementary Fig. 9A-D). We identified a number of 
protein-di-nucleosome interactions that were either specific to or modulated 
by either H3K4me3 or H3K9AcK14Ac (Fig 3B, Fig. 3D-E). Across all baits, 
coefficients of variation were reasonably low indicating good data quality 
(Fig 3C). We observed SWI/SNF and ISWI binding with significantly lower 
Kd
app to H3K9AcK14Ac-containing di-nucleosomes compared to unmodified 
di-nucleosomes (Supplementary Fig. 10A/D). Indeed, many accessory SWI/
SNF subunits were uniquely identified with the H3K9AcK14Ac di-nucleosome 
bait. We identified one SWI/SNF subunit, PHF10, which harbors a C-terminal 
double PHD finger (DPF) and may preferentially interact with H3K9AcK14Ac 
compared to unmodified H3 or H3K4me3 as has been reported for another DPF 
domain53. PHF10 shows one of the lowest Kd
app values of all identified SWI/
SNF subunits (~35 nM, Fig 3E) for H3K9AcK14Ac di-nucleosomes and was 
similarly identified exclusively with the H3K9AcK14Ac di-nucleosome. To 
further investigate the H3K9AcK14Ac specificity of PHF10, we used bacterial 
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lysates expressing the recombinant GST-tagged DPF domain of PHF10 in 
histone H3 peptide pull-down experiments (Supplementary Fig. 10B). This 
experiment clearly confirmed that recombinant PHF10-DPF binding to H3 is 
strongly agonised by H3K9AcK14Ac in contrast to the SMARCB1-WHD, as 
has been reported for the bromodomain of Swi2/Snf2 and the DPF domains 
of SWI/SNF accessory subunits DPF2 and DPF3 (Supplementary Fig. 10C)54-
56. Thus, PHF10 represents an additional high affinity H3 acetylation reader 
in the human SWI/SNF complex. Intriguingly, PHF10-DPF seems to be 
repelled by H3K4me3, and our data suggests this might confer a lower affinity 
“fine-tuning” on PHF10-SWI/SNF nucleosome binding. However, even in 
the absence of the acetylation specificity conferred by SWI/SNF acetylation 
reader domains, we observed that catalytic SWI/SNF subunits SMARCA2 and 
SMARCA4 still engage in relatively high affinity interactions with H3K4me3 
modified and unmodified di-nucleosomes (Supplementary Fig. 10A/D). 
Similarly, we observed relatively high affinity interactions between modified 
or unmodified di-nucleosomes and ISWI catalytic subunit SMARC5 and 
ISWI accessory subunits including BPTF, C17orf49 (Fig. 3E), BAZ1A, and 
BAZ1B. The binding patterns we observe between different di-nucleosome 
baits are complex and highlight an important point and a unique benefit of 
measuring apparent affinities from complex lysates: we measure the average 
binding profile over what is likely a pool of heterogeneous multimeric protein 
complexes. For example, we observe catalytic subunit SMARCA5 binding with 
highest affinity to H3K9AcK14Ac di-nucleosomes compared to unmodified or 
H3K4me3 di-nucleosomes (Supplementary Fig. 10D). Yet, accessory subunits 
BPTF, C17orf49, BAZ1A, and BAZ1B exhibit binding curves that are both 
similar to and distinct from the binding curve of SMARCA5 depending on 
the accessory subunit and di-nucleosome pair in question, suggesting these 
subunits regulate differential H3 modification-specific binding (Supplementary 
Fig. 10D). Moreover, these ISWI accessory subunits, along with SMARCA5, 
form at least three unique and independent protein complexes (the NuRF, 
ACF, and WICH complexes)57. More generally, deconvoluting the individual 
contributions of different subcomplexes with recombinant systems is 
indisputably critical (for example, as with SMARCB1 and its G-quadruplex 
interaction and PHF10-H3K9AcK14Ac binding in SWI/SNF). In the future, a 
data-driven strategy for assessing the contributions of shared subunits within 
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independent subcomplexes might involve a combinatorial approach utilizing 
many DNA or modified nucleosome baits as was demonstrated, for example, 
with the stoichiometry of different SET1/MLL subcomplexes28. Additionally, 
we argue that the ability to measure binding affinities for multimeric complexes 
in the complex environment of the nucleus offers an important holistic, system-
wide view.
Discussion
By measuring protein-DNA and protein-nucleosome Kd
app values via mass 
spectrometry, we provide another avenue for extending protein-nucleic acid 
interaction proteomics beyond comparative, semi-quantitative workflows. From 
a systems biology perspective, absolute binding affinities within the nuclear 
environment create a quantitative link between transcription factor expression 
and target gene regulation via the TF-DNA interaction. However, our data 
implies a situation where DNA sequences, structures, and chromatinized DNA 
integrate signals from a variety of binding partners at a spectrum of biologically 
relevant affinities. Indeed, we observe that both DNA structures, including 
G-quadruplexes, and (modified) nucleosomes engage in high affinity binding 
interactions with various independent chromatin remodeling and modifying 
complexes. Of note, we observe SWI/SNF as a complex that recognizes both 
DNA structure and histone modification state, and we identify SMARCB1 and 
PHF10, respectively, as specific “readers” that contribute to these high affinity 
substrate recognitions. While targeted biochemical analysis reveals direct 
mediators of specific substrate interactions within a complex, combining these 
analyses with affinity measurements in the context of multimeric assemblies 
in complex lysates takes into consideration the possibility of larger molecular 
regulatory networks. This work demonstrates an assay for revealing not only 
these regulatory interactions but also their absolute affinities and thereby 
profiling the proteome-wide quantitative binding landscape of nuclear proteins 
for DNA oligonucleotides and nucleosome complexes.
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Supplementary Figure 1 Example MS3 TMT reporter ion spectra used for protein quantification
A) Example MS3 TMT reporter ion spectrum of an identified SP1 peptide. Only the low m/z range of the MS3 spectrum, 
where the TMT reporter ions are observed,  is displayed for clarity. Plotted on the y-axis are signal-to-noise values from the 
orbitrap at 60,000 resolution. 
B) Example MS3 TMT reporter ion spectrum of an identified SP3 peptide.
C) Example MS3 TMT reporter ion spectrum of an identified KLF4 peptide.
Supplementary Figure 1. Example MS3 TMT reporter ion spectra used for protein 
quantification
A Example MS3 TMT reporter ion spectrum of an identified SP1 peptide. Only the low m/z range 
of the MS3 spectrum, where the TMT reporter ions ar  observed, is displayed for clarity. Plotted 
on the y-axis are signal-to-noise values from the orbitrap at 60,000 resolution.
B Example MS3 TMT reporter ion spectrum of an identified SP3 peptide.
C Example MS3 TMT reporter ion spectrum of an identified KLF4 peptide.
15609_M-Makowski_BNW.indd   175 11-06-18   14:30
4
Global profiling of protein-DNA and protein-nucleosome binding affinities
175
SUPPLEMENTARY FIGURES
13
1.
13
80
8
13
0.
14
10
4
12
9.
13
77
0
12
8.
13
43
8
12
8.
08
17
4
12
7.
13
09
8
13
1.
14
41
7
12
6.
12
75
7
12
9.
98
67
9
12
7.
04
99
7
12
8.
86
42
3
12
7.
62
76
0
126 128 129 130 131 132m/z
0
50
100
150
200
250
S
ig
na
l/N
oi
se
127
13
1.
13
82
4
13
0.
14
11
6
12
9.
13
78
6
12
8.
13
45
2
12
8.
12
82
8
12
7.
13
12
1
12
6.
12
78
2
12
9.
10
23
4
12
6.
09
16
1
13
0.
06
27
9
12
7.
05
02
0
13
1.
06
86
3
12
5.
58
35
7
126 127 128 129 130 131 132m/z
0
100
200
300
400
500
600
700
800
S
ig
na
l/N
oi
se
13
0.
14
11
6
13
1.
13
82
1
12
9.
13
78
5
12
7.
08
66
4
12
8.
13
44
8
12
8.
12
83
3
12
6.
05
51
5
13
0.
05
00
9
12
7.
13
12
9
13
1.
08
15
1
12
6.
12
78
8
12
9.
06
60
9
126 127 128 129 130 131 132m/z
0
50
100
150
200
250
300
Si
gn
al
/N
oi
se
A
C
B
Supplementary Figure 1
Supplementary Figure 1 Example MS3 TMT reporter ion spectra used for protein quantification
A) Example MS3 TMT reporter ion spectrum of an identified SP1 peptide. Only the low m/z range of the MS3 spectrum, 
where the TMT reporter ions are observed,  is displayed for clarity. Plotted on the y-axis are signal-to-noise values from the 
orbitrap at 60,000 resolution. 
B) Example MS3 TMT reporter ion spectrum of an identified SP3 peptide.
C) Example MS3 TMT reporter ion spectrum of an identified KLF4 peptide.
Supplementary Figure 1. Example MS3 TMT reporter ion spectra used for protein 
quantification
A Example MS3 TMT reporter ion spectrum of an identified SP1 peptide. Only the low m/z range 
of the MS3 spectrum, where the TMT reporter ions ar  observed, is displayed for clarity. Plotted 
on the y-axis are signal-to-noise values from the orbitrap at 60,000 resolution.
B Example MS3 TMT reporter ion spectrum of an identified SP3 peptide.
C Example MS3 TMT reporter ion spectrum of an identified KLF4 peptide.
15609_M-Makowski_BNW.indd   175 11-06-18   14:30
        
Chapter 4
176
100 kDa
AP-WB, HeLa
α-SP1
EMSA-WB, HeLa
α-SP1
-5%
 Input -3 μM
 R
eference
EMSA-WB, GST-SP3
α-GST
A B
C
0.15 nM 3 µM
Before Bead Immobilization
After Bead Immobilization
SP/KLF Consensus Motif Oligo
D
AP-WB, GST-SP3
α-GST
-5%
 Input
EMSA-WB, HeLa
α-SP3
AP-WB, GST-SP3+HeLa
α-SP3, α-GST
GST-SP3
130 kDa
-3 μM
 R
eference
Supplementary Figure 2
α-SP1
α-SP3
α-KLF4
5% Input
SP/KLF_wt
SP/KLF_mut
5% Input
SP/KLF_wt
SP/KLF_mut
Low 
Exposure
High
Exposure
−1 0 1 2 3
log10 SP/KLF Oligo Concentration, nM
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
B
ou
nd
SP3, KdApp: 19.3 nM, r-squared: 0.99
−1 0 1 2 3
log10 SP/KLF Oligo Concentration, nM
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
B
ou
nd
SP1, KdApp: 37.9 nM, r-squared: 0.99
Supplementary Figure 2 Gel-based validation of oligo depletion and protein binding to SP/KLF motif
A) Agarose gel electrophoresis of SP/KLF consensus oligo titration, both before and after binding to streptavidin-sepharose 
beads, to indicate depletion of the oligo by bead immobilization. 
B) Western blot analysis of canonical SP/KLF binding factors (SP1, SP3, and KLF4) binding to the SP/KLF wild-type oligonu-
cleotide and not the SP/KLF mutated oligonucleotide. 
C) Validation of mass spectrometry binding profile for SP1 to the SP/KLF consensus oligo. The mass spectrometry binding 
curve is shown above. Affinity purification western blot and electrophoretic mobility shift assay (EMSA) data are shown below. 
Mass spectrometry data points and protein bands are approximately aligned on the vertical axis. 
D) Validation of mass spectrometry binding profile for SP3 to the SP/KLF consensus oligo. The mass spectrometry binding 
curve is shown above. Affinity purification western blot and electrophoretic mobility shift assay (EMSA) data of recombinant SP3 
are shown below. Affinity purification western blot of recombinant SP3 spiked into HeLa lysate for pulldown analysis is shown next, 
with recombinant SP3 and endogenous SP3 separately noted. Finally, EMSA analysis of endogenous SP3 in HeLa nuclear lysate 
is shown at the bottom. Mass spectrometry data points and protein bands are approximately aligned on the vertical axis. 
Binding curves were generated by fitting the parameters of the Hill equation including KdApp. Each data point is the mean of three experiments (n=3), and the error bars represent the standard error of the mean. 
Endogenous SP3 
100 kDa
Supplementary Figure 2. Gel-bas d validatio  of oligo depletion and protein binding 
to SP/KLF motif
A Agarose gel electrophoresis of SP/KLF consensus oligo titration, both before and after binding 
to streptavidin-sepharose bead , to indicat  de letion f the oligo by bead immobilizati n.
B Western blot analysis of canonical SP/KLF binding factors (SP1, SP3, and KLF4) binding to the 
SP/KLF wild-type oligonucleotide and not the SP/KLF mutated oligonucleotide.
C Validation of mass spectrometry binding profile for SP1 to the SP/KLF consensus oligo. 
The mass spectrometry binding curve is shown above. Affinity purification western blot and 
electrophoretic mobility shift assay (EMSA) data are shown below. Mass spectrometry data 
points and protein bands are approximately aligned on the vertical axis.
D Validation of mass spectrometry binding profile for SP3 to the SP/KLF consensus oligo. 
The mass spectrometry binding curve is shown above. Affinity purification western blot and 
electrophoretic mobility shift assay (EMSA) data of recombinant SP3 are shown below. Affinity 
purification western blot of recombinant SP3 spiked into HeLa lysate for pulldown analysis 
is shown next, with recombinant SP3 and endogenous SP3 separately noted. Finally, EMSA 
analysis of endogenous SP3 in HeLa nuclear lysate is shown at the bottom. Mass spectrometry 
data points and protein bands are approximately aligned on the vertical axis. 
Binding curves were generated by fitting the parameters of the Hill equation including 
KdApp. Each data point is the mean of three experiments (n=3), and the error bars 
represent the standard error of the mean.
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curve is shown above. Affinity purification western blot and electrophoretic mobility shift assay (EMSA) data are shown below. 
Mass spectrometry data points and protein bands are approximately aligned on the vertical axis. 
D) Validation of mass spectrometry binding profile for SP3 to the SP/KLF consensus oligo. The mass spectrometry binding 
curve is shown above. Affinity purification western blot and electrophoretic mobility shift assay (EMSA) data of recombinant SP3 
are shown below. Affinity purification western blot of recombinant SP3 spiked into HeLa lysate for pulldown analysis is shown next, 
with recombinant SP3 and endogenous SP3 separately noted. Finally, EMSA analysis of endogenous SP3 in HeLa nuclear lysate 
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A Agarose gel electrophoresis of SP/KLF consensus oligo titration, both before and after binding 
to streptavidin-sepharose bead , to indicat  de letion f the oligo by bead immobilizati n.
B Western blot analysis of canonical SP/KLF binding factors (SP1, SP3, and KLF4) binding to the 
SP/KLF wild-type oligonucleotide and not the SP/KLF mutated oligonucleotide.
C Validation of mass spectrometry binding profile for SP1 to the SP/KLF consensus oligo. 
The mass spectrometry binding curve is shown above. Affinity purification western blot and 
electrophoretic mobility shift assay (EMSA) data are shown below. Mass spectrometry data 
points and protein bands are approximately aligned on the vertical axis.
D Validation of mass spectrometry binding profile for SP3 to the SP/KLF consensus oligo. 
The mass spectrometry binding curve is shown above. Affinity purification western blot and 
electrophoretic mobility shift assay (EMSA) data of recombinant SP3 are shown below. Affinity 
purification western blot of recombinant SP3 spiked into HeLa lysate for pulldown analysis 
is shown next, with recombinant SP3 and endogenous SP3 separately noted. Finally, EMSA 
analysis of endogenous SP3 in HeLa nuclear lysate is shown at the bottom. Mass spectrometry 
data points and protein bands are approximately aligned on the vertical axis. 
Binding curves were generated by fitting the parameters of the Hill equation including 
KdApp. Each data point is the mean of three experiments (n=3), and the error bars 
represent the standard error of the mean.
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Supplementary Figure 3 KLF4-ZF fluorescence polarization and fluorescence intensity assays 
A) Validation of mass spectrometry binding profile for KLF4 to the SP/KLF consensus oligo. The mass spectrometry binding 
curve is shown above. Affinity purification western blot and electrophoretic mobility shift assay (EMSA) data of endogenous KLF4 
are shown below. Mass spectrometry data points and protein bands are approximately aligned on the vertical axis. 
B) Imperial protein stain following SDS-PAGE of 3.5 µg of purified GST-KLF4-ZF recombinant protein. 
C) Agarose gel electrophoretic mobility shift assay of GST-KLF4-ZF binding to the consensus SP/KLF oligonucleotide. 
Concentrations of either SP/KLF oligonucleotide or GST-KLF4-ZF are indicated above in picomoles. 
D) Fluorescence polarization assay of GST-KLF4-ZF binding to the Cy5 labelled SP/KLF oligonucleotide. 
E) Fluorescence intensity (de-quenching) assay of GST-KLF4-ZF binding to the Cy5 labelled SP/KLF oligonucleotide. 
Binding curves were generated by fitting the parameters of the Hill equation including Kd
App. Each data point is the mean of three 
experiments (n=3), and the error bars represent the standard error of the mean. 
Supplementary Figure 3. KLF4-ZF fl uorescence polarization and fl uorescence 
inten ity assays
A Validation f m ss spectrometry bindin  profi le for KLF4 to the SP/KLF consensus oligo. 
The mass spectrometry binding curve is shown above. Affi nity purifi cation western blot and 
electrophoretic mobility shift assay (EMSA) data of endogenous KLF4 are shown below. Mass 
spectrometry data points and protein bands are approximately aligned on the vertical axis.
B Imperial protein stain following SDS-PAGE of 3.5 μg of purifi ed GST-KLF4-ZF recombinant 
protein.
C Agarose gel electrophoretic mobility shift assay of GST-KLF4-ZF binding to the consensus SP/
KLF oligonucleotide. Concentrations of either SP/KLF oligonucleotide or GST-KLF4-ZF are 
indicated above in picomoles.
D Fluorescence polarization assay of GST-KLF4-ZF binding to the Cy5 labelled SP/KLF 
oligonucleotide.
E Fluorescence intensity (de-quenching) assay of GST-KLF4-ZF binding to the Cy5 labelled SP/
KLF oligonucleotide.
Binding curves were generated by fi tting the parameters of the Hill equation including KdApp. 
Each data point is the mean of three experiments (n=3), and the error bars represent the standard 
error of the mean.
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A) Validation of mass spectrometry binding profile for KLF4 to the SP/KLF consensus oligo. The mass spectrometry binding 
curve is shown above. Affinity purification western blot and electrophoretic mobility shift assay (EMSA) data of endogenous KLF4 
are shown below. Mass spectrometry data points and protein bands are approximately aligned on the vertical axis. 
B) Imperial protein stain following SDS-PAGE of 3.5 µg of purified GST-KLF4-ZF recombinant protein. 
C) Agarose gel electrophoretic mobility shift assay of GST-KLF4-ZF binding to the consensus SP/KLF oligonucleotide. 
Concentrations of either SP/KLF oligonucleotide or GST-KLF4-ZF are indicated above in picomoles. 
D) Fluorescence polarization assay of GST-KLF4-ZF binding to the Cy5 labelled SP/KLF oligonucleotide. 
E) Fluorescence intensity (de-quenching) assay of GST-KLF4-ZF binding to the Cy5 labelled SP/KLF oligonucleotide. 
Binding curves were generated by fitting the parameters of the Hill equation including Kd
App. Each data point is the mean of three 
experiments (n=3), and the error bars represent the standard error of the mean. 
Supplementary Figure 3. KLF4-ZF fl uorescence polarization and fl uorescence 
inten ity assays
A Validation f m ss spectrometry bindin  profi le for KLF4 to the SP/KLF consensus oligo. 
The mass spectrometry binding curve is shown above. Affi nity purifi cation western blot and 
electrophoretic mobility shift assay (EMSA) data of endogenous KLF4 are shown below. Mass 
spectrometry data points and protein bands are approximately aligned on the vertical axis.
B Imperial protein stain following SDS-PAGE of 3.5 μg of purifi ed GST-KLF4-ZF recombinant 
protein.
C Agarose gel electrophoretic mobility shift assay of GST-KLF4-ZF binding to the consensus SP/
KLF oligonucleotide. Concentrations of either SP/KLF oligonucleotide or GST-KLF4-ZF are 
indicated above in picomoles.
D Fluorescence polarization assay of GST-KLF4-ZF binding to the Cy5 labelled SP/KLF 
oligonucleotide.
E Fluorescence intensity (de-quenching) assay of GST-KLF4-ZF binding to the Cy5 labelled SP/
KLF oligonucleotide.
Binding curves were generated by fi tting the parameters of the Hill equation including KdApp. 
Each data point is the mean of three experiments (n=3), and the error bars represent the standard 
error of the mean.
15609_M-Makowski_BNW.indd   177 11-06-18   14:30
        
Chapter 4
178
A B
Supplementary Figure 4
S
P
/K
LF W
T, Im
m
obilized
S
P
/K
LF m
ut, Im
m
obilized
S
P
/K
LF W
T, Free
S
P
/K
LF m
ut, Free
KLF3
SP1
ZNF148
KLF4
ZBTB7A
VEZF1
TFAP2A
DHX36
KLF16
SP3
TOP3A
DAZAP1
CIRBP
HNRNPDL; HNRPDL
CNBP
DDB2
HSPA9
KLF5
MPG
TFAM
DDB1
BANF1
HNRNPAB
WRN
RMI1
HLTF
CETN2
TREX1
PNKP
APTX
XRCC1
LIG3
PARP1
XRCC6
XRCC5
C3orf37; HMCES
RPA2
RPA3
RPA1
−2
−1
0
1
2
log10[fm
ol/100 µg]−4
−2
0
2
4log10[K
d A
pp], nM
1.0 1.2 1.4 1.6 1.8 2.0 2.2
Measured log10(Kd
App-Immobilized), nM
−1.0
−0.5
0.0
0.5
1.0
1.5
2.0
M
ea
su
re
d 
lo
g1
0(
K
dA
pp
-F
re
e )
, n
M
Non-Sequence Specific Proteins, 
r=0.81, n=2.03
Sequence Specific Proteins, 
r=0.83, n=0.77
N
on-sequence specific proteins
S
equence specific proteins
1.0 1.5 2.0 2.5
log10 Kd
App, SP/KLF WT Oligo, nM
−3
−2
−1
0
1
2
3
4
5
lo
g1
0 
P
ro
te
in
 A
bu
nd
an
ce
, f
m
ol
/1
00
 µ
g
pearsonr=0.31, N.S., p=0.08
C
1.0 1.5 2.0 2.5 3.0
log10 Kd
App, SP/KLF WT Oligo, nM
1.0
1.5
2.0
2.5
3.0
lo
g1
0 
K
dA
pp
, S
P
/K
LF
 W
T 
O
lig
o 
+p
ho
sp
ho
 P
TM
s,
 n
M
pearsonr=0.99, p-value=4e-68
D
−1 0 1 2 3
log10 SP/KLF Oligo Concentration, nM
0.0
0.2
0.4
0.6
0.8
1.0
Fr
ac
tio
n 
B
ou
nd SP1, Kd
App: 37.9 nM, 
r-squared: 0.99
SP1, SP/KLF WT free competitor,
IC50: 191 nM, r-squared: 0.97
E
Supplementary Figure 4. KdApp calculated from competition experiment derived 
IC50 values correlates with KdApp measured for immobilized baits for sequence-
specifi c proteins
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A Heatmap analysis of log10-transformed KdApp values for SP/KLF consensus oligonucleotide 
experiments, including with mutated sequence and with competition experiments. KdApp 
values for competition experiments were calculated applying the Cheng-Prusoff correction to 
fi t IC50 values as described in the Methods.
B Hill-like curve for SP1 binding to the consensus SP/KLF motif (KdApp) and for competition of 
SP1 by free SP/KLF motif(IC50). 
C Regression analysis of KdApp values measured in experiments with immobilized baits compared 
to KdApp values calculated from IC50 values measured in competition experiments. Sequence-
specifi c proteins (as indicated in panel A based on specifi c high affi nity binding for the wild-
type SP/KLF oligonucleotide), are plotted in red, as is the correlation between experiments. 
Non-sequence specifi c proteins (as indicated in panel A based on high affi nity binding for both 
the wild-type SP/KLF oligonucleotide and the mutated SP/KLF oligonucleotide), are plotted in 
blue, as is the correlation between experiments. r is the pearson correlation, and n is the slope of 
the regression line.
D Regression analysis of KdApp values measured for the wild-type SP/KLF oligonucleotide in 
immobilized bait experiments compared to absolute protein abundance in nuclear lysates. Each 
data point represents a single protein. The correlation is not signifi cant at a p-value of 0.05.
E Regression analysis of KdApp values measured for the wild-type SP/KLF oligonucleotide in 
immobilized bait experiments. Two analysis were performed and plotted, as described in the 
methods, either considering or not considering STY peptide phosphorylation. Each data point 
represents a single protein.
Binding curves were generated by fi tting the parameters of the Hill equation including KdApp. 
Each data point is the mean of three experiments (n=3), and the error bars represent the standard 
error of the mean.
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Supplementary Figure 5 Observed Kd
App correlates with transcription factor motif score
Regression analysis between the log10-transformed Kd
App value for sequence-specific SP/KLF wild-type oligonucleotide binding 
factors and the normalized JASPAR motif score for the SP/KLF consensus oligo as defined in the Methods. The grey dashed line, 
therefore, indicates the significance threshold for each individual factor.
Supplementary Figure 5. Observed KdApp correlates with transcription factor motif 
score 
Regression analysis between the log10-transformed KdApp value for sequence-specifi c SP/KLF 
wild-type oligonucleotide binding factors and the normalized JASPAR motif score for the SP/
KLF consensus oligo as defi ned in the Methods. The grey dashed line, therefore, indicates the 
signifi cance threshold for each individual factor.
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data point represents a single protein. The correlation is not signifi cant at a p-value of 0.05.
E Regression analysis of KdApp values measured for the wild-type SP/KLF oligonucleotide in 
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Supplementary Figure 6 Chromatin modifying complexes bind with lower Kd
App to the mycG4 sequence in G4-permissive conditions
A) Regression analysis of Kd
App values measured for the mycG4 ssDNA oligonucleotide in LiCl binding conditions compared to 
PhenDC3 binding conditions as described in the methods. Each data point represents a single protein. 
B) Binding curves for SMARCA4 (Fig. 2A, Cluster 7), a SWI/SNF catalytic subunit, are shown for the mycG4 oligonucleotide 
in NaCl (G4-permissive), LiCl (G4 non-permissive), and PhenDC3 (G4 ligand) binding conditions. Above are boxplots of all identi-
fied KdApp values SWI/SNF and ISWI subunits in these conditions, with LiCl and PhenDC3 grouped together given their similar 
overall effect (also shown in panel A). 
C) Binding curves for CHD3 (Cluster 7), a NuRD catalytic subunit, are shown for the mycG4 oligonucleotide in NaCl (G4-per-
missive), LiCl (G4 non-permissive), and PhenDC3 (G4 ligand) binding conditions. Boxplots and data points are colored as in panel 
B.
D) Permutation based testing of G4-seq (generated in primary B cells) peak enrichment in ENCODE ChIP-seq peaks for 
SWI/SNF, PRC2, and NuRD subunits in various cell lines. ChIP-seq peaks were randomized 1000 times across the genome, and 
the distribution of enrichment values for randomized G4-seq intersected peak counts, compared to the mean of peak randomiza-
tions, is displayed as a white boxplot with parameters as described previously. The enrichment of ChIP-seq peak enrichment 
compared to peak randomizations is indicated as a blue bar. An empirical p-value was calculated by comparing the distribution of 
randomized peak intersections with the true peak intersections. 
Boxplots are displayed such that the center line is the median of the distribution, the box represents the first and third quartile of 
the data, and the whiskers represent 1.5 inter-quartile ranges. Significance is indicated based on a two-sided t-test, with all meas-
ured values per sample, as indicated by the colored grouping, treated as sample populations.
Binding curves were generated by fitting the parameters of the Hill equation including Kd
App. Each data point is the mean of two 
experiments (n=2), and the error bars represent the standard error of the mean.
pl menta y Figure 6. Chromatin mo ifying complexes bind with lower KdApp to 
the mycG4 sequence in G4-per issive conditions
A Regression analysis of Kd App values measured for the mycG4 ssDNA oligonucleotide in LiCl 
binding conditions compared to PhenDC3 binding conditions as described in the methods. Each 
data point represe ts a single protein.
B Binding curves for SMARCA4 (Fig. 2A, Cluster 7), a SWI/SNF catalytic subunit, are shown for 
the mycG4 oligonucleotide in NaCl (G4-permissive), LiCl (G4 non-permissive), and PhenDC3 
(G4 ligand) binding conditions. Above are boxplots of all identifi ed KdApp values SWI/SNF 
and ISWI subunits in these conditions, with LiCl and PhenDC3 grouped tog ther given their 
similar overall effect (also shown in panel A).
C Binding curves for CHD3 (Cluster 7), a NuRD catalytic subunit, are shown for the mycG4 
oligonucleotide in NaCl (G4-permissive), LiCl (G4 non-permissive), and PhenDC3 (G4 ligand) 
bindi g conditions. Boxplots and da a points are colored as in panel B.
D Permutation based testing of G4-seq (generated in primary B cells) peak enrichment in ENCODE 
ChIP-seq pe ks for SWI/SNF, PRC2, an  NuRD subunits in various cell lines. ChIP-seq peaks 
were randomized 1000 times across the genome, and the distribution of enrichment values for 
randomized G4seq intersected peak counts, compared to the mean of peak randomizations, is 
displayed as a white boxplot with parameters as described previously. The enrichment of ChIP-
seq peak enrichment compared to peak randomizations is indicated as a blue bar. An empirical 
p-value was calculated by comparing the distribution of randomized peak intersections with the 
true peak intersections. 
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Supplementary Figure 6 Chromatin modifying complexes bind with lower Kd
App to the mycG4 sequence in G4-permissive conditions
A) Regression analysis of Kd
App values measured for the mycG4 ssDNA oligonucleotide in LiCl binding conditions compared to 
PhenDC3 binding conditions as described in the methods. Each data point represents a single protein. 
B) Binding curves for SMARCA4 (Fig. 2A, Cluster 7), a SWI/SNF catalytic subunit, are shown for the mycG4 oligonucleotide 
in NaCl (G4-permissive), LiCl (G4 non-permissive), and PhenDC3 (G4 ligand) binding conditions. Above are boxplots of all identi-
fied KdApp values SWI/SNF and ISWI subunits in these conditions, with LiCl and PhenDC3 grouped together given their similar 
overall effect (also shown in panel A). 
C) Binding curves for CHD3 (Cluster 7), a NuRD catalytic subunit, are shown for the mycG4 oligonucleotide in NaCl (G4-per-
missive), LiCl (G4 non-permissive), and PhenDC3 (G4 ligand) binding conditions. Boxplots and data points are colored as in panel 
B.
D) Permutation based testing of G4-seq (generated in primary B cells) peak enrichment in ENCODE ChIP-seq peaks for 
SWI/SNF, PRC2, and NuRD subunits in various cell lines. ChIP-seq peaks were randomized 1000 times across the genome, and 
the distribution of enrichment values for randomized G4-seq intersected peak counts, compared to the mean of peak randomiza-
tions, is displayed as a white boxplot with parameters as described previously. The enrichment of ChIP-seq peak enrichment 
compared to peak randomizations is indicated as a blue bar. An empirical p-value was calculated by comparing the distribution of 
randomized peak intersections with the true peak intersections. 
Boxplots are displayed such that the center line is the median of the distribution, the box represents the first and third quartile of 
the data, and the whiskers represent 1.5 inter-quartile ranges. Significance is indicated based on a two-sided t-test, with all meas-
ured values per sample, as indicated by the colored grouping, treated as sample populations.
Binding curves were generated by fitting the parameters of the Hill equation including Kd
App. Each data point is the mean of two 
experiments (n=2), and the error bars represent the standard error of the mean.
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A Regression analysis of Kd App values measured for the mycG4 ssDNA oligonucleotide in LiCl 
binding conditions compared to PhenDC3 binding conditions as described in the methods. Each 
data point represe ts a single protein.
B Binding curves for SMARCA4 (Fig. 2A, Cluster 7), a SWI/SNF catalytic subunit, are shown for 
the mycG4 oligonucleotide in NaCl (G4-permissive), LiCl (G4 non-permissive), and PhenDC3 
(G4 ligand) binding conditions. Above are boxplots of all identifi ed KdApp values SWI/SNF 
and ISWI subunits in these conditions, with LiCl and PhenDC3 grouped tog ther given their 
similar overall effect (also shown in panel A).
C Binding curves for CHD3 (Cluster 7), a NuRD catalytic subunit, are shown for the mycG4 
oligonucleotide in NaCl (G4-permissive), LiCl (G4 non-permissive), and PhenDC3 (G4 ligand) 
bindi g conditions. Boxplots and da a points are colored as in panel B.
D Permutation based testing of G4-seq (generated in primary B cells) peak enrichment in ENCODE 
ChIP-seq pe ks for SWI/SNF, PRC2, an  NuRD subunits in various cell lines. ChIP-seq peaks 
were randomized 1000 times across the genome, and the distribution of enrichment values for 
randomized G4seq intersected peak counts, compared to the mean of peak randomizations, is 
displayed as a white boxplot with parameters as described previously. The enrichment of ChIP-
seq peak enrichment compared to peak randomizations is indicated as a blue bar. An empirical 
p-value was calculated by comparing the distribution of randomized peak intersections with the 
true peak intersections. 
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Boxplots are displayed such that the center line is the median of the distribution, the box represents 
the first and third quartile of the data, and the whiskers represent 1.5 inter-quartile ranges. 
Significance is indicated based on a two-sided t-test, with all measured values per sample, as 
indicated by the colored grouping, treated as sample populations. 
Binding curves were generated by fitting the parameters of the Hill equation including KdApp. 
Each data point is the mean of two experiments (n=2), and the error bars represent the standard 
error of the mean.
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Boxplots are displayed such that the center line is the median of the distribution, the box represents 
the first and third quartile of the data, and the whiskers represent 1.5 inter-quartile ranges. 
Significance is indicated based on a two-sided t-test, with all measured values per sample, as 
indicated by the colored grouping, treated as sample populations. 
Binding curves were generated by fitting the parameters of the Hill equation including KdApp. 
Each data point is the mean of two experiments (n=2), and the error bars represent the standard 
error of the mean.
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A Validation of mass spectrometry binding profiles for EZH2 (PRC2 subunit, Fig. 2A, Cluster 
7) to the mycG4 consensus oligo. The mass spectrometry binding curve is shown above with 
affinity purification western blot data shown below. Mass spectrometry data points and protein 
bands are approximately aligned on the vertical axis.
B Validation of mass spectrometry binding profiles for SUZ12 (PRC2 subunit, Cluster 7) to the 
mycG4 consensus oligo. The mass spectrometry binding curve is shown above, with affinity 
purification western blot data shown below. Mass spectrometry data points and protein bands 
are approximately aligned on the vertical axis.
C Validation of mass spectrometry binding profiles for GATAD2B (NuRD subunit, Cluster 7) 
to the mycG4 consensus oligo. The mass spectrometry binding curves are shown above, with 
affinity purification western blot data shown below. Mass spectrometry data points and protein 
bands are approximately aligned on the vertical axis. 
Binding curves were generated by fitting the parameters of the Hill equation including KdApp. 
Each data point is the mean of two experiments (n=2), and the error bars represent the standard 
error of the mean.
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Supplementary Figure 8. The SMARCB1 winged helix domain directly binds to and 
prefers the mycG4 sequence
A Workfl ow for formaldehyde protein-DNA cross-linking experiments. Briefl y, proteins were 
covalently cross-linked to DNA oligonucleotides. Proteins were digested and non-linked 
peptides were removed by stringent 8 M urea washes. After de-crosslinking, enriched peptides 
were identifi ed by tandem mass spectrometry analysis, and enrichment was quantifi ed using 
dimethyl chemical labeling.
B Signifi cantly enriched peptides for the XRCC5/6 heterodimer are colored on the crystal 
structure (PDB:1JEY) in red. Co-crystallized DNA is colored in blue.
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185
C Outlier plot of enriched peptides for the mycG4 sequence. Each axis is the log2 transformed 
light/heavy dimethyl ratio from a single replicate. Each data point is a peptide. Enriched 
peptides using a significance cutoff of 1.5 interquartile ranges are colored in red. Background 
proteins are colored in black. Background proteins that are members of the SWI/SNF, PRC2, or 
NuRD complexes are colored in blue.
D Domain schematic of SMARCB1. The enriched peptide identified as significant in panel C is 
colored in red below the protein cartoon. Amino acid peptide indices are indicated by number.
E Binding curve for SMARCB1 (Fig. 2A, Cluster 8) to the mycG4 ssDNA oligo in NaCl binding 
conditions. The binding curve were generated by fitting the parameters of the Hill equation 
including KdApp. Each data point is the mean of three experiments (n=3), and the error bars 
represent the standard error of the mean.
F DNA pulldown and western blot experiments with bacterial lysates expressing either the 
SMARCB1 winged helix domain or the PHF10 double PHD finger. DNA pulldowns were 
performed as described as in the Methods using the mycG4 sequence and a variety of control 
sequences and analyzed by western blot. rs144361550 is a oligonucleotide representing a small 
insertion/deletion single nucleotide polymorphism predicted by computation to be G4-forming 
but characterized biochemically as non-G4 forming. The SP/KLF wild-type ssDNA is a GC-rich 
control sequence which is not predicted to form G4 structures. The SP/KLF mutated ssDNA is 
an AT-rich control sequence which is similarly not predicted to form G4 structures.
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Supplementary Figure 9 Quality control checks of mono-nucleosomes and modified and unmodified di-nucleosomes
A) 17.5% SDS-PAGE gels stained with Coomassie Brilliant Blue of Reverse-phase chromatography fractions indicating the 
separation of ligated full-length histone H3 (unmodified, K4me3 and K9AcK14Ac) and the truncated histone H3.1. Fractions 
underlined with a dashed line were pooled for refolding into histone octamers.
B) 17.5% SDS-PAGE gels stained with Coomassie Brilliant Blue of the H3unmodified, H3K4me3 and H3K9AcK14Ac histone 
octamers.
C) 5% native PAGE gels stained with ethidium bromide or SYBR safe of the biotinylated mono-/di-nucleosomes. The free 
DNA and band-shifted nucleosomes are indicated. 
D) Input di-nucleosome substrate and the supernatant after binding to streptavidin beads indicating that the free competitor 
MMTV-A DNA and mono-nucleosomes do not bind to the beads and the biotinylated di-nucleosomes do bind.
Supplementary Figure 9. Quality control checks of mono-nucleosomes and modifi ed 
and unmodifi ed di-nucleosomes
A 17.5% SDS-PAGE gels stained with Coomassie Brilliant Blue of Reverse-phase chromatography 
fractions indicating the separation of ligated full-length histone H3 (unmodifi ed, K4me3 and 
K9AcK14Ac) and the truncated istone H3.1. F action  underlined with a dashe  line were 
pooled for refolding into histone octamers.
B 17.5% SDS-PAGE gels stained with Coomassie Brilliant Blue of the H3unmodifi ed, H3K4me3 
and H3K9AcK14Ac histone octamers.
C 5% native PAGE gels stained with ethidium bromide or SYBR safe of the biotinylated mono-/
di nucleosomes. The free DNA and band-shifted nucleosomes are indicated.
D Input di-nucleosome substrate and the supernatant after binding to streptavidin beads indicating 
that the free competitor MMTV-A DNA and mono-nucleosomes do not bind to the beads and 
the biotinylated di-nucleosomes do bind.
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Supplementary Figure 10. SWI/SNF and ISWI di-nucleosome binding affinity is 
modulated by H3 modifications
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Supplementary Figure 10. SWI/SNF and ISWI di-nucleosome binding affinity is 
modulated by H3 modifications
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A Binding curves for SMARCA2 (Fig. 3B, Cluster 5) and SMARCA4 (Cluster 5), SWI/SNF 
catalytic subunits, and PHF10 (Cluster 3), a SWI/SNF accessory subunit, are shown for 
unmodified, H3K4me3, and H3K9AcK14Ac modified di-nucleosomes. Above are boxplots of 
all identified KdApp values SWI/SNF and ISWI subunits for these substrates.
B Domain schematic of PHF10. The DPF domain used for cloning, protein expression, and DNA 
pulldown experiments is specifically indicated.
C Histone peptide pulldown and western blot experiments with bacterial lysates expressing 
either the PHF10 double PHD finger or the SMARCB1 winged helix. Peptide pulldowns 
were performed as described as in the Methods using the H3 peptides with the indicated post-
translational modifications.
D Binding curves for SMARCA5 (Cluster 3), ISWI catalytic subunit, and BPTF (Cluster 3), 
C17orf49 (Cluster 1), BAZ1A (Cluster 4), and BAZ1B (Cluster 3), SWI/SNF accessory 
subunits, are shown for unmodified, H3K4me3, and H3K9AcK14Ac modified di-nucleosomes. 
Above are boxplots of all identified KdApp values SWI/SNF and ISWI subunits for these 
substrates. Significance is indicated based on a two sided t-test, with all measured values per 
sample, as indicated by the colored grouping, treated as sample populations.
Boxplots are displayed such that the center line is the median of the distribution, the box represents 
the first and third quartile of the data, and the whiskers represent 1.5 inter-quartile ranges. 
Significance is indicated based on a two-sided t-test, with all measured values per sample, as 
indicated by the colored grouping, treated as sample populations.
Binding curves were generated by fitting the parameters of the Hill equation including KdApp. 
Each data point is the mean of three experiments (n=3), and the error bars represent the standard 
error of the mean.
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Supplementary Table 1. Oligonucleotides used in this study
Name Sequence Sequence 2
Sp/KLF Wild-type Consensus
/5Biosg/GAGAGCCCCG
CCCCCTGGCT
AGCCAGGGGGCGGGG
CTCTC
Sp/KLF Mutated
/5Biosg/GAGAGAAAAT
AAAACTGGCT
AGCCAGTTTTATTTTCT
CTC
AP-1 /5Biosg/AGTCGGCTAGCTGACTCAGGATGTCC
GGACATCCTGAGTC
AGCTAGCCGACT
CTCF
/5Biosg/TCAGAGTGGC
GGCCAGCAGGGGGCGC
CCTTGCCAGA
TCTGGCAAGGGCGC
CCCCTGCTGGCCGC
CACTCTGA
E-box /5Biosg/GGAAGCAGACCACGTGGTCTGCTTCC
GGAAGCAGACCAC
GTGGTCTGCTTCC
NF-Y /5Biosg/ATTGACCAATCAGAGGTAGGATGAT
ATCATCCTACCTCTG
ATTGGTCAAT
TATA-box /5Biosg/GCGGCGCTCTATATAAGTGGGCAGTG
CACTGCCCACTTATA
TAGAGCGCCGC
TEAD /5Biosg/TCGGGACCCAGGCCTGGAATGTTTCCACC
GGTGGAAACATTCC
AGGCCTGGGTCCCGA
MycG4 /5Biosg/TGGGGAGGGTGGGGAGGGTGGGGAAGG
Telomere /5Biosg/TTAGGGTTAGGGTTAGGGTTAGGG
rs144361550_PARP1_ins_biotin_
rev (predicted G4, biochemically 
characterized as non-G4)
/5Biosg/GAGCGAGCGGGCCCGGGCCCgggcccT
CGGAGCGGCACTTGGGGCC
*Free sequences for competition experiments were ordered without biotinylation
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Supplementary Table 2 Antibodies and recombinant proteins used in this study
Factor Source Catalog Number Ab Dilution Used
SP1 Sigma S9809 1:100
SP3 abcam ab72594 1:500
KLF4 Sigma HPA002926 1:1000
EZH2
Cell signaling 
technologies 5246 1:500
GATAD2B Bethyl laboratories A301-282A 1:2000
Suz12 abcam ab12073 1:2000
GST Thermo MA4-004 1:1000
Recombinant protein used
Protein Source
SP3 Abnova H00006670-P01
KLF4-ZF Spruijt et al. Cell. 2012.
PHF10 Double 
PHD finger domain 
(aa358-aa498)
This study For primer:
CCCGGATCCCCAAACG
TTCTGTACTGTCC
Rev Primer:
GGGAAGCTTATTAT
CCCTCTTTGCTGTT
TTTC
SMARCB1 winged 
helix domain 
(aa1-aa112)
This study For primer:
CAATCCATGGGAATG
ATGATGATGGCGCT
GAG
Rev Primer:
TCGGGATCCTTATTA
GATGGACACAGCCTT
GTAC
Supplementary Table 3 Public data sets used in this study
Factor Cell Line Database Accession Number
ChIP-Sequencing
SMARCB1 HeLaS3 ENCODE ENCFF002CSN
SMARCB2 K562 ENCODE ENCFF993YKH
GATAD2B MCF7 ENCODE ENCFF046BRP
EED GM12878 ENCODE ENCFF023ALY
EZH2 NHEK Keratinocytes ENCODE ENCFF002CFB
EZH2 GM12878 ENCODE ENCFF615NYO
EZH2 Primary human CD20+ 
B-cells, RO01794
ENCODE ENCFF434OEY
G4-sequencing
Induced G4 (K+, PDS), 
plus strand
Primary human B-cells, 
NA18507 GEO GSE63874
Induced G4 (K+, PDS), 
minus strand
Primary human B-cells, 
NA18507 GEO GSE63874
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[They go] into non-being, which is to say, everything.
 -Harry Potter and the Deathly Hallows, J.K. Rowling
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The emergence of cancer genomics as a major discipline in biomedical 
research has precipitated the discovery of a genetic menagerie of disease related 
genotype-phenotype associations and putative functional sequence variants. 
The benefit of hypothesis-generating, data-driven, multi-omics science is that 
we now have far more molecular and genetic information about the cellular 
state that is “cancer” than ever before. But the ability to describe the features 
of a certain state does not equal a functional, mechanistic understanding of 
how that state arose, how it behaves, or what causes it to respond in one way or 
another. In the 18th century, Carl Linnaeus attempted to describe and categorize 
all living things according to their features, similarities, and differences. But 
a taxonomy is a descriptive categorization of life. Not until the insights of 
Darwin and Wallace, and the concept of common descent, variation, and natural 
selection, did a satisfying mechanistic explanation for the diversity of living 
things arise. The challenge currently facing the (biomedical) molecular biology 
community is how to translate the continually increasing deluge of information 
into knowledge. In other words, how to turn the molecular taxonomy of genetic 
variants and molecular phenotypes that is currently being produced into a 
satisfying mechanistic explanation for how a cell, tissue, organ, organism, 
genome, proteome, epigenome, metabolome, protein, protein complex, etc. 
actually behaves, or misbehaves in the context of disease? How to turn a 
description into a prediction?
This thesis has presented positive cases where mass spectrometry was 
leveraged to connect a particular DNA sequence, variant, or nucleosome with a 
set of specific or high affinity interactors; however, these examples all exhibit 
one serious disadvantage. It is the very same disadvantage that, at the moment, 
all protein-based studies possess compared with DNA, RNA, or sequencing 
based studies. All research presented here was conducted essentially on a 
“case-by-case” basis, which in essence means it was slow compared to high-
throughput sequencing approaches. Sequencing data is being produced at a pace 
that rapidly outstrips the speed with which comparable proteomics data can 
currently be produced. Many more mutations and sequence variants are being 
discovered via NGS and whole-genome sequencing (WGS) than can reasonably 
be profiled by proteomics methodologies, or by any other standard molecular 
biological or biochemical technique for that matter. Thus, it is critical that 
future research incorporates innovative high-throughput methods for profiling 
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many (i.e. hundreds or even thousands) of sequence variants. In Chapter 4 of 
this thesis, we use a filter-plate based system which can in principle perform 
~100 affinity purifications in parallel. However, this approach still only allows 
for semi-quantitative profiling of ~25 variants per 96-well plate or absolutely 
quantitative profiling of 8 sequences or baits. Maximizing the number of 
sequence variants that can be profiled with filter plate based systems will likely 
require robotic automation. Similarly, microfluidics platforms could enable 
automated and standardized affinity purification protocols while having the 
additional benefit of dramatically downscaling the material requirements (i.e., 
protein and DNA amounts) per affinity purification. On the other hand, pooling 
and deconvolution experimental designs might be a promising experimental 
avenue for increasing the throughput of variant profiling by MS without 
demanding additional technology investment. In any case, though there have 
recently been a few isolated cases of research studies reporting 1000+ affinity 
purifications in a single manuscript, these cases are still few and far between. 
Future developments in the automation of DNA focused AP-MS experiments 
and analysis will undoubtedly be a subject of keen interest in a variety of multi-
disciplinary fields. 
The canonical role of transcription factors in binding to specific DNA 
sequence motifs, often monomerically or in limited size multimers such 
as dimers or trimers, and regulating transcription of target genes via direct 
interactions with the core transcriptional machinery or chromatin remodeling 
or modifying enzymes is by now relatively well established. Indeed, in Chapter 
2 we reported mass spectrometry studies of precisely this type of canonical 
DNA binding and gene regulatory function. On the other hand, our analysis of 
tetrameric GABP binding at novel and endogenous TERT promoter mutations 
already suggests that more than simple motif creation or disruption can influence 
TF binding. In that case, it was the precise spacing of nearby ETS motifs 
that dictated stable GABP binding. In contrast, this motif spacing appeared 
unimportant for GABP binding at SDHD promoter mutations, showing that 
motif architecture itself can be a context-specific form of regulation. Indeed, 
understanding the role that motif spacing plays in facilitating co-regulation of 
target genes via direct or functional interactions between TFs binding at co-
occurring motifs is an important topic of current research and an area where 
mass spectrometry protein-DNA interactomics is sure to play a role. However, 
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we observe that in addition to motif spacing as a higher-order determinant of 
TF binding, DNA structure can itself act as recognition site for some proteins 
and protein complexes. Although such structure-specific interactions have been 
reported previously, most often for DNA helicases, we report in Chapter 3 that 
differential DNA structures can also regulate transcription allele-specifically 
for cancer-associated insertion/deletion variants. Future research might well 
consider if, and to what extent, small insertion/deletion variants in repetitive 
regions (i.e., variants that add no novel sequence or motif content) regulate 
transcription via structure-specific interaction normally and abnormally if 
the variant is associated with cancer risk. Additionally, we show in Chapter 
4 that structure-specific DNA recognition may be more widespread than 
previously realized, given that ligand affinity is marginally but not dramatically 
decreased when DNA structure is chemically disrupted. Such structure-specific 
recognition might not be readily identified using traditional AP-MS outlier 
calling methods. G-quadruplex RNA recognition has been reported for PRC2, 
yet there is very little in the literature connecting G-quadruplexes or a litany 
of other DNA secondary structures with proteins and protein complexes that 
regulate chromatin state. That G-quadruplexes are preferentially observed in 
regulatory regions that are nucleosome depleted suggests at least a connection 
between DNA structural elements and chromatin maintenance. To what extent 
this connection exists, and its functional implications, will surely be a topic for 
future research in chromatin biochemistry and structure. In addition, profiling 
the high affinity “readers” of the various reported non-G4 DNA secondary 
and higher-order structures (including i-motifs, cruciform, triplexes, alternate 
quadruplexes including inter-molecular quadruplexes, and hairpins) would shed 
some much needed light into regulation of, and regulation by, these interesting 
and largely uncharacterized structural elements. 
In Chapter 4 of this thesis, we identify high affinity interactors of (modified) 
nucleosomes and predominantly di-nucleosomes. Although we did not expect 
the “compactness” of di-nucleosomes (as opposed to, for example, 12mer 
or 24mer nucleosome arrays) to make a major contribution to the affinities 
we measured, it is well known that some histone PTMs including histone 
acetylation can dramatically affect the stability, DNA wrapping, and high-order 
compaction of nucleosomes and nucleosome arrays. Therefore, we cannot 
exclude the possibility that nucleosome or DNA accessibility might increase 
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or decrease protein-nucleosome binding affinities differentially based on the 
nucleosome modification state. Surprisingly, however, the binding assay we 
describe in Chapter 4, along with differentially modified nucleosomes and 
nucleosome arrays of different lengths, actually enables new experimental 
strategies for studying the effect histone PTM mediated nucleosome compaction 
has on protein-nucleosome binding affinities. In addition to measuring protein-
nucleosome affinities for nucleosome arrays of the same length but with different 
PTMs, one could in principle measure nucleosome arrays of different lengths 
but with the same set of PTMs. In doing so, if different affinities were measured 
for nucleosome arrays of different lengths, it could be inferred that any changes 
in affinity would be due to the structural factors of nucleosome compaction, 
accessibility, and stability. Additionally, analysis of the rate of affinity changes 
might provide additional structural/functional biochemical data: a rapidly 
saturating decrease in affinity with longer nucleosome array length could be 
correlated with maximally compact units of few nucleosomes, for example. 
It has been well known for some time that chromatin is a plastic and dynamic 
molecular structure; an analysis of the PTM-dependent relationship between 
protein complex affinity and nucleosome/chromatin compaction would add to 
our knowledge of the dynamic structural properties of chromatin. Finally, most 
studies with recombinant nucleosome systems use a relatively small number 
of well-defined sequences (synthetic nucleosome positioning sequences, 
palindromic alpha satellite repeats, etc). A major next step is to use different, 
biologically interesting sequences to assess how underlying DNA sequences 
interact with histones and histone PTMs to influence compaction (or indeed 
de-compaction) of chromatin via specific TF or chromatin factor interactions. 
What are the next imminent advances in the field of mass spectrometry based 
protein-DNA interactomics? Cross-linking mass spectrometry (XL-MS) has 
advanced rapidly in the past decade or so, and now XL-MS studies proteome-
wide identifying thousands of unique residue-level cross-linked peptide pairs 
are seen somewhat regularly. RNA XL-MS studies using UV cross-linking have 
been a more recent research topic. Presumably, some of the advances made 
in protein and RNA XL-MS technologies will begin finding applications in 
protein-DNA cross-linking studies, potentially in combination with hydrogen-
deutrium exchange or limited proteolysis approaches. The ability to identify 
direct DNA binding proteins from a DNA affinity purification experiment, at a 
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residue level, will be broadly useful. Additionally, Native MS and Ion Mobility 
MS are promising methods for studying structural and biochemical aspects of 
protein-DNA interactions in near native conditions, including stoichiometry 
information and conformational states or changes. Ensemble, hybrid methods 
that combine some or all of these data types with additional structural data, 
such as SAXS or low resolution EM data, may be more broadly accessible 
as data collection, integration, and modeling technologies become optimized 
and generalized. Finally, there has been some long-term interest in developing 
pharmaceutical ligands to specifically inhibit sequence-specific DNA binding 
properties of transcription factors. Though these efforts are still very much 
ongoing, DNA-protein AP-MS approaches will likely be instrumental in 
profiling the potency and specificity of future TF inhibitors, possibly in 
combination with Thermal Proteome Profiling experiments to assess off-target 
effects. 
Since Jacob and Monod’s famous work in the 1950’s and 1960’s, it has 
become increasingly clear that the early model of a single transcription factor 
regulating a single gene that becomes a single protein is little more than fantasy. 
We now know that each transcription factor binds in many places in the genome, 
and in addition, these locations often differ depending on the type of cell in 
question. The functions enacted by TFs are complex, involving transcriptional 
activation and repression, recruitment of the basal transcriptional machinery, 
regulating chromatin state, and mediating genome folding. Furthermore, this 
complexity increases exponentially given the interplay between different 
TFs and between their various effector functions. As such, the dysregulation 
of TF mediated transcriptional regulatory processes in disease states can be 
similarly complex. It is very true that, if you love complex systems, now is a 
golden time to be a molecular biologist. But there is much more to be gained 
from integrative science that combines a top-down, systems-level approach 
to descriptive biology with a bottom-up, mechanistic approach to defining 
molecular functions. Understanding a cell, understanding the sum of the parts, 
still requires a reductionist, bottom-up understanding of the parts. And it is here 
that mass spectrometry based protein-DNA interaction proteomics has made, 
and will continue to make, considerable scientific contributions in biology.
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Summary
Throughout this thesis, I have argued by demonstration that mass 
spectrometry is a useful tool for connecting a description (a variant, a genetic 
association, a sequence) with a prediction (a regulatory TF or protein). I first 
introduce in Chapter 1 the scientific background of this thesis, giving a thorough 
overview of transcriptional gene regulation and chromatin biology, cancer 
genomics, and mass spectrometry. I emphasize in particular the opportunities 
for collaboration between these traditionally somewhat delimited fields. 
In Chapter 2, we identified a TF, GABP, that binds sequence-specifically to 
novel ETS motifs formed by recurrent TERT promoter mutations in melanoma 
and other cancers, yet is inhibited from binding by the disruption of endogenous 
ETS motifs by SDHD promoter mutations. Particularly in the case of the 
TERT promoter, the genetic disease association of the recurrent mutations was 
described relatively far before a functional mechanism was proposed. Yet the 
observation that GABP binds sequence-specifically at the mutation-induced 
ETS motifs immediately suggested just such a functional mechanism: that 
GABP binds mutation specifically and, in the manner of many TFs, activates 
transcription of TERT. The identification of mutation-specific binding at SDHD 
followed immediately from a search for mutation-induced motif changes with 
a similar genetic signature. 
Chapter 3 describes a biologically more complex case with a similar 
conceptual rationale. In contrast to the TERT and SDHD promoter mutations, 
the putative functional germline variant at the PARP1 melanoma locus was an 
insertion/deletion SNP that fell in a hexameric (GGGCCC) repeat that created 
no new sequence motifs. As such, it was highly unlikely that any putative 
protein regulator binding at that site would be a canonical sequence-specific TF. 
Instead, we identified a number of proteins annotated as binding preferentially 
to DNA structural elements including G-quadruplexes. Further analysis showed 
an insertion allele preferential binding protein, the DNA helicase RECQL, 
transcriptionally regulated PARP1 expression. While the insertion allele was 
predicted by computation to form a G-quadruplex and the deletion allele was not, 
we observed that any differential secondary structures between the insertion and 
deletion alleles was not due to canonical G-quadruplex formation, highlighting 
the diversity of possible DNA secondary structures. Yet, intriguingly, additional 
proteomics analysis suggested that ligand stabilized DNA secondary structures 
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dramatically affected protein binding. In any case, the underlying logic was the 
same; a DNA structural variant was connected, by mass spectrometry, with a 
putative functional regulator to offer a mechanistic explanation for a disease 
association. 
Furthermore, Chapter 4 shows that mass spectrometry can be utilized to offer 
biochemical affinity information about protein-DNA interactions in addition to 
the semi-quantitative specificity data described in the previous chapters. It is 
relevant to note, at this point, that not all protein-DNA regulatory interactions 
are completely equal. On the contrary, they differ in both the specificity and the 
affinity of the protein-DNA pair in question. We show in Chapter 4 that many 
putative regulatory TFs can bind the same DNA sequence specifically, but with 
quite different absolute affinities. Furthermore, in addition to estimating absolute 
affinities, we show how chemical modulation of G-quadruplex structure can 
decrease high affinity binding of some chromatin remodeling and modifying 
enzymes. We show a similar modulated binding affinity for many proteins and 
protein complexes by histone tail PTMs in the context of nucleosomes, and in 
fact, we show that high affinity binding may be modulated by histone PTMs 
for only some, but not all, subunits of large chromatin remodeling complexes. 
But more generally, what this approach facilitates is a “narrowing down” of 
putative functional regulators, under the general hypothesis that higher affinity 
interactors are more likely to be functional than lower affinity interactors. 
Finally, Chapter 5 provides a more colloquial discussion of the scientific 
contents of the thesis. I generally contextualize the contents of this thesis, 
focusing on limitations of the described research and research methods while 
also emphasizing opportunities and directions for future research.  
In general, this thesis has contributed to our understanding of sequence-
specific transcription factor-DNA interactions and their deregulation in cancer. 
Concurrently, this thesis has established mass spectrometry based interaction 
proteomics as a powerful tool for identifying such sequence-specific protein-
DNA interactions and has developed a new mass spectrometry assay for 
quantifying these interactions. 
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Samenvatting
In dit proefschrift heb ik laten zien dat massaspectrometrie een geschikt 
hulpmiddel is om een feitelijkheid (een variant, een genetische associatie, een 
sequentie) te verbinden met een voorspelling (een regulerende transcriptie 
factor (TF) of eiwit). In Hoofdstuk 1 introduceer ik eerst de wetenschappelijke 
achtergrond van dit proefschrift, met een grondig overzicht van transcriptionele 
genregulatie en chromatine biologie, kankergenetica, en massaspectrometrie. 
Ik benadruk met name de mogelijkheden voor samenwerking tussen deze twee 
– traditioneel enigszins afgebakende – onderzoeksgebieden.
In Hoofdstuk 2 hebben we een TF geïdentificeerd, GABP, die sequentie-
specifiek bindt aan een nieuw ETS-motief dat gevormd wordt door herhaaldelijk 
voorkomende mutaties in de TERT-promotor in melanoom en andere vormen 
van kanker, maar waarvan de binding wordt verhinderd door het verstoren van 
endogene ETS-motieven door mutaties in de SDHD-promotor. In het bijzonder 
in het geval van de TERT-promotor was het genetische ziekteverband met 
de herhaaldelijk voorkomende mutaties al relatief lang beschreven voordat 
hiervoor een functioneel mechanisme werd voorgesteld. Toch suggereert de 
observatie dat GABP sequentie-specifiek bindt aan de ETS motieven die zijn 
ontstaan door mutaties meteen een dergelijk functioneel mechanisme: dat 
GABP specifiek aan de mutatie bindt en, zoals veel TFs, transcriptie van TERT 
activeert. De identificatie van mutatie-specifieke binding aan SDHD volgde 
direct uit een zoektocht naar veranderingen van motieven door mutaties met 
soortgelijke genetische kenmerken.
Hoofdstuk 3 beschrijft een biologisch complexer geval met een soortgelijke 
conceptuele redenering. In tegenstelling tot de mutaties op de TERT en SDHD 
promotors was de vermeende functionele kiembaanvariant op het PARP1 
melanoom locus een insertie/deletie SNP, gelegen in een hexamere repetitieve 
regio (GGGCCC), die geen nieuwe sequentiemotieven creëerde. Daardoor was 
het hoogst onwaarschijnlijk dat een eventuele vermeende eiwitregulator die op 
die plek kon binden een canonieke sequentie-specifieke TF zou zijn. In plaats 
daarvan hebben we een aantal eiwitten geïdentificeerd waarvan bekend was dat 
die preferentieel binden aan structurele DNA-elementen zoals G-quadruplexen. 
Verdere analyse wees uit dat de DNA helicase RECQL, die preferentieel bindt 
aan het insertieallel, de expressie van PARP1 transcriptioneel reguleerde. 
Hoewel computeranalyses voorspelden dat het insertieallel een G-quadruplex 
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zou vormen en het deletieallel niet, constateerden we dat eventuele differentiële 
secundaire structuren tussen de insertie- en deletieallelen niet te wijten waren 
aan canonieke G-quadruplex formatie, wat de diversiteit van mogelijke 
DNA secundaire structuren benadrukt. Intrigerend was daarom dat verdere 
proteomicsanalyse suggereerde dat eiwitbinding dramatisch werd beïnvloed 
door ligand-gestabiliseerde DNA structuren. In elk geval was de onderliggende 
logica hetzelfde; een structurele DNA variant werd door massaspectrometrie 
gelinkt aan een vermeende functionele regulator, waarmee een mechanistische 
verklaring voor een ziekteverband werd gegeven. 
Daarnaast laat Hoofdstuk 4 zien dat massaspectrometrie gebruikt kan 
worden om biochemische informatie over de affiniteit van eiwit-DNA 
interacties te verkrijgen, naast de semi-kwantitatieve specificiteitsgegevens 
zoals beschreven in de voorgaande hoofdstukken. Op dit punt is het relevant 
om op te merken dat niet alle regulerende eiwit-DNA interacties volledig 
gelijkwaardig zijn. In tegendeel, ze verschillen in zowel de specificiteit als de 
affiniteit van het betreffende eiwit-DNA-koppel. We laten in hoofdstuk 4 zien dat 
veel vermeende regulerende TFs specifiek aan dezelfde DNA sequentie kunnen 
binden, maar met vrij verschillende absolute affiniteiten. Naast het schatten 
van absolute affiniteiten laten we bovendien zien hoe de chemische modulatie 
van de G-quadruplex structuur de hoge affiniteitsbinding van sommige 
chromatine remodellerende en modificerende enzymen kan veranderen. We 
laten voor veel eiwitten en eiwitcomplexen een bindingsaffiniteit zien die 
soortgelijk gemoduleerde wordt door post-translationele modificaties (PTMs) 
op histonstaarten in de context van nucleosomen. In feite laten we zien dat 
alleen voor sommige, maar niet alle, subeenheden van grote chromatine 
remodellerende complexen de hoge affiniteitsbinding gemoduleerd kan worden 
door histon PTMs. Meer in het algemeen, wat deze aanpak mogelijk maakt 
is het selecteren van vermeende functionele regulatoren, onder de algemene 
hypothese dat het meer waarschijnlijk is dat interactoren met een hogere 
affiniteit functioneel zijn dan interactoren met een lagere affiniteit.
Ten slotte geeft Hoofdstuk 5 een meer informele discussie over de 
wetenschappelijke inhoud van het proefschrift. Ik plaats de inhoud van het 
proefschrift in een meer algemene context, waarbij ik focus op de beperkingen 
van het beschreven onderzoek en onderzoeksmethoden en tegelijkertijd ook de 
mogelijkheden en richtingen voor vervolgonderzoek benadruk.
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Dit proefschrift heeft algemeen bijgedragen aan ons begrip van sequentie-
specifieke interacties tussen TFs en DNA en hun deregulering in kanker. 
Tegelijkertijd heeft dit proefschrift op massaspectrometrie gebaseerde 
interactie-proteomics vastgesteld als een krachtig hulpmiddel om zulke 
sequentie-specifieke eiwit-DNA interacties te identificeren en beschrijft het een 
nieuwe massaspectrometrie methode, ontwikkeld voor het kwantificeren van 
deze interacties. 
[Translation into Dutch by Ino Karemaker, to whom I offer my sincere gratitude.]
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